

Logging in to Dialog

Trying 3106900061...Open

DIALOG INFORMATION SERVICES

PLEASE LOGON:

\*\*\*\*\*

ENTER PASSWORD:

lt840lcpq

\*\*\*\*\*

Welcome to DIALOG

Dialog leel 00.05.02D

Lat logoff: 15ma00 21:05:00

Logon file001 16ma00 13:14:00

\*\*\* ANNOUNCEMENT \*\*\*

NEW FILE RELEASED

\*\*\*New Scientit (File 369)

\*\*\*Newweek Flltext (File 482)

\*\*\*WIPO/PCT Patent Flltext (File 349)

UPDATING RESUMED

\*\*\*Bridge World Market New (File 609,809)

\*\*\*Fort Worth Star-Telegram (File 427)

\*\*\*Federal New Serice (File 660)

\*\*\*Kana Cit Star (File 147)

\*\*\*

RELOADED

\*\*\*AIDSLINE (File 157)

\*\*\*MEDLINE (File 154,155)

\*\*\*Book in Print (File 470)

\*\*\*Kompa Latin America (File 586)

\*\*\*

Edialog

REMOVED

\*\*\*Global Mobility (File 64). Please use 2,6,8,63,65,94,99,108,238,266,583.

>>>Get immediate news with Dialog's First Release news service. First Release updates major newswire databases within 15 minutes of transmission over the wire. First Release provides full Dialog searchability and full-text features. To search First Release files in OneSearch simply BEGIN FIRST for coverage from Dialog's broad spectrum of news wires.

>>> Enter BEGIN HOMEBASE for Dialog Announcements <<<  
>>> of new databases, price changes, etc. <<<

\*\*\*\*

File 1:ERIC 1966-2000/Mar

(c) format only 2000 The Dialog Corporation

\*File 1: File has been reloaded. See HELP NEWS 1.

Set Items Description

>>>'IALOG' not recognized as set or accession number  
 ? set hi ;set hi

16may00 13:14:06 User233835 Session D405.1  
 \$0.41 0.118 DialUnits File1  
 \$0.41 Estimated cost File1  
 \$0.05 TYMNET  
 \$0.46 Estimated cost this search  
 \$0.46 Estimated total session cost 0.118 DialUnits

File 410:Chronolog(R) 1981-2000 Mar/Apr  
 (c) 2000 The Dialog Corporation plc

Set	Items	Description
---	-----	-----

?  
 HIGHLIGHT set on as ''  
 HIGHLIGHT set on as ''  
 ? b 155, 5, 399

16may00 13:16:22 User233835 Session D405.2  
 \$0.00 0.056 DialUnits File410  
 \$0.00 Estimated cost File410  
 \$0.15 TYMNET  
 \$0.15 Estimated cost this search  
 \$0.61 Estimated total session cost 0.174 DialUnits

SYSTEM:OS - DIALOG OneSearch  
 File 155:MEDLINE(R) 1966-2000/Jul W1  
 (c) format only 2000 Dialog Corporation  
 \*File 155: MEDLINE has been reloaded. Accession numbers changed.  
 File 5:Biosis Previews(R) 1969-2000/May W2  
 (c) 2000 BIOSIS  
 File 399:CA SEARCH(R) 1967-2000/UD=13219  
 (c) 2000 American Chemical Society  
 \*File 399: Use is subject to the terms of your user/customer agreement.  
 RANK charge added; see HELP RATES 399.

Set	Items	Description
---	-----	-----

? b 155, 5, 399, 357

16may00 13:16:39 User233835 Session D405.3  
 \$0.06 0.020 DialUnits File155  
 \$0.06 Estimated cost File155  
 \$0.11 0.020 DialUnits File5  
 \$0.11 Estimated cost File5  
 \$0.25 0.020 DialUnits File399  
 \$0.25 Estimated cost File399  
 OneSearch, 3 files, 0.060 DialUnits FileOS  
 \$0.01 TYMNET  
 \$0.43 Estimated cost this search  
 \$1.04 Estimated total session cost 0.234 DialUnits

SYSTEM:OS - DIALOG OneSearch  
 File 155:MEDLINE(R) 1966-2000/Jul W1  
 (c) format only 2000 Dialog Corporation  
 \*File 155: MEDLINE has been reloaded. Accession numbers changed.  
 File 5:Biosis Previews(R) 1969-2000/May W2  
 (c) 2000 BIOSIS  
 File 399:CA SEARCH(R) 1967-2000/UD=13219  
 (c) 2000 American Chemical Society

\*File 399: Use is subject to the terms of your user/customer agreement.  
RANK charge added; see LP RATES 399.

File 357:Derwent Biotechnology Abs 1982-2000/May Bi  
(c) 2000 Derwent Publ Ltd

Set Items Description

7 s (pulmonary or lung or aerosol or aerosolize or inhale or inhalation)  
and (oligonucleotide or vector or antisense or ribozyme)

529981 PULMONARY  
581875 LUNG  
46986 AEROSOL  
23 AEROSOLIZE  
10 INHALATE  
81613 INHALATION  
67566 OLIGONUCLEOTIDE  
188264 VECTOR  
37681 ANTISENSE  
7274 RIBOZYME  
S1 6596 (PULMONARY OR LUNG OR AEROSOL OR AEROSOLIZE OR INHALATE  
OR INHALATION) AND (OLIGONUCLEOTIDE OR VECTOR OR  
ANTISENSE OR RIBOZYME)

1 e au=Bennett, Clarence

Ref	Items	Index-term
E1	2	AU=BENNETT, CLAIRE
E2	1	AU=BENNETT, CLAIRE E.
E3	0	*AU=BENNETT, CLAPENCE
E4	1	AU=BENNETT, CLAFENCE F.
E5	12	AU=BENNETT, CLAPENCE FRANK
E6	3	AU=BENNETT, CLAPK
E7	1	AU=BENNETT, CLAYTON
E8	3	AU=BENNETT, CLAYTON R.
E9	3	AU=BENNETT, CLAYTON ROSS
E10	15	AU=BENNETT, CLEAVES M.
E11	1	AU=BENNETT, CLIFF
E12	2	AU=BENNETT, CLIFFORD

Enter P or PAGE for more

7 s e4 or e5

1 AU=BENNETT, CLAPENCE F.  
12 AU=BENNETT, CLAPENCE FRANK  
S2 13 AU="BENNETT, CLARENCE F." OR AU="BENNETT, CLARENCE FRANK"

1 e au=Bennett, C

Ref	Items	Index-term
E1	3	AU=BENNETT, BYRON L.
E2	1	AU=BENNETT, BYRON LEE
E3	0	*AU=BENNETT, C
E4	22	AU=BENNETT, C.
E5	21	AU=BENNETT, C. A.
E6	7	AU=BENNETT, C. A., JP.
E7	12	AU=BENNETT, C. B.
E8	10	AU=BENNETT, C. D.
E9	5	AU=BENNETT, C. E.
E10	4	AU=BENNETT, C. E. G.
E11	2	AU=BENNETT, C. EUGENE
E12	7	AU=BENNETT, C. F.

Enter P or PAGE for more

7 p

Ref	Items	Index-term
E13	109	AU=BENNETT, C. FRANK
E14	8	AU=BENNETT, C. G.
E15	7	AU=BENNETT, C. H.
E16	7	AU=BENNETT, C. J.
E17	2	AU=BENNETT, C. K.
E18	72	AU=BENNETT, C. L.
E19	2	AU=BENNETT, C. M.
E20	2	AU=BENNETT, C. N.
E21	44	AU=BENNETT, C. O.
E22	39	AU=BENNETT, C. P.
E23	2	AU=BENNETT, C. RICHARD
E24	1	AU=BENNETT, C. T.

Enter P or PAGE for more

? s e12 or e13

	7	AU=BENNETT, C. F.
	109	AU=BENNETT, C. FRANK
S3	116	AU="BENNETT, C. F." OR AU="BENNETT, C. FRANK"

? ds

Set	Items	Description
S1	6596	(PULMONARY OF LUNG OR AEROSOL OR AEROSOLIZE OR INHALATE OR INHALATION) AND (OLIGONUCLEOTIDE OR VECTOR OR ANTISENSE OR RI-BOZYME)
S2	13	AU="BENNETT, CLARENCE F." OR AU="BENNETT, CLARENCE FRANK"
S3	116	AU="BENNETT, C. F." OR AU="BENNETT, C. FRANK"

? s s2 or s3

	13	S2
	116	S3
S4	129	S2 OR S3

? rd

...examined 50 records (50)  
 ...examined 50 records (100)  
 ...completed examining records  
 S5 123 RD (unique items)  
 ? s s1 and s5

	6596	S1
	123	S5
S6	17	S1 AND S5

? rd

...completed examining records  
 S7 17 RD (unique items)  
 ? t s7/7/1-17

7/7/1 (Item 1 from file: 399)  
 DIALOG(R)File 399:CA SEARCH(F)  
 (c) 2000 American Chemical Society. All rts. reserv.

132216514 CA: 132(17)216514n JOURNAL  
 Phosphorothioate oligodeoxynucleotides distribute similarly in class A scavenger receptor knockout and wild-type mice  
 AUTHOR(S): Butler, Madeline; Crocke, Rosanne M.; Graham, Mark J.; Lemtridis, Kristina M.; Loughheed, Marilee; Murray, Susan F.; Witchell, Donna; Steinbrecher, Urs; Bennett, C. Frank  
 LOCATION: ISIS Pharmaceuticals, Carlsbad, CA, USA



Therapeutics

SECTION:

CA11100 Pharmacology

IDENTIFIERS: phosphorothioate oligodeoxynucleotide tissue distribution  
scavenger receptor

DESCRIPTORS:

Peritoneum...

macrophage; phosphorothioate oligodeoxynucleotides distribute similarly  
in class A scavenger receptor knockout and wild-type mice

Macrophage...

peritoneal; phosphorothioate oligodeoxynucleotides distribute similarly  
in class A scavenger receptor knockout and wild-type mice

Antisense oligonucleotides... Kidney... Liver... Lung... Macrophage...

Phosphorothioate oligodeoxyribonucleotides... Scavenger receptors... Spleen

...

phosphorothioate oligodeoxynucleotides distribute similarly in class A  
scavenger receptor knockout and wild-type mice

CAS REGISTRY NUMBERS:

136116-43-8 138330-98-0 141442-18-6 155362-55-3 175333-07-5

185219-68-9 phosphorothioate oligodeoxynucleotides distribute

similarly in class A scavenger receptor knockout and wild-type mice

7/7/2 (Item 2 from file: 399)

DIALOG(F)File 399:CA SEARCH(F)

(c) 2000 American Chemical Society. All rts. reserv.

132089321 CA: 132(6)69321s PATENT

Oligonucleotides for enhanced modulation of protein kinase C expression

INVENTOR(AUTHOR): Bennett, C. Frank; Dean, Nicholas M.

LOCATION: USA

ASSIGNEE: Isis Pharmaceuticals, Inc.

PATENT: PCT International ; WO 9965502 A1 DATE: 19991223

APPLICATION: WO 99US13451 (19990615) \*US 94714 (19980615)

PAGES: 57 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-031/70A;

A61K-048/00B; C07H-021/00B; C07H-021/02B; C07H-021/04B

DESIGNATED COUNTRIES: AE; AL; AM; AT; AU; AZ; BA; BB; BG; BF; BY; CA; CH;  
CN; CU; CZ; DE; DK; EE; ES; FI; GB; GD; GE; GH; GM; HP; HU; ID; IL; IN; IS;  
JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MD; MG; MK; MN; MW; MX;  
NO; NZ; PL; PT; PO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; UA; UG; US;  
UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; ML; RU; TJ; TM

DESIGNATED REGIONAL: GH; GM; KE; LS; MW; SD; SL; SS; UG; ZW; AT; BE; CH;  
CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG;  
CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

SECTION:

CA263006 Pharmaceuticals

CA201XXX Pharmacology

CA23XXXX Carbohydrates

IDENTIFIERS: antisense oligonucleotide sequence protein kinase C

DESCRIPTORS:

Animal tissue culture... Antisense oligonucleotides... Antitumor agents...

Anti-inflammatory agents... DNA sequences... Drug delivery systems...

Nucleic acid hybridization... Phosphorothioate oligonucleotides...

Psoriasis...

antisense oligonucleotides for enhanced modulation of protein kinase C  
expression

Lung,neoplasm...

carcinoma, inhibitors; antisense oligonucleotides for enhanced  
modulation of protein kinase C expression

Neuroglia...

glioblastoma, inhibitors; antisense oligonucleotides for enhanced  
modulation of protein kinase C expression

Antitumor agents...  
 glioblastoma; antisense oligonucleotides for enhanced modulation of  
 protein kinase C expression  
 Cell proliferation...  
 inhibitors, in hyperproliferative diseases; antisense oligonucleotides  
 for enhanced modulation of protein kinase C expression  
 Antitumor agents...  
 lung carcinoma; antisense oligonucleotides for enhanced modulation of  
 protein kinase C expression  
 mRNA...  
 protein kinase C-specifying; antisense oligonucleotides for enhanced  
 modulation of protein kinase C expression  
 Codons...  
 termination; antisense oligonucleotides for enhanced modulation of  
 protein kinase C expression  
 Genetic element...  
 3'-untranslated region; antisense oligonucleotides for enhanced  
 modulation of protein kinase C expression  
 Genetic element...  
 5'-untranslated region; antisense oligonucleotides for enhanced  
 modulation of protein kinase C expression  
 CAS REGISTRY NUMBERS:  
 93-97-0 784-71-4P 1463-10-1 3736-77-4 10212-20-1P 14983-42-7  
 12423-26-3P 40615-36-9 78842-13-4P 182691-36-1 129935-17-2  
 146954-65-6P 146954-67-8P 146954-76-9P 151879-73-1 163759-49-7P  
 163759-50-0P 163759-94-2P 164910-36-5 164910-37-6 164910-38-7  
 164910-39-8 164910-40-1 164910-41-2 182495-98-3P 182495-99-4P  
 182496-00-0P 182496-01-1P 195397-91-2 250705-05-6 252963-72-7  
 252963-73-8 252963-74-9 252963-75-0 252963-81-8 252963-83-0  
 252963-84-1 252963-86-3 252963-87-4 252963-89-6 252963-90-9  
 252963-91-0 252963-93-2 252963-94-3 252963-95-4 252963-97-6  
 252963-98-7 252963-99-8 252964-01-5 252964-02-6 252964-03-7  
 252964-04-3 252964-07-1 252964-08-2 252964-09-3 252964-10-6  
 252964-12-8 252964-14-0 252964-15-1 252964-17-3 252964-18-4  
 252964-19-5 252964-21-9 252964-22-0 252964-23-1 252964-25-3  
 252964-26-4 252964-27-5 252964-29-7 252964-30-0 252964-31-1  
 252964-32-3 252964-34-4 252964-35-5 252964-37-7 252964-38-8  
 252964-39-9 252964-40-2 252964-41-3 252964-42-4 252964-44-6  
 252964-45-7 252964-46-8 252964-48-0 252964-49-1 252964-50-4  
 252964-52-6 252964-53-7 252964-54-8 252964-55-9 252964-56-0  
 253134-23-5 antisense oligonucleotides for enhanced modulation of  
 protein kinase C expression  
 141436-78-4 inhibitors; antisense oligonucleotides for enhanced modulation  
 of protein kinase C expression  
 139848-39-8 nucleotide sequence; antisense oligonucleotides for enhanced  
 modulation of protein kinase C expression  
 2140-61-6D nucleotides; antisense oligonucleotides for enhanced modulation  
 of protein kinase C expression

7/7/3 (Item 3 from file: 399)  
 DIALOG(F)File 399:CA SEARCH(F)  
 (c) 1999 American Chemical Society. All rts. reserv.

132049021 CA: 132(5)49021r PATENT  
 Antisense modulation of CD71 expression  
 INVENTOR(AUTHOR): Bennett, C. Frank; Cowser, Lex M.  
 LOCATION: USA  
 ASSIGNEE: Isis Pharmaceuticals Inc.  
 PATENT: United States ; US 6004614 A DATE: 19991221  
 APPLICATION: US 161244 (19980925)  
 PAGES: 34 pp. CODEN: USXXAM LANGUAGE: English CLASS: 435375000;  
 C07H-021/04A; C07H-021/02B; C12N-015/11B  
 SECTION:  
 CA211002 Immunochemistry

CA203XXX Biochemical Genetics

IDENTIFIERS: antisense oligonucleotide CD71 inhibition cancer therapy

DESCRIPTORS:

Antisense DNA... Antitumor agents... Drug delivery systems... Transferrin receptors...

antisense modulation of CD71 expression for treating cancer  
oligonucleotides...

antisense; antisense modulation of CD71 expression for treating cancer  
Bladder... Lung, neoplasm...

carcinoma; antisense modulation of CD71 expression for treating cancer  
Disease, animal...

CD71 expression-associ.; antisense modulation of CD71 expression for  
treating cancer  
Drug delivery systems...

colloids; antisense modulation of CD71 expression for treating cancer  
Animal cell... Animal tissue...

human; antisense modulation of CD71 expression for treating cancer  
Carbohydrates, biological studies...

modified moiety; antisense modulation of CD71 expression for treating  
cancer

CAS REGISTRY NUMBERS:

93-97-0 102-09-0 108-24-7 288-83-0 554-01-8 784-71-4 838-07-3  
1463-10-1 3736-77-4 10212-20-1 15181-41-6 78842-13-4 79896-97-2  
93791-88-9 136834-20-3 139460-39-2 146954-76-9P 163759-50-0  
182495-98-3P 182495-99-4P 182496-00-0P 182496-01-1P 204633-63-6P  
252770-65-3P 252770-66-4P 252932-84-6 252932-86-8 252932-87-9  
252932-89-1 252932-91-5 252932-94-3 252933-04-3 252933-11-2  
252933-16-7 252933-17-8 252933-23-6 252933-24-7 252933-25-3  
252933-26-9 252933-27-0 252933-29-2 252933-31-6 252933-32-7  
252933-36-1 252933-37-2 252933-38-3 252933-39-4 252933-40-7  
252933-41-8 252933-42-9 252933-43-0 252933-44-1 252933-45-2  
252933-46-3 252933-47-4 252933-50-9 antisense modulation of CD71  
expression for treating cancer

144-55-8 reactions, antisense modulation of CD71 expression for treating  
cancer

220481-59-4 220481-60-7 244224-62-2 252933-99-6 252934-02-4  
252934-13-7 252934-14-8 252934-15-9 252934-16-0 252934-17-1  
252934-18-2 252934-19-3 252934-20-6 252934-21-7 252934-22-8  
252934-23-9 252934-24-0 252934-25-1 252934-26-2 252934-27-3  
252934-28-4 252934-35-3 252934-42-2 252934-50-2 252934-56-9  
252934-57-9 252934-58-0 252934-60-4 252934-71-7 252934-72-8  
252934-73-9 252934-74-0 252934-75-1 252934-76-2 252934-77-3  
252934-78-4 252934-79-5 252934-80-8 252934-81-9 252934-82-0  
252934-83-1 252934-84-2 252934-85-3 252934-86-4 252934-87-5  
252934-88-6 252934-89-7 252934-90-0 252934-91-1 252934-92-2  
252934-93-3 252934-94-4 252934-95-5 252934-96-6 252934-97-7  
252934-98-8 252934-99-9 252935-00-5 unclaimed nucleotide sequence;

antisense modulation of CD71 expression

252935-01-6 unclaimed sequence; antisense modulation of CD71 expression

7/7 4 (Item 4 from file: 399)

DIALOG(P)File 399:CA SEARCH(R)

(c) 2000 American Chemical Society. All rts. reserv.

132015684 CA: 132015684 PATENT

Compositions and methods for the pulmonary delivery of nucleic acids

INVENTOR(AUTHOR): Bennett, Clarence Frank; Ecker, David J.; Cook, Phillip

Dan

LOCATION: USA

ASSIGNEE: Isis Pharmaceuticals, Inc.

PATENT: PCT International ; WO 990166 A1 DATE: 19991125

APPLICATION: WO 99US11141 (19990520) \*US 82586 (19980511)

PAGES: 90 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12Q-001/68A;

C12N-015/00B; C12N-015/85B; C12N-015/63B; C12N-015/11B; C12P-012/34B;

C07H-021/04B; A61K-048/00B DESIGNATED COUNTRIES: AE; AG; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN; CU; CZ; DE; DK; EE; ES; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; SD; SL; SZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

SECTION:

CA263006 Pharmaceuticals

IDENTIFIERS: nucleic acid pulmonary delivery aerosol nebulization, lung delivery antisense oligonucleotide aerosol

DESCRIPTORS:

Drug delivery systems...

aerosols; compns. and methods for the pulmonary delivery of nucleic acids

Nucleic acids... Peptide nucleic acids... Phosphorothioate oligodeoxyribonucleotides...

antisense; compns. and methods for the pulmonary delivery of nucleic acids

Antisense RNA...

aptamers or mol. decoys; compns. and methods for the pulmonary delivery of nucleic acids

Bronchi...

bronchitis, treatment with antisense oligonucleotides; compns. and methods for the pulmonary delivery of nucleic acids

Gene, animal...

c-Ha-ras, oligonucleotides antisense to; compns. and methods for the pulmonary delivery of nucleic acids

Gene, animal...

c-Ki-ras, oligonucleotides antisense to; compns. and methods for the pulmonary delivery of nucleic acids

Antiasthmatics... Antisense oligonucleotides... Drug delivery systems...

Lung... Pharmacokinetics... Fibrozymes... Tuberculostatics...

compns. and methods for the pulmonary delivery of nucleic acids

Selectins...

E-, oligonucleotides antisense to; compns. and methods for the pulmonary delivery of nucleic acids

Lung, disease...

fibrosis, treatment with antisense oligonucleotides; compns. and methods for the pulmonary delivery of nucleic acids

RNA...

guide, antisense; compns. and methods for the pulmonary delivery of nucleic acids

Cell adhesion molecules...

ICAM-1 (intercellular adhesion mol. 1), oligonucleotides antisense to; compns. and methods for the pulmonary delivery of nucleic acids

Medical goods...

inhalers; compns. and methods for the pulmonary delivery of nucleic acids

Lung, neoplasm...

inhibitors; compns. and methods for the pulmonary delivery of nucleic acids

Antitumor agents...

lung; compns. and methods for the pulmonary delivery of nucleic acids

CD40(antigen)... CD80(antigen)... CD86(antigen)... Cell adhesion molecules

... LFA-3(antigen)... Mycobacterium bovis... Mycobacterium tuberculosis...

Streptococcus pneumoniae...

oligonucleotides antisense to; compns. and methods for the pulmonary delivery of nucleic acids

Cell adhesion molecules...

PECAM-1, oligonucleotides antisense to; compns. and methods for the pulmonary delivery of nucleic acids

Gene, animal...

ras, oligonucleotides antisense to; compns. and methods for the

pulmonary delivery of nucleic acids  
Pneumonia... Rhinovirus...  
treatment with antisense oligonucleotides; compns. and methods for the  
pulmonary delivery of nucleic acids  
Cell adhesion molecules...  
VCAM-1, oligonucleotides antisense to; compns. and methods for the  
pulmonary delivery of nucleic acids  
CAS REGISTRY NUMBERS:  
133320 98-0 195397-89-8 195397-90-1 214841-85-7 215860-95-0  
246519-46-0 250705-05-6 250705-06-7 250705-07-8 250705-62-5  
250755-32-9 compns. and methods for the pulmonary delivery of nucleic  
acids  
141436-78-4 176023-80-2 oligonucleotides antisense to; compns. and  
methods for the pulmonary delivery of nucleic acids  
1463-10-1 22423-26-3P 163759-49-7P 163759-50-0P 163759-94-2P  
132495-98-3P 182495-99-4P 132496-00-0P 132496-01-1P synthesis of  
antisense oligonucleotides; compns. and methods for the pulmonary  
delivery of nucleic acids

7/7-5 (Item 5 from file: 399)  
DIALOG R)File 399:CA SEARCH(R)  
(c) 1990 American Chemical Society. All rts. reserv.

131252589 CA: 131(19)252589d PATENT  
Antisense oligonucleotides against human protein kinase C for diagnostic  
and therapeutic use  
INVENTOR(AUTHOR): Bennett, C. Frank; Dean, Nicholas  
LOCATION: USA  
ASSIGNEE: Isis Pharmaceuticals, Inc.  
PATENT: United States ; US 5959096 A DATE: 19990928  
APPLICATION: US 481066 (19950607) \*US 852852 (19920316) \*US 88996  
(19910709)

PAGES: 56 pp., Cont.-in-part of U.S. 5,703,054. CODEN: USXXAM  
LANGUAGE: English CLASS: 536024500; C07H-021/04A; C12Q-001/63B  
SECTION:

CA231012 Pharmacology  
CA238XXX Biochemical Methods  
CA238XXX Carbohydrates  
CA268XXX Pharmaceuticals

IDENTIFIERS: antisense oligonucleotide protein kinase C therapeutic,  
diagnosis antisense oligonucleotide protein kinase C

DESCRIPTORS:  
Lung carcinoma inhibitors...  
adenocarcinoma; antisense oligonucleotides against human protein kinase  
C for diagnostic and therapeutic use  
Antisense oligonucleotides... Bladder carcinoma inhibitors... Breast  
carcinoma inhibitors... Colon carcinoma inhibitors... Drug delivery systems  
... Glioblastoma inhibitors... mRNA... Phosphorothioate oligonucleotides...  
antisense oligonucleotides against human protein kinase C for  
diagnostic and therapeutic use  
Lung adenocarcinoma...  
inhibitors; antisense oligonucleotides against human protein kinase C  
for diagnostic and therapeutic use  
Adenocarcinoma inhibitors...  
lung; antisense oligonucleotides against human protein kinase C for  
diagnostic and therapeutic use

CAS REGISTRY NUMBERS:  
784-71-4P 136834-22-5P 141436-78-4 151879-72-0P 151879-73-1P  
151879-74-2P 151879-75-3P 151879-76-4P 151879-77-5P 151879-78-6P  
151879-79-7P 151879-80-0P 151879-81-1P 151879-82-2P 151879-83-3P  
151879-84-4P 151879-85-5P 151879-86-6P 151879-87-7P 151879-88-9P  
151879-89-9P 151879-90-2P 151879-91-3P 151880-11-4P 151880-12-5P  
151880-13-6P 151880-14-7P 151880-15-8P 151880-16-9P 151880-17-0P  
151880-18-1P 151880-19-2P 151880-27-2P 151880-31-8P 160676-03-9P

163665-59-6 163665-60-9 163665-61-0 163665-63-2 163665-64-3  
 163665-65-4 163665-66-5 163665-67-6 163665-68-7 163665-69-8  
 163665-70-1 163665-71-2 163665-72-3 163665-73-4 163665-74-5  
 163665-75-6 163665-76-7 163665-77-8 163665-78-9 163665-79-0  
 163665-80-3 163665-81-4 163665-82-5 163665-83-6 163665-84-7  
 163665-85-8 163665-86-9 163665-87-0 163665-88-1 163665-89-2P  
 163665-90-5P 163665-91-6P 163665-92-7P 163665-93-8P 163665-94-9P  
 163665-95-0P 163665-96-1P 163665-97-2P 163665-98-3P 163665-99-4P  
 163666-00-0P 163666-03-3P 163666-04-4P 163666-05-5P 163666-07-7P  
 163666-09-9P 163666-11-3P 163666-12-4P 163666-13-5P 163666-15-7P  
 163666-16-8P 163666-17-9P 163666-19-1P 163666-20-4P 163666-21-5P  
 163666-22-6P 163666-23-7P 163666-24-8P 163666-25-9P 163666-26-0P  
 163666-27-1P 163666-28-2P 163666-29-3P 163666-30-6P 163666-31-7P  
 163666-32-8P 163666-33-9P 163666-34-0P 163666-35-1P 163666-36-2P  
 163666-37-3P 164910-29-6P 164910-30-9P 164910-31-0P 164910-33-2P  
 164910-34-3P 164910-36-5P 164910-37-6P 164910-38-7P 164910-39-8P  
 164910-40-1P 164910-41-2P 182792-63-2P 201427-01-2P 201427-03-3P  
 201427-03-4P 204720-35-4 218966-89-3P 221134-52-7P 221368-96-3P  
 221368-97-4P 221369-03-5P 221369-07-9P 221369-10-4P 221369-11-5P  
 221369-12-6P 221369-13-7P 221369-14-8P 221369-15-9P 221369-16-0P  
 221369-17-1P 221369-18-2P 221369-19-3P 221369-20-6P 221369-82-0  
 221369-85-3 221369-86-4 221369-87-5 221369-88-6 221369-89-7  
 221369-90-0 221369-91-1 221369-92-2 221369-94-4 221369-95-5  
 221369-96-6 221369-97-7 221369-98-8 221369-99-9 221370-00-0  
 221370-01-0 221370-03-2 221370-05-4 221370-06-5 221370-07-6  
 221370-08-7 221370-09-8 221370-10-1 244771-78-6 antisense  
 oligonucleotides against human protein kinase C for diagnostic and  
 therapeutic use  
 79396-97-2P 136833-95-9P 136834-18-9P 136834-19-0P 136834-20-3P  
 136834-21-4P prepn. and reaction; antisense oligonucleotides against  
 human protein kinase C for diagnostic and therapeutic use  
 93-84-4 358-23-6 3736-77-4 5536-17-4 25512-65-6 40615-36-9 83392-70-1  
 reaction; antisense oligonucleotides against human protein kinase C  
 for diagnostic and therapeutic use  
 245053-57-0 245053-59-2 245053-60-5 245053-61-6 245053-62-7  
 245053-63-8 245053-64-9 245053-65-0 245053-66-1 245053-67-2  
 unclaimed sequence; antisense oligonucleotides against human protein  
 kinase C for diagnostic and therapeutic use

7/7/96 (Item 6 from file: 399)  
 DIALOG(P)File 399:CA SEARCH(P)  
 (c) 1999 American Chemical Society. All rts. reserv.

131115020 CA: 131(10)125020m JOURNAL  
 Antisense oligonucleotides to the epidermal growth factor receptor  
 AUTHOR(S): Witters, Lois; Kumar, Rakesh; Mandal, Mahitosh; Bennett, C.  
 Frank; Miraglia, Loren; Lipton, Allan  
 LOCATION: Department of Medicine, The Milton S. Hershey Medical Center,  
 Hershey, PA, USA  
 JOURNAL: Breast Cancer Res. Treat. DATE: 1999 VOLUME: 53 NUMBER: 1  
 PAGES: 41-50 CODEN: BCTRD6 ISSN: 0167-6806 LANGUAGE: English  
 PUBLISHER: Kluwer Academic Publishers  
 SECTION:  
 CA201006 Pharmacology  
 IDENTIFIERS: antitumor phosphorothioate oligonucleotide EGFP mRNA,  
 antisense oligonucleotide tumor epidermal growth factor  
 DESCRIPTORS:  
 Antisense oligonucleotides... Epidermal growth factor receptors... Lung  
 carcinoma inhibitors... mRNA... Ovarian carcinoma inhibitors...  
 Phosphorothioate oligodeoxyribonucleotides...  
 inhibition of epidermal growth factor receptor expression in tumor  
 cells by antisense phosphorothioate oligodeoxynucleotides  
 CAS REGISTRY NUMBERS:  
 233262-67-4 233262-68-5 233262-70-9 233262-71-0 233262-72-1

233262-74-3 233262-84-5 233262-96-9 233263-28-0 233263-40-6  
233263-55-3 233263-67-7 233263-78-0 233263-96-2 Inhibition of  
epidermal growth factor receptor expression in tumor cells by antisense  
phosphorothioate oligodeoxynucleotides

7/7/7 (item 7 from file: 399;  
DIALOG(R) File 399:CA SEARCH(R)  
(c) 2000 American Chemical Society. All rts. reserv.

131097589 CA: 131(8)97589h PATENT  
Oligonucleotide modulation of protein kinase C  
INVENTOR(AUTHOR): Bennett, C. Frank; Dean, Nicholas  
LOCATION: USA  
ASSIGNEE: Isis Pharmaceuticals, Inc.  
PATENT: United States ; US 5902686 A DATE: 19990713  
APPLICATION: US 664336 (19960614) \*US 852852 (19920316) \*US 83896  
(19910709)  
PAGES: 56 pp., Cont.-in-part of U.S. 5,703,054. CODEN: USXXAM  
LANGUAGE: English CLASS: 514044000; A61K-031/70A; C07H-021/00B  
SECTION:  
CA201006 Pharmacology  
IDENTIFIERS: protein kinase C modulation oligonucleotide therapeutic,  
antitumor antisense oligonucleotide protein kinase C  
DESCRIPTORS:  
Lung carcinoma inhibitors...  
adenocarcinoma; oligonucleotide modulation of protein kinase C  
Lung adenocarcinoma...  
inhibitors; oligonucleotide modulation of protein kinase C  
Adenocarcinoma inhibitors...  
lung; oligonucleotide modulation of protein kinase C  
Antisense oligonucleotides... Bladder carcinoma inhibitors... Breast  
carcinoma inhibitors... Colon carcinoma inhibitors... DNA sequences... Drug  
delivery systems... Glioblastoma inhibitors... Isoenzymes... Lung carcinoma  
inhibitors... Phosphorothioate oligonucleotides...  
oligonucleotide modulation of protein kinase C  
Nucleic acids...  
protein kinase C-encoding; oligonucleotide modulation of protein kinase  
C

CAS REGISTRY NUMBERS:  
141436-78-4 151879-72-0 151879-73-1 151879-74-2 151879-75-3  
151879-76-4 151879-77-5 151879-78-6 151879-79-7 151879-80-0  
151879-81-1 151879-82-2 151879-83-3 151879-84-4 151879-85-5  
151879-86-6 151879-87-7 151879-88-8 151879-89-9 151879-90-2  
151879-91-3 151880-11-4 151880-12-5 151880-13-6 151880-14-7  
151880-15-8 151880-16-9 151880-17-0 151880-18-1 151880-19-2  
151880-27-2 151880-31-8 163665-03-9 163665-39-2 163665-40-5  
163665-41-6 163665-42-7 163665-43-8 163665-44-9 163665-45-0  
163665-46-1 163665-47-2 163665-48-3 163665-49-4 163665-50-7  
163665-51-8 163665-52-9 163665-53-0 163665-54-1 163665-55-2  
163665-56-3 163665-57-4 163665-58-5 163665-89-2 163665-90-5  
163665-91-6 163665-92-7 163665-93-8 163665-94-9 163665-95-0  
163665-96-1 163665-97-2 163665-98-3 163665-99-4 163666-00-0  
163666-03-3 163666-04-4 163666-05-5 163666-07-7 163666-09-9  
163666-11-3 163666-12-4 163666-13-5 163666-15-7 163666-17-8  
163666-19-9 163666-19-1 163666-20-4 163666-21-5 163666-22-6  
163666-23-7 163666-24-8 163666-25-9 163666-26-0 163666-27-1  
163666-28-2 163666-29-3 163666-30-6 163666-31-7 163666-32-8  
163666-33-9 163666-34-0 163666-35-1 163666-36-2 163666-37-3  
164910-29-6 164910-30-9 164910-31-0 164910-33-2 164910-34-3  
164910-36-5 164910-37-6 164910-38-7 164910-39-8 164910-40-1  
164910-41-2 192702-63-2 201427-01-2 201427-02-3 201427-03-4  
221369-05-7 221369-06-3 221369-07-4 221369-08-5 221369-09-9  
221369-10-4 221369-11-5 221369-12-6 221369-13-7 221369-14-8  
221369-15-9 221369-16-0 221369-17-1 221369-18-2 221369-19-3

221369-20-6 221369-83-1 221369-84-2 oligonucleotide modulation of  
protein kinase C  
163665-39-2D 163665-40-5D 163665-41-6D 163665-42-7D 163665-43-8D  
163665-44-9D 163665-45-0D 163665-46-1D 163665-47-2D 163665-48-3D  
163665-49-4D 163665-50-7D 163665-51-8D 163665-52-9D 163665-53-0D  
163665-54-1D 163665-55-2D 163665-56-3D 163665-57-4D 163665-58-5D  
221369-93-1D 221369-94-2D sugar-modified and phosphorothioate  
derivs., oligonucleotide modulation of protein kinase C

7/7/8 (Item 8 from file: 399)  
DIALOG(R) File 399:CA SEARCH(R)  
(c) 2000 American Chemical Society. All rts. reserv.

131068129 CA: 131(6)68129c PATENT  
Antisense oligonucleotides against human protein kinase C, and  
therapeutic use  
INVENTOR(AUTHOR): Bennett, C. Frank; Dean, Nicholas  
LOCATION: USA  
ASSIGNEE: ISIS Pharmaceuticals, Inc.  
PATENT: United States ; US 5916807 A DATE: 19990629  
APPLICATION: US 481072 (19950607) \*US 852852 (19920316) \*US 89996  
(19930709)  
PAGES: 54 pp., Cont.-in-part of U.S. 5,703,954. CODEN: USXXAM  
LANGUAGE: English CLASS: 435375000; C07H-021/04A; C12Q-001/68B;  
C12N-015/85B  
SECTION:  
CA201606 Pharmacology  
CA233XXX Carbohydrates  
IDENTIFIERS: human protein kinase C antisense oligonucleotide, isoenzyme  
protein kinase C antisense oligonucleotide, antitumor antisense  
oligonucleotide protein kinase C, therapeutic antisense oligonucleotide  
protein kinase C  
DESCRIPTORS:  
Lung carcinoma inhibitors...  
adenocarcinoma; antisense oligonucleotides against human protein kinase  
C, and therapeutic use  
Bladder carcinoma inhibitors... Breast carcinoma inhibitors... Colon  
carcinoma inhibitors... DNA sequences... Glioblastoma inhibitors...  
antisense oligonucleotides against human protein kinase C, and  
therapeutic use  
Antisense oligonucleotides...  
including chimeric antisense oligonucleotides; antisense  
oligonucleotides against human protein kinase C, and therapeutic use  
Lung adenocarcinoma...  
inhibitors; antisense oligonucleotides against human protein kinase C,  
and therapeutic use  
Adenocarcinoma inhibitors...  
lung; antisense oligonucleotides against human protein kinase C, and  
therapeutic use

CAS REGISTRY NUMBERS:  
784-71-4F 136834-22-5P 141436-78-4 151879-72-0P 151879-73-1P  
151879-74-2F 151879-75-3P 151879-76-4F 151879-77-5P 151879-78-6F  
151879-79-7F 151879-80-0P 151879-81-1F 151879-82-2P 151879-83-3F  
151879-84-4P 151879-85-5P 151879-86-6F 151879-87-7P 151879-88-8F  
151879-89-9P 151879-90-2P 151879-91-3P 151880-11-4P 151880-12-5F  
151880-13-6P 151880-14-7P 151880-15-8F 151880-16-9P 151880-17-0F  
151880-18-1P 151880-19-2P 151880-27-2F 151880-31-8P 160676-03-9F  
163665-39-2 163665-40-5 163665-42-7 163665-43-8 163665-44-9  
163665-45-0 163665-46-1 163665-47-2 163665-48-3 163665-49-4  
163665-50-7 163665-51-8 163665-52-9 163665-53-0 163665-54-1  
163665-55-2 163665-56-3 163665-57-4 163665-58-5 163665-59-6  
163665-60-9 163665-61-0 163665-63-2 163665-64-3 163665-65-4  
163665-66-5 163665-67-6 163665-68-7 163665-69-8 163665-70-1  
163665-71-2 163665-72-3 163665-73-4 163665-74-5 163665-75-6



163665-76-7 163665-77-8 163665-78-9 163665-79-0 163665-80-3  
 163665-81-4 163665-82-5 163665-83-6 163665-84-7 163665-85-8  
 163665-86-9 163665-87-0 163665-88-1 163665-89-2P 163665-90-5P  
 163665-91-6P 163665-92-7P 163665-93-8P 163665-94-9P 163665-95-0P  
 163665-96-1P 163665-97-2P 163665-98-3P 163665-99-4P 163665-00-0P  
 163666-03-3P 163666-04-4P 163666-05-5P 163666-07-7P 163666-08-8P  
 163666-11-3P 163666-12-4P 163666-13-5P 163666-15-7P 163666-16-8P  
 163666-17-9P 163666-19-1P 163666-20-4P 163666-21-5P 163666-22-6P  
 163666-23-7P 163666-24-8P 163666-25-9P 163666-26-0P 163666-27-1P  
 163666-28-2P 163666-29-3P 163666-30-6P 163666-31-7P 163666-32-8P  
 163666-33-9P 163666-34-0P 163666-35-1P 163666-36-2P 163666-37-3P  
 164910-29-6P 164910-30-9P 164910-31-0P 164910-33-2P 164910-34-3P  
 164910-36-5P 164910-37-6P 164910-38-7P 164910-39-8P 164910-40-1P  
 164910-41-2P 201427-01-2P 201427-02-3P 201427-03-4P 204720-35-4  
 221369-52-7P 221369-96-3P 221369-97-4P 221369-03-5P 221369-07-9P  
 221369-10-4P 221369-11-5P 221369-12-6P 221369-13-7P 221369-14-8P  
 221369-15-9P 221369-16-0P 221369-17-1P 221369-18-2P 221369-19-3P  
 221369-20-6P 221369-82-0 221369-83-1 221369-84-2 221369-85-3  
 221369-86-4 221369-87-5 221369-88-6 221369-89-7 221369-90-0  
 221369-91-1 221369-92-2 221369-93-3 221369-94-4 221369-95-5  
 221369-96-6 221369-97-7 221369-98-8 221369-99-9 221370-00-9  
 221370-01-0 221370-03-2 221370-05-4 221370-06-5 221370-07-6  
 221370-08-7 221370-09-8 221370-10-1 228852-24-2 228852-25-3  
 228852-26-4 228852-27-5 228852-28-6 228852-29-7 228852-30-0  
 228852-31-1 228852-34-4 228852-55-9 228852-56-0 antisense  
 oligonucleotides against human protein kinase C, and therapeutic use  
 163665-39-2D 163665-40-5D 163665-42-7D 163665-43-8D 163665-44-9D  
 163665-45-0D 163665-46-1D 163665-47-2D 163665-48-3D 163665-49-4D  
 163665-50-7D 163665-51-8D 163665-52-9D 163665-53-0D 163665-54-1D  
 163665-55-2D 163665-56-3D 163665-57-4D 163665-58-5D 163665-59-6D  
 163665-60-9D 163665-61-0D 163665-63-2D 163665-64-3D 163665-65-4D  
 163665-66-5D 163665-67-6D 163665-68-7D 163665-69-8D 163665-70-1D  
 163665-71-2D 163665-72-3D 163665-73-4D 163665-74-5D 163665-75-6D  
 163665-76-7D 163665-77-8D 163665-78-9D 163665-79-0D 163665-80-3D  
 163665-81-4D 163665-82-5D 163665-83-6D 163665-84-7D 163665-85-8D  
 163665-86-9D 163665-87-0D 163665-88-1P 204720-35-4D 221369-82-0D  
 221369-83-1D 221369-84-2D 221369-85-3D 221369-86-4D 221369-87-5D  
 221369-88-6D 221369-89-7D 221369-90-0D 221369-91-1D 221369-92-2D  
 221369-93-3D 221369-94-4D 221369-95-5D 221369-96-6D 221369-97-7D  
 221369-98-8D 221369-99-9D 221370-00-9D 221370-01-0D 221370-03-2D  
 221370-05-4D 221370-06-5D 221370-07-6D 221370-08-7D 221370-09-8D  
 221370-10-1D 228852-24-2D 228852-25-3D 228852-26-4D 228852-27-5D  
 228852-28-6D 228852-29-7D 228852-30-0D 228852-31-1D 228852-34-4D  
 228852-55-9D 228852-56-0D phosphorothioate-linked and modified  
 derivs., antisense oligonucleotides against human protein kinase C, and  
 therapeutic use  
 79896-97-2P 136834-18-9P 136834-20-3P 136834-21-4P prepn. and reaction;  
 antisense oligonucleotides against human protein kinase C, and  
 therapeutic use  
 98-38-4 3736-77-4 5536-17-4 25512-65-6 40615-36-9 89992-70-1  
 136834-19-0 reaction; antisense oligonucleotides against human protein  
 kinase C, and therapeutic use

7/7/93 (Item 9 from file: 399)  
 DIALOG(R) File 399:CA SEARCH(R)  
 (c) 2000 American Chemical Society. All rts. reserv.

131039725 CA: 131(4)39725p PATENT  
 Antisense oligonucleotide inhibition of epidermal growth factor receptor  
 gene expression  
 INVENTOR(AUTHOR): Bennett, C. Frank; Lipton, Allan; Witters, Lois M.  
 LOCATION: USA  
 ASSIGNEE: Isis Pharmaceuticals, Inc.; The Penn State Research Foundation  
 PATENT: United States ; US 5914269 A DATE: 19990622

APPLICATION: US 832658 (19970404)

PAGES: 11 pp. CODEN: SXXAM LANGUAGE: English CLASS: 435375000;

007H-021/04A; A61K-048/00B

SECTION:

CA201006 Pharmacology

CA203XXX Biochemical Genetics

CA214XXX Mammalian Pathological Biochemistry

IDENTIFIERS: antisense oligonucleotide EGFR gene expression inhibition

DESCRIPTORS:

Proliferation inhibition...

after antisense oligonucleotide treatment of SKOV3 cells; antisense oligonucleotide inhibition of epidermal growth factor receptor gene expression

Antisense oligonucleotides... Phosphorothioate oligodeoxyribonucleotides...

antisense oligonucleotide inhibition of epidermal growth factor receptor gene expression

Antitumor agents...

antisense oligonucleotides as; antisense oligonucleotide inhibition of epidermal growth factor receptor gene expression

Tumors (animal)...

assocd. with EGFR overexpression; antisense oligonucleotide inhibition of epidermal growth factor receptor gene expression

Genes (animal)...

c-erbB; antisense oligonucleotide inhibition of epidermal growth factor receptor gene expression

Epidermal growth factor receptors...

EGFR, antisense oligonucleotides caused redn. of prodn. of; antisense oligonucleotide inhibition of epidermal growth factor receptor gene expression

mRNA...

EGFR, redn. of; antisense oligonucleotide inhibition of epidermal growth factor receptor gene expression

A549 cell...

human lung carcinoma, EGFR/c-erbB gene expression in; antisense oligonucleotide inhibition of epidermal growth factor receptor gene expression

Gene expression...

of c-erbB, antisense inhibition of; antisense oligonucleotide inhibition of epidermal growth factor receptor gene expression

Animal cell line...

SKOV3, ovarian carcinoma, EGFR/c-erbB gene expression in; antisense oligonucleotide inhibition of epidermal growth factor receptor gene expression

CAS REGISTRY NUMBERS:

227305-76-2 EGFR antisense oligonucleotide, ISIS10560; antisense oligonucleotide inhibition of epidermal growth factor receptor gene expression

227305-82-1 EGFR antisense oligonucleotide, ISIS10561; antisense oligonucleotide inhibition of epidermal growth factor receptor gene expression

227305-91-1 EGFR antisense oligonucleotide, ISIS10562; antisense oligonucleotide inhibition of epidermal growth factor receptor gene expression

227305-99-9 EGFR antisense oligonucleotide, ISIS10563; antisense oligonucleotide inhibition of epidermal growth factor receptor gene expression

227306-08-3 EGFR antisense oligonucleotide, ISIS10564; antisense oligonucleotide inhibition of epidermal growth factor receptor gene expression

227306-16-3 EGFR antisense oligonucleotide, ISIS10565; antisense oligonucleotide inhibition of epidermal growth factor receptor gene expression

140028-86-0 148087-61-0 nucleotide sequence; antisense oligonucleotide inhibition of epidermal growth factor receptor gene expression

554-01-8 oligonucleotide in which every cytosine residue replaced by;

antisense oligonucleotide inhibition of epidermal growth factor  
receptor gene expression

7/7/10 (Item 10 from file: 399)  
DIALOG(R)File 399:CA SEAPCH(R)  
(c) 2000 American Chemical Society. All rts. reserv.

130247054 CA: 130(19)247054a PATENT  
Antisense oligonucleotide inhibition of protein kinase C  
INVENTOR(AUTHOR): Bennett, C. Frank; Dean, Nicholas  
LOCATION: USA  
ASSIGNEE: Isis Pharmaceuticals, Inc.  
PATENT: United States ; US 5882927 A DATE: 19990316  
APPLICATION: US 478178 (19950607) \*US 852852 (19920316) \*US 89996  
(19910709)  
PAGES: 56 pp., Cont.-in-part of U.S. 5,703,054. CODEN: USXXAM  
LANGUAGE: English CLASS: 435375000; C12Q-001/66A; C12N-015/85B;  
C07H-021/04B  
SECTION:  
CA201012 Pharmacology  
IDENTIFIERS: protein kinase C disease antisense oligonucleotide  
DESCRIPTORS:  
Antisense oligonucleotides... Antitumor agents... Breast carcinoma  
inhibitors... Chemotherapy... Colon tumor inhibitors... Glioblastoma  
inhibitors... Lung carcinoma inhibitors... Lung tumor inhibitors...  
Antisense oligonucleotide inhibition of protein kinase C  
Phosphorothioate oligodeoxyribonucleotides...  
Antisense; antisense oligonucleotide inhibition of protein kinase C  
Antitumor agents...  
Bladder; antisense oligonucleotide inhibition of protein kinase C  
Bladder tumors...  
inhibitors; antisense oligonucleotide inhibition of protein kinase C  
Gene expression...  
modulation of; antisense oligonucleotide inhibition of protein kinase C  
DNA sequences...  
of oligos; antisense oligonucleotide inhibition of protein kinase C  
CAS REGISTRY NUMBERS:  
151879-72-0 151879-73-1 151879-74-2 151879-76-4 151879-80-0  
151879-81-1 151879-82-2 151879-83-3 151879-84-4 151879-85-5  
151879-86-6 151879-87-7 151879-88-8 151879-89-9 151879-90-2  
151879-91-3 151880-27-2 151880-31-8 160676-03-9 164910-29-6  
164910-30-9 164910-31-0 164910-32-1 164910-33-2 164910-34-3  
164910-35-4 164910-36-5 164910-37-6 164910-38-7 164910-39-8  
164910-40-1 164910-41-2 201427-01-2 201427-02-3 201427-03-4  
antisense oligo targeted to PKC-.alpha.; antisense oligonucleotide  
inhibition of protein kinase C  
221369-96-3 221369-97-4 221369-98-5 221369-99-9 221369-10-4  
221369-11-5 221369-12-6 221369-13-7 221369-14-8 221369-15-9  
221369-16-0 221369-17-1 221369-18-2 221369-19-3 221369-20-6  
antisense oligo targeted to PKC-.delta.; antisense oligonucleotide  
inhibition of protein kinase C  
163666-20-4 163666-21-5 163666-22-6 163666-23-7 163666-24-8  
163666-25-9 163666-26-0 163666-27-1 163666-28-2 163666-29-3  
163666-30-6 163666-31-7 163666-32-8 163666-33-9 163666-34-0  
163666-35-1 163666-36-2 163666-37-3 221181-02-9 221181-03-9  
221181-04-0 221181-08-4 221181-11-9 221181-14-2 221181-16-4  
221181-17-5 221181-18-6 221181-19-7 antisense oligo targeted to  
PKC-.epsilon.; antisense oligonucleotide inhibition of protein kinase C  
151880-11-4 151880-12-5 151880-13-6 151880-14-7 151880-15-8  
151880-16-9 151880-17-0 151880-18-1 151880-19-2 163665-89-2  
163665-90-5 163665-91-6 163665-92-7 163665-93-8 163665-94-9  
163665-95-0 163665-96-1 163665-97-2 antisense oligo targeted to  
PKC-.eta.; antisense oligonucleotide inhibition of protein kinase C  
163665-98-3 163665-99-4 163666-00-0 163666-03-3 163666-04-4

163666-05-5 163666-07-7 163666-09-9 163666-11-3 163666-12-4  
 163666-13-5 163666-15-7 163666-16-8 163666-17-9 163666-19-1  
 180702-63-2 221184-52-7 antisense oligo targeted to PKC- $\zeta$ .;  
 antisense oligonucleotide inhibition of protein kinase C  
 141436-78-4 antisense oligonucleotide inhibition of protein kinase C  
 784-71-4 3736-77-4 78842-13-4 79896-97-2P 136833-95-9P 136834-18-9P  
 136834-19-0P 136834-20-3P 136834-21-4P 136834-22-5P 146954-75-8P  
 200404-36-0P 221097-88-7P chem. synthesis of 2'-fluoro-modified  
 oligonucleotides; antisense oligonucleotide inhibition of protein  
 kinase C  
 58-61-7 reactions, chem. synthesis of 2'-fluoro-modified oligonucleotides;  
 antisense oligonucleotide inhibition of protein kinase C

7/7/11 (Item 11 from file: 399)  
 DIALOG(P)File 399:CA SEARCH(R)  
 (c) 2000 American Chemical Society. All rts. reserv.

130147031 CA: 130(19)247031r PATENT  
 Antisense oligonucleotides against human protein kinase C  
 INVENTOR(AUTHOR): Bennett, C. Frank; Dean, Nicholas  
 LOCATION: USA  
 ASSIGNEE: Isis Pharmaceuticals, Inc.  
 PATENT: United States ; US 5885970 A DATE: 19990323  
 APPLICATION: US 488177 (19950607) \*US 852852 (19920316) \*US 89996  
 (19930709)  
 PAGES: 55 pp., Cont.-in-part of U.S. 5,703,054. CODEN: USKKAM  
 LANGUAGE: English CLASS: 514044000; A61K-048/00A; C07H-021/04B;  
 C12Q-001/68B; C12N-015/85B  
 SECTION:  
 CASH0006 Pharmacology  
 CASHXXXX Carbohydrates  
 CASHXXXX Pharmaceuticals  
 IDENTIFIERS: antisense oligonucleotide protein kinase C antitumor  
 DESCRIPTORS:  
 Antisense oligonucleotides...  
 alkyl and fluoro-modified; antiproliferative antisense oligonucleotides  
 against human protein kinase C  
 Antiproliferative agents... Antisense oligonucleotides... Antitumor agents  
 ... Bladder tumors... Brain tumor inhibitors... Brain tumors... Breast  
 tumor inhibitors... Breast tumors... cDNA sequences... Colorectal tumors...  
 Liposomes(drug delivery systems)... Lung tumor inhibitors... Lung tumors...  
 Phosphorothioate oligonucleotides... Tumors(animal)...  
 antiproliferative antisense oligonucleotides against human protein  
 kinase C  
 Antitumor agents...  
 bladder; antiproliferative antisense oligonucleotides against human  
 protein kinase C  
 Colon tumor inhibitors...  
 colorectal; antiproliferative antisense oligonucleotides against human  
 protein kinase C  
 Glioblastoma...  
 glioblastoma multiforme; antiproliferative antisense oligonucleotides  
 against human protein kinase C  
 Cell proliferation...  
 hyperproliferative disorders; antiproliferative antisense  
 oligonucleotides against human protein kinase C  
 Bladder tumors... Colorectal tumors...  
 inhibitors; antiproliferative antisense oligonucleotides against human  
 protein kinase C  
 mRNA...  
 oligonucleotides binding protein kinase C-specifying; antiproliferative  
 antisense oligonucleotides against human protein kinase C  
 CAS REGISTRY NUMBERS:  
 151879-72-0 151879-73-1 151879-74-2 151879-75-3 151879-76-4

151879-77-5 151879-78-6 151879-79-7 151879-80-0 151879-81-1  
 151879-82-2 151879-83-3 151879-84-4 151879-85-5 151879-86-6  
 151879-87-7 151879-88-8 151879-89-9 151879-90-0 151879-91-1  
 151880-11-4 151880-12-5 151880-13-6 151880-14-7 151880-15-8  
 151880-16-9 151880-17-0 151880-18-1 151880-19-2 151880-20-3  
 151880-31-8 160676-03-9 163665-39-2P 163665-40-5P 163665-41-6P  
 163665-42-7P 163665-43-8P 163665-44-9P 163665-45-0P 163665-46-1P  
 163665-47-2P 163665-48-3P 163665-49-4P 163665-50-7P 163665-51-8P  
 163665-52-9P 163665-53-0P 163665-54-1P 163665-55-2P 163665-56-3P  
 163665-57-4P 163665-58-5P 163665-59-6P 163665-60-9P 163665-61-0P  
 163665-63-2P 163665-64-3P 163665-65-4P 163665-66-5P 163665-67-6P  
 163665-68-7P 163665-69-8P 163665-70-1P 163665-71-2P 163665-72-3P  
 163665-73-4P 163665-74-5P 163665-75-6P 163665-76-7P 163665-77-8P  
 163665-78-9P 163665-79-0P 163665-80-3P 163665-81-4P 163665-82-5P  
 163665-83-6P 163665-84-7P 163665-85-8P 163665-86-9P 163665-87-0P  
 163665-88-1P 163665-89-2 163665-90-5 163665-91-6 163665-92-7  
 163665-93-8 163665-94-9 163665-95-0 163665-96-1 163665-97-2  
 163665-98-3 163665-99-4 163666-00-0 163666-03-3 163666-04-4  
 163666-05-5 163666-07-7 163666-09-9 163666-11-3 163666-12-4  
 163666-13-5 163666-15-7 163666-16-8 163666-17-9 163666-19-1  
 163666-20-4 163666-21-5 163666-22-6 163666-23-7 163666-24-8  
 163666-25-9 163666-26-0 163666-27-1 163666-28-2 163666-29-3  
 163666-30-6 163666-31-7 163666-32-8 163666-33-9 163666-34-0  
 163666-35-1 163666-36-2 163666-37-3 164910-29-6P 164910-30-9P  
 164910-31-0P 164910-32-1P 164910-33-2P 164910-34-3P 164910-35-4P  
 164910-36-5P 164910-37-6P 164910-38-7P 164910-39-8P 164910-40-1P  
 164910-41-2P 182702-63-2 204720-35-4P 221181-02-8 221181-03-9  
 221181-04-0 221181-08-4 221181-11-9 221181-14-2 221181-16-4  
 221181-17-5 221181-18-6 221181-19-7 221184-52-7 221368-96-3  
 221368-97-4 221369-03-5 221369-07-9 221369-10-4 221369-11-5  
 221369-12-6 221369-13-7 221369-14-8 221369-15-9 221369-16-0  
 221369-17-1 221369-18-2 221369-19-3 221369-20-6 221369-82-0P  
 221369-83-1P 221369-84-2P 221369-85-3P 221369-86-4P 221369-87-5P  
 221369-88-6P 221369-89-7P 221369-90-0P 221369-91-1P 221369-92-2P  
 221369-93-3P 221369-94-4P 221369-95-5P 221369-96-6P 221369-97-7P  
 221369-98-8P 221369-99-9P 221370-00-9P 221370-01-0P 221370-03-2P  
 221370-05-4P 221370-06-5P 221370-07-6P 221370-08-7P 221370-09-8P  
 221370-10-1P antiproliferative antisense oligonucleotides against  
 human protein kinase C  
 141436-73-4 oligonucleotides antisense to human; antiproliferative  
 antisense oligonucleotides against human protein kinase C  
 136833-95-9P prepn. and deprotection of; antiproliferative antisense  
 oligonucleotides against human protein kinase C  
 784-71-4P 78842-13-4P 79896-97-2P 136834-18-9P 136834-19-0P  
 136834-20-3P 136834-22-5P 146954-75-8P 200404-36-0P 221897-83-7P  
 prepn. and reaction of; antiproliferative antisense oligonucleotides  
 against human protein kinase C  
 358-13-6 3736-77-4 5536-17-4 89992-70-1 reactant; antiproliferative  
 antisense oligonucleotides against human protein kinase C

7/7-12 (Item 12 from file: 399)  
 DIALOG(R) File 399:CA SEARCH(R)  
 (c) 2000 American Chemical Society. All rts. reserv.

129211701 CA: 129(17)211701z PATENT  
 Antisense oligonucleotide modulation of multidrug resistance-associated  
 protein  
 INVENTOR(AUTHOR): Baracchini, Edgardo; Bennett, C. Frank; Dean, Nicholas  
 M.  
 LOCATION: USA  
 ASSIGNEE: Isis Pharmaceuticals, Inc.  
 PATENT: United States ; US 5801154 A DATE: 19980901  
 APPLICATION: US 835770 (19970408) \*US 136811 (19931018) \*US 628731  
 (19960416)

PAGES: 29 pp. Cont.-part of U. S. Ser. No. 628,731 CODEN: USXXAM  
LANGUAGE: English C S: 514044000; C12N-015/85A; A6 043/00B;  
C12Q-001/08B; C07H-021/04B

SECTION:

CA201000 Pharmacology

IDENTIFIERS: multidrug resistance protein antisense oligonucleotide,  
chemotherapy multidrug resistance antisense oligonucleotide

DESCRIPTORS:

Antitumor agents... Chemotherapy... Multidrug resistance proteins...

Multidrug resistance... Small-cell carcinoma inhibitors(lung)...

antisense oligonucleotide modulation of multidrug resistance-assocd.  
protein

Antisense oligonucleotides...

phosphorothioated and 2'-modified; antisense oligonucleotide modulation  
of multidrug resistance-assocd. protein

Phosphorothioate oligodeoxyribonucleotides...

2'-modified antisense; antisense oligonucleotide modulation of  
multidrug resistance-assocd. protein

CAS REGISTRY NUMBERS:

57-02-7 1463-10-1 22423-26-3P 23214-92-8 163759-49-7P 163759-50-0P  
163759-94-2P 166875-47-4 166875-48-5 166875-49-6 166875-50-9  
166875-51-0 166875-52-1 166875-53-2 166875-54-3 166875-55-4  
166875-56-5 166875-57-6 166875-58-7 166875-59-8 166875-60-1  
166875-61-2 166875-62-3 166875-63-4 166875-64-5 166875-65-6  
166875-66-7 166875-67-8 166875-68-9 166875-69-0 166875-70-3  
166875-71-4 166875-97-4 166875-98-5 166875-99-6 166875-00-2  
182495-98-3P 182495-99-4P 182496-01-1P 212321-35-2 212321-36-3  
212321-37-4 212321-38-5 212321-39-6 212321-40-9 antisense  
oligonucleotide modulation of multidrug resistance-assocd. protein  
166875-79-2D phosphorothioated and 2'-fluoro or 2'-O-Pr or  
2'-O-hexylaminocholesterol derivs., antisense oligonucleotide  
modulation of multidrug resistance-assocd. protein

7/7/13 (Item 13 from file: 399)

DIALOG(P)File 399:CA SEARCH(R)

(c) 2000 American Chemical Society. All rts. reserv.

127283393 CA: 127(20)283393g PATENT

Combinations of drugs with antisense oligonucleotides for treatment of  
proliferative diseases

INVENTOR(AUTHOR): Muller, Marcel; Geiger, Thomas; Altmann, Karl-Heinz;  
Fabbro, Dorian; Dean, Nicholas Mark; Monia, Brett; Bennett, Clarence Frank

LOCATION: Switz.

ASSIGNEE: Novartis A.-G.

PATENT: PCT International ; WO 9732589 A1 DATE: 19970912

APPLICATION: WO 97EP876 (19970224) \*US 612775 (19960307)

PAGES: 108 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-031/70A;  
A61K-031/71B; A61K-031/66B; A61K-031/28B; A61K-045/06B; A61K-031/71B;  
A61K-031/70B; A61K-031/70B; A61K-031/66B; A61K-031/28B

DESIGNATED COUNTRIES: AL; AU; BA; BB; BG; BR; CA; CN; CU; EE; GE; HU;  
IL; IS; JP; KP; KR; LC; LK; LR; LT; LV; MG; MK; MN; MX; NO; NZ; PL; RO; SG;  
SI; SK; TR; TT; UA; UZ; VN; YU; AM; AZ; BY; KG; KE; MD; RU; TJ; TM

DESIGNATED REGIONAL: KE; LS; MW; SD; SZ; UG; AT; BE; CH; DE; DK; ES; FI;  
FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; ML;  
MR; NE; SN; TD; TG

SECTION:

CA263-06 Pharmaceuticals

CA201XXX Pharmacology

CA202XXX Mammalian Hormones

CA215XXX Immunochemistry

IDENTIFIERS: antiproliferative combination drug antisense oligonucleotide  
, antitumor combination antisense oligonucleotide antiproliferative

DESCRIPTORS:

Purine nucleosides...

analogs; combinations of drugs with antisense oligonucleotides for treatment of proliferative diseases

Nutrients...

anti-; combinations of drugs with antisense oligonucleotides for treatment of proliferative diseases

Interferons...

B1B2B3D4; combinations of drugs with antisense oligonucleotides for treatment of proliferative diseases

Alkaloids, biological studies... Alkanesulfonates... Alkylating agents (biological)... Androgens... Angiogenesis inhibitors... Anthracyclines... Antiandrogens... Antiatherosclerotics... Antiestrogens... Antisense oligonucleotides... Antitumor agents... Antitumor antibiotics... Breast tumors... Corticosteroids, biological studies... Differentiation inducers... Enzymes, biological studies... Estrogens... Immunomodulators... Interferon .alpha.... Interferons... Lung carcinoma... Lymphokines... Melanoma inhibitors... Phosphorothioate oligodeoxynucleotides... Progesterins... Prostatic carcinoma... Vaccines...

combinations of drugs with antisense oligonucleotides for treatment of proliferative diseases

Fibrosis... Hyperplasia... Psoriasis...

inhibitors; combinations of drugs with antisense oligonucleotides for treatment of proliferative diseases

Non-small-cell carcinoma inhibitors (lung)...

large-cell carcinoma inhibitors; combinations of drugs with antisense oligonucleotides for treatment of proliferative diseases

Antikodies...

neoplasm-inhibiting; combinations of drugs with antisense oligonucleotides for treatment of proliferative diseases

Mitotic spindle...

poisons; combinations of drugs with antisense oligonucleotides for treatment of proliferative diseases

Diseases (animal)...

proliferative; combinations of drugs with antisense oligonucleotides for treatment of proliferative diseases

Polyamines (nonpolymeric)...

synthesis, inhibitors of; combinations of drugs with antisense oligonucleotides for treatment of proliferative diseases

Alkaloids, biological studies...

vincetaxibine; combinations of drugs with antisense oligonucleotides for treatment of proliferative diseases

CAS REGISTRY NUMBERS:

59-30-3D 289-95-2D 9034-40-6D 51110-01-1D analogs, combinations of drugs with antisense oligonucleotides for treatment of proliferative diseases

50-28-2 biological studies, combinations of drugs with antisense oligonucleotides for treatment of proliferative diseases

50-03-2 50-18-0 50-44-2 50-76-0 50-91-9 51-21-8 52-24-4 53-03-2 53-19-0 55-98-1 55-53-1 57-22-7 58-22-0 59-05-2 68-96-2 76-43-7 84-65-1 125-84-8 127-07-1 147-94-4 148-32-3 154-42-7 302-79-4 305-03-3 320-67-2 520-85-4 566-48-3 595-33-5 671-16-9 865-21-4 878-73-2 4291-63-3 4342-03-4 4891-15-0 9015-68-3 10540-29-1 11056-06-7 13311-84-7 15663-27-1 18378-89-7 18883-66-4 20830-81-3 29787-20-2 33069-62-4 33419-42-0 39800-16-3 41575-94-4 51264-14-3 52128-35-5 53643-48-4 53714-56-0 53910-25-1 56420-45-2 58957-92-9 63531-85-7 65807-02-5 75607-67-9 83150-76-9 88359-04-5 102676-47-1 110942-02-4 112809-51-5 120685-11-2 141436-78-4 143030-47-1 144378-33-6 149281-19-6 149400-88-4 157168-02-0 173458-56-5 196108-31-6 196102-76-8 196102-77-9 196102-78-0 combinations of drugs with antisense oligonucleotides for treatment of proliferative diseases

55-96-7D 60-34-4D 151-56-4D 290-87-9D 4375-07-9D 13010-20-3D derivs., combinations of drugs with antisense oligonucleotides for treatment of proliferative diseases

9026-43-1 9039-48-9 9081-34-9 80449-02-1 141907-41-7 inhibitors; combinations of drugs with antisense oligonucleotides for treatment of

7/7/14 (Item 14 from file: 399)

DIALOG(P)File 399:CA SEARCH(R)

(c) 2000 American Chemical Society. All rts. reserv.

124346749 CA: 124(25)340749s JOURNAL

Role of the intercellular adhesion molecule-1 (ICAM-1) in endotoxin-induced pneumonia evaluated using ICAM-1 antisense oligonucleotides, anti-ICAM-1 monoclonal antibodies, and ICAM-1 mutant mice

AUTHOR(S): Kumasaka, Toshio; Quinlan, William M.; Doyle, Nicholas A.; Condon, Thomas P.; Sligh, James; Takei, Fumio; Beaudet, Arthur L.; Bennett, C. Frank; Doerschuk, Claire M.

LOCATION: Dep. Pediatrics, Indiana Univ., Indianapolis, IN, 46202, USA

JOURNAL: J. Clin. Invest. DATE: 1996 VOLUME: 97 NUMBER: 10 PAGES: 2382-2389 CODEN: JGINAO ISSN: 0021-9738 LANGUAGE: English

SECTION:

CAL15009 Immunochemistry

CAL01XXX Pharmacology

CAL14XXX Mammalian Pathological Biochemistry

IDENTIFIERS: ICAM1 adhesion mol endotoxin pneumonia

DESCRIPTORS:

Neutrophil...

role of ICAM-1 in endotoxin-induced pneumonia and effect on neutrophil migration

Lung...

role of ICAM-1 in endotoxin-induced pneumonia and effect on neutrophil migration in lung

Adhesion, bio-... Antibodies, monoclonal... Deoxyribonucleic acids, complementary, antisense... Glycoproteins, specific or class, ICAM-1 (intercellular adhesion mol. 1)... Pneumonia... Toxins, endo-...

role of ICAM-1 in endotoxin-induced pneumonia evaluated using antisense oligonucleotides, monoclonal antibodies, and mutant mice

7/7/14 (Item 15 from file: 399)

DIALOG(P)File 399:CA SEARCH(R)

(c) 2000 American Chemical Society. All rts. reserv.

123188580 CA: 123(15)188580z PATENT

Oligonucleotide inhibitors of the expression of protein kinase C isoenzyme genes and their therapeutic uses

INVENTOR(AUTHOR): Bennett, C. Frank; Boggs, Russell T.; Dean, Nicholas M.

LOCATION: USA

ASSIGNEE: Isis Pharmaceuticals, Inc.

PATENT: PCT International ; WO 9502069 A1 DATE: 950119

APPLICATION: WO 94US7770 (940708) \*US 89996 (930709) \*US 199779 (940222)

PAGES: 146 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12Q-001/68A;

A61K-048/00B; C07H-021/04B DESIGNATED COUNTRIES: AM; AT; AU; BB; BG; BR; BY; CA; CH; CN; CZ; DE; DK; ES; FI; GB; GE; HU; JP; KE; KG; KP; KR; KZ; LK; LT; LU; LV; MD; MG; MN; MW; NL; NO; NZ; PL; PT; RO; RU; SD; SE; SI; SK; TJ; TT; UA; US; UZ; VN DESIGNATED REGIONAL: KE; MW; SD; AT; BE; CH; DE; DK; ES ; FF; GE; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; ML; MF; NE; SN; TD; TG

SECTION:

CAL11117 Pharmacology

CAL07XXX Enzymes

IDENTIFIERS: protein kinase C inflammation antisense DNA, proliferation inhibitor PKC antisense DNA

DESCRIPTORS:

Nucleotides, oligo-, thiophosphate-linked, biological studies...

antisense DNA to protein kinase C; oligonucleotide inhibitors of expression of protein kinase C genes and their therapeutic uses

Nucleic acid hybridization...



for detection of protein kinase C isoenzyme mRNAs; oligonucleotide inhibitors of expression of protein kinase C genes and their therapeutic uses

Deoxyribonucleic acid sequences...

of protein kinase C.alpha. gene of human; oligonucleotide inhibitors of expression of protein kinase C genes and their therapeutic uses

Deoxyribonucleic acids, complementary, antisense... Gene, animal...

Inflammation inhibitors... Intestine, neoplasm, large, inhibitors...

Lung, neoplasm, inhibitors... Mammary gland, neoplasm, inhibitors... Neoplasm

inhibitors... Neoplasm inhibitors, large intestine... Neoplasm

inhibitors, lung... Neoplasm inhibitors, mammary gland... Neoplasm

inhibitors, skin... Skin, neoplasm, inhibitors...

oligonucleotide inhibitors of expression of protein kinase C genes and their therapeutic uses

Nucleotides, oligo-, O-Me, biological studies... Nucleotides, oligo-,

2'-O-alkyl, biological studies...

phosphorothioate-linked, antisense DNA to protein kinase C;

oligonucleotide inhibitors of expression of protein kinase C genes and their therapeutic uses

Genetic element...

translation start site; oligonucleotide inhibitors of expression of protein kinase C genes and their therapeutic uses

Psoriasis...

treatment of; oligonucleotide inhibitors of expression of protein kinase C genes and their therapeutic uses

Nucleotides, oligo-, biological studies...

2'-fluoro, optionally phosphorothioate-linked, antisense DNA to protein kinase C; oligonucleotide inhibitors of expression of protein kinase C genes and their therapeutic uses

Nucleotides, oligo-, biological studies...

2'-O-Pr, optionally phosphorothioate-linked, antisense DNA to protein kinase C; oligonucleotide inhibitors of expression of protein kinase C genes and their therapeutic uses

#### CAS REGISTRY NUMBERS:

151879-74-2 151880-11-4 151880-12-5 151880-13-6 151880-14-7

151880-15-8 151880-16-9 151880-17-0 151880-18-1 151880-19-2

151880-27-2 162876-14-4 163665-39-2 163665-40-5 163665-41-6

163665-42-7 163665-43-8 163665-44-9 163665-45-0 163665-46-1

163665-47-2 163665-48-3 163665-49-4 163665-50-7 163665-51-8

163665-52-9 163665-53-0 163665-54-1 163665-55-2 163665-56-3

163665-57-4 163665-58-5 163665-59-6 163665-60-9 163665-61-0

163665-62-1 163665-63-2 163665-64-3 163665-65-4 163665-66-5

163665-67-6 163665-68-7 163665-69-8 163665-70-1 163665-71-2

163665-72-3 163665-73-4 163665-74-5 163665-75-6 163665-76-7

163665-77-8 163665-78-9 163665-79-0 163665-80-3 163665-81-4

163665-82-5 163665-83-6 163665-84-7 163665-85-8 163665-86-9

163665-87-0 163665-88-1 163665-89-2 163665-90-5 163665-91-6

163665-92-7 163665-93-8 163665-94-9 163665-95-0 163665-96-1

163665-97-2 163665-98-3 163665-99-4 163666-00-0 163666-01-1

163666-02-2 163666-03-3 163666-04-4 163666-05-5 163666-06-6

163666-07-7 163666-08-8 163666-09-9 163666-10-2 163666-11-3

163666-12-4 163666-13-5 163666-14-6 163666-15-7 163666-16-8

163666-17-9 163666-18-0 163666-19-1 163666-20-4 163666-21-5

163666-22-6 163666-23-7 163666-24-8 163666-25-9 163666-26-0

163666-27-1 163666-28-2 163666-29-3 163666-30-6 163666-31-7

163666-32-8 163666-33-9 163666-34-0 163666-35-1 163666-36-2

163666-37-3 163666-38-4 163666-39-5 163666-40-8 163666-41-9

163666-42-0 163666-43-1 163666-44-2 163666-45-3 163666-46-4

163666-47-5 163666-48-6 164910-29-6 164910-30-9 164910-31-0

164910-32-1 164910-33-2 164910-34-3 164910-35-4 164910-36-5

164910-37-6 164910-38-7 164910-39-8 164910-40-1 164910-41-2

nucleotide sequence; oligonucleotide inhibitors of expression of protein kinase C genes and their therapeutic uses

141436-78-4 oligonucleotide inhibitors of expression of protein kinase C genes and their therapeutic uses

7/7/16 (Item 16 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2000 American Chemical Society. All rts. reserv.

123132892 CA: 123(11)132892k PATENT  
Oligonucleotide modulation of multidrug resistance-associated protein  
INVENTOR(AUTHOR): Baracchini, Edgardo, Jr.; Bennett, Clarence Frank  
LOCATION: USA  
ASSIGNEE: ISIS Pharmaceuticals, Inc.  
PATENT: PCT International ; WO 9510938 A1 DATE: 950427  
APPLICATION: WO 94US10827 (940923) \*US 136811 (931018)  
PAGES: 36 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A01N-043/04A;  
A61K-031/70B; C07H-017/00B DESIGNATED COUNTRIES: AM; AU; BB; BG; BR; BY;  
CA; CN; CZ; FI; GE; HU; JP; KE; KG; KP; KR; KZ; LK; LT; LV; MD; MG; MN; MW;  
NO; NZ; PL; PO; RU; SD; SI; SK; TJ; TT; UA; US; UZ; VN  
DESIGNATED REGIONAL: KE; MW; SD; SZ; AT; BE; CH; DE; DK; ES; FR; GB; GR;  
IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; ML; MR; NE; SN;  
TD; TG

SECTION:  
CA201012 Pharmacology  
IDENTIFIERS: antisense oligonucleotide multidrug resistance protein MRP,  
cancer chemotherapy multidrug resistance oligonucleotide

DESCRIPTORS:  
Nucleotides,oligo-, deoxyribo-,biological studies... Nucleotides,oligo-,  
deoxyribo-, thiophosphate-linked,biological studies...  
antisense; oligonucleotide modulation of multidrug resistance-assocd.  
protein  
Proteins,specific or class...  
multidrug resistance-assocd.; oligonucleotide modulation of multidrug  
resistance-assocd. protein  
Drug resistance,multi-... Lung,neoplasm, small-cell carcinoma... Neoplasm  
inhibitors... Neoplasm...

oligonucleotide modulation of multidrug resistance-assocd. protein  
CAS REGISTRY NUMBERS:  
166875-47-4P 166875-48-5P 166875-49-6P 166875-50-9P 166875-51-0P  
166875-52-1P 166875-53-2P 166875-54-3P 166875-55-4P 166875-56-5P  
166875-57-6P 166875-58-7P 166875-59-8P 166875-60-1P 166875-61-2P  
166875-62-3P 166875-63-4P 166875-64-5P 166875-65-6P 166875-66-7P  
166875-67-8P 166875-68-9P 166875-69-0P 166875-70-3P 166875-71-4P  
166875-72-5P 166875-73-6P 166875-74-7P 166875-75-8P 166875-76-9P  
166875-77-0P 166875-78-1P 166875-79-2P 166875-80-5P 166875-81-6P  
166875-82-7P 166875-83-8P 166875-84-9P 166875-85-0P 166875-86-1P  
166875-87-2P 166875-88-3P 166875-89-4P 166875-90-7P 166875-91-8P  
166875-92-9P 166875-93-0P 166875-94-1P 166875-95-2P 166875-96-3P  
166875-97-4P 166875-98-5P 166875-99-6P 166876-00-2P oligonucleotide  
modulation of multidrug resistance-assocd. protein

7/7/17 (Item 17 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2000 American Chemical Society. All rts. reserv.

121099747 CA: 121(9)99747a JOURNAL  
Inhibition of protein kinase C-.alpha. expression in human A549 cells by  
antisense oligonucleotides inhibits induction of intercellular adhesion  
molecule 1 (ICAM-1) mRNA by phorbol esters  
AUTHOR(S): Dean, Nicholas M.; McKay, Robert; Condon, Thomas P.; Bennett,  
C. Frank  
LOCATION: Dep. Mol. Cell. Biol., ISIS Pharm., Carlsbad, CA, 92008, USA  
JOURNAL: J. Biol. Chem. DATE: 1994 VOLUME: 269 NUMBER: 23 PAGES:  
16416-24 CODEN: JBCHA3 ISSN: 0021-9258 LANGUAGE: English  
SECTION:  
CA201012 Pharmacology

CA213XXX Mammalian Biochemistry

IDENTIFIERS: protein kinase C alpha antisense oligonucleotide

DESCRIPTORS:

Nucleotides, oligo-, deoxyribo-, biological studies...

antisense; ICAM-1 and proteins kinase C-.alpha. expression response to, in human lung carcinoma cells

Glycoproteins, specific or class, ICAM-1 (intercellular adhesion mol. 1)... expression of, proteins kinase C-.alpha. mediation of phorbol ester-induced changes in, in human lung carcinoma cells

CAS REGISTRY NUMBERS:

141436-78-4 .alpha., expression of, antisense phosphorothioate oligonucleotides inhibition of, in human lung carcinoma cells

151978-90-2 fICAM-1 and proteins kinase C-.alpha. expression response to, in human lung carcinoma cells

151879-72-0 151879-73-1 151879-74-2 151879-75-3 151879-76-4

151879-77-5 151879-78-6 151879-79-7 151879-80-0 151879-81-1

151879-82-2 151879-83-3 151879-84-4 151879-85-5 151879-86-6

151879-87-7 151879-88-8 151879-89-9 151879-91-3 ICAM-1 and proteins kinase C-.alpha. expression response to, in human lung carcinoma cells

9050-76-4 protein kinase C inhibition by phosphorothioate oligodeoxynucleotides in relation to

Ends

Set	Items	Description
S1	6596	(PULMONARY OR LUNG OR AEFOSOL OR AEROSOLIZE OR INHALATE OR INHALATION) AND (OLIGONUCLEOTIDE OR VECTOR OR ANTISENSE OR RI-BOZYME)
S2	13	AU="BENNETT, CLARENCE F." OR AU="BENNETT, CLARENCE FRANK"
S3	116	AU="BENNETT, C. F." OR AU="BENNETT, C. FRANK"
S4	129	S2 OR S3
S5	123	FD (unique items)
S6	17	S1 AND S5
S7	17	FD (unique items)
? s s1 and nebulizer		

6596 S1

3242 NEBULIZER

S8 13 S1 AND NEBULIZER

End

...completed examining records

S9 11 FD (unique items)

? s s9 not s6

11 S9

17 S6

S10 11 S9 NOT S6

? t s10/7/1-11

10/7/1 (Item 1 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

c) format only 2000 Dialog Corporation. All rts. reserv.

09543419 98281072

**Aerosol** delivery of lipid:DNA complexes to lungs of rhesus monkeys.

McDonald RJ; Liggitt HD; Roche L; Nguyen HT; Pearlman R; Faabe OG; Bussey LB; Gorman CM

University of California, Department of Pediatrics and California Regional Primate Research Center, Davis 95616, USA.

Pharmaceutical research (UNITED STATES) May 1998, 15 (5) p671-9, ISSN 0724-8741 Journal Code: PHS

Languages: ENGLISH

Document type: JOURNAL ARTICLE

PURPOSE: The potential use of **aerosol** delivery for non-viral gene therapy was tested by nebulization of lipid:DNA complexes to the lungs of rhesus monkeys. METHODS: Four female rhesus monkeys were dosed with lipid:DNA formulations via **aerosol inhalation**, where the DNA coded for the human Cystic Fibrosis Transmembrane Conductance Regulator (hCFTR) protein. Delivery of DNA was determined in **lung** samples by polymerase chain reaction (PCR) by qualitative and quantitative methods. Transgene specific messenger RNA was measured by reverse transcriptase PCR (RT-PCR) and protein expression and localization were evaluated by immunohistochemistry (IHC). RESULTS: Approximately four mg of DNA, complexed with cationic lipid 1,2-dimyristoyl-sn-glycero-3-ethylphosphatidylcholine (EDMPC) and cholesterol were delivered to the lungs of animals by airjet **nebulizer**. Three days after dosing, tissue samples from the **lung** were collected and shown to have **vector** specific DNA, RNA and the presence of CFTR protein. Specifically, the hCFTR protein was distributed widely, although non-uniformly, throughout airway epithelium being located on the apical surface of epithelial cells. Importantly, no adverse clinical effects were observed and the lungs showed no histological abnormalities or signs of acute inflammation. CONCLUSIONS: This study shows that lipid:DNA formulations based on EDMPC and cholesterol can be administered to primates by nebulization resulting in measurable expression of the hCFTR protein. The absence of inflammation is also encouraging and such systems may have utility for delivery of genes to the lungs for the treatment of a variety of **pulmonary** diseases including cystic fibrosis.

10/7/2 (Item 2 from file: 155)  
DIALOG(R) File 155:MEDLINE(R)  
(c) format only 2000 Dialog Corporation. All rts. reserv.

09403746 98117445

Aerosolization of cationic lipid:pDNA complexes--in vitro optimization of **nebulizer** parameters for human clinical studies.

Eastman SJ; Tousignant JD; Lukason MJ; Chu Q; Cheng SH; Scheule PK  
Genzyme Corporation, Framingham, MA 01701-9322, USA.

Human gene therapy (UNITED STATES) Jan 1 1998, 9 (1) p43-52, ISSN 1043-0342 Journal Code: A12

Languages: ENGLISH

Document type: JOURNAL ARTICLE

Previously, we have described the optimization of the **aerosol** delivery of a nonviral gene therapy **vector** to the lungs of rodents (Eastman et al., 1997b). Although aerosolizing cationic lipid:pDNA complexes into a whole-body exposure chamber resulted in high levels of reporter gene expression in the lungs of BALB/c mice, the conditions employed were not optimal for the delivery of lipid:pDNA complexes to the lungs of human patients. That is, the consumption rate of the material in the **nebulizer**, and thus the delivery time, were very slow and the **aerosol** was delivered in a continuous flow. Here we describe in vitro experiments used to develop a cationic lipid:pDNA **aerosol** with characteristics more suitable for delivery to the lungs of humans, as a necessary prerequisite for conducting a clinical study with human cystic fibrosis patients. Using cascade impactors and all-glass impingers, we have screened several commercially available nebulizers for their ability to deliver intact, respirable, active lipid:pDNA complexes in the shortest time possible, and have identified the Pari LC Jet Plus **nebulizer** as the optimal **nebulizer** that meets these criteria. Using this **nebulizer** in an intermittent mode to mimic breath actuation, consumption rates of approximately 0.6 ml/min of the cationic lipid:pDNA complexes (6 mM cationic lipid:3 mM pDNA) were obtained. The plasmid DNA remained intact and the complexes were shown to maintain activity throughout the nebulization run. Based on measurements of the nebulized dose and the mass median aerodynamic diameter, we calculate a delivered dose of approximately 22 micromol (7.2 mg) of pDNA for each 8 ml of cationic lipid:pDNA complex aerosolized to the lungs of a human patient.

This dose should be sufficient to test the clinical efficacy of cationic lipid-mediated gene delivery for the treatment of cystic fibrosis.

10/7/3 (Item 1 from file: 5)  
DIALOG(R)File 5:BIOSIS Previews(R)  
(c) 2000 BIOSIS. All rts. reserv.

11840791 BIOSIS NO.: 199900086900

Subdivision of the Escherichia coli K-12 genome for sequencing:

Manipulation and DNA sequence of transposable elements introducing unique restriction sites.

AUTHOR: Mahillon Jacques(a); Kirkpatrick Heather A; Kijenski Heidi L; Bloch Craig A; Rode Christopher K; Mayhew George F; Rose Debra J; Plunkett Guy III; Burland Valerie; Blattner Frederick R

AUTHOR ADDRESS: (a)Lab. Genetique Microbienne, Univ. Catholique Louvain, Place Croix Sud 5/12, B-1348 Louvaine-la-N\*\*Belgium

JOURNAL: Gene (Amsterdam) 223 (1-2):p47-54 Nov. 26, 1998

ISSN: 0378-1119

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: A transposon-based method of introducing unique restriction sites was used for subdivision of the Escherichia coli genome into a contiguous series of large non-overlapping segments spanning 2.5 Mb. The segments, sizes ranging from 150 to 250 kb, were isolated from the chromosome using the inserted restriction sites and shotgun cloned into an M13

**vector** for DNA sequencing. These shotgun sizes proved easily manageable, allowing the genomic sequence of E. coli to be completed more efficiently and rapidly than was possible by previously available methods. The 9 bp duplication generated during transposition was used as a tag for accurate splicing of the segments; no further sequence redundancy at the junction sites was needed. The system is applicable to larger genomes even if they are not already well-characterized. We present the technology for segment sequencing, results of applying this method to E. coli, and the sequences of the transposon cassettes.

10/7/4 (Item 2 from file: 5)  
DIALOG(R)File 5:BIOSIS Previews(R)  
(c) 2000 BIOSIS. All rts. reserv.

1112145 BIOSIS NO.: 199799753290

Safety of a single **aerosol** administration of escalating doses of the cationic lipid GL-67/DOPE/DMPE-PEG-5000 formulation to the lungs of normal volunteers.

AUTHOR: Chadwick S L; Kingston H D; Stern M; Cook R M; O'Connor B J; Lukasson M; Balfour R P; Rosenberg M; Cheng S H; Smith A E; Meeker D P; Geddes D M; Alton E W F W(a)

AUTHOR ADDRESS: (a)Ion Transport Unit, Natl. Heart Lung Inst., Manresa Rd., London SW3 6LR\*\*UK

JOURNAL: Gene Therapy 4 (9):p937-942 1997

ISSN: 0969-7128

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: Several groups are assessing the use of cationic lipids for respiratory gene therapy. To date no human data are available regarding the safety of intra-**pulmonary** cationic lipid delivery. In preparation for a trial of **pulmonary** delivery of the CFTR gene, we have assessed the safety of nebulized lipid GL-67/DOPE/DMPE-PEG-5000 (GL-67A), the cationic lipid formulation to be used in this study. Fifteen healthy volunteers were given incremental doses of GL-67A via a Pari LC Jet **nebulizer**, three volunteers in each of five dosing

cohorts with a week interval between cohorts. Markers of safety included clinical assessment, measurement of lung function, chest CT scan, serological testing and analysis of induced sputum. Measurements were taken before administration and at intervals up to 21 days thereafter. No adverse clinical events were seen or any statistically significant changes in spirometry or gas transfer. There were no clinically significant changes in any of the blood parameters and no CT changes were seen. Comparisons of the cellular subpopulations (neutrophils, eosinophils, lymphocytes and macrophages) in induced sputum showed no significant alterations following administration of the GL-67A. This study suggests that a single application of aerosol formulation of GL-67A does not result in clinically detectable changes when given by nebulization, into the lungs of normal volunteers and provides an indication of a lipid dose tolerated in man.

10/7/5 (Item 3 from file: 5)  
DIALOG(R)File 5: BIOSIS Previews(R)  
(c) 2000 BIOSIS. All rts. reserv.

11077001 BIOSIS NO.: 199799698146  
Low bacterial contamination of nebulizers in home treatment of cystic fibrosis patients.  
AUTHOR: Jakobsson B-M; Onnered A-B; Hjelte L(a); Nystrom B  
AUTHOR ADDRESS: (a)Dep. Paediatr., Karolinska Inst., Huddinge Hosp., B 57, 141 86 Huddinge\*\*Sweden  
JOURNAL: Journal of Hospital Infection 36 (3):p201-207 1997  
ISSN: 0195-6701  
RECORD TYPE: Abstract  
LANGUAGE: English

ABSTRACT: Many reports have shown bacterial contamination of nebulizers used by patients with cystic fibrosis (CF) at home. At the Stockholm CF centre we recommend dismantling the equipment, washing, rinsing and drying it after each use, and disinfecting it once daily by boiling water or by 1% acetic acid followed by drying without rinsing. We studied whether patients comply with these recommendations and whether they are sufficient to prevent bacterial contamination. Nebulizers from 49 CF patients were investigated, 21 of whom are chronically colonized with *Pseudomonas aeruginosa* and one with *Burkholderia cepacia*. All patients were visited at home. Thirty-nine patients (79%) disinfected their equipment after the latest use in accordance with our recommendations. Thirty-eight pieces showed no, or only scanty, growth of micro-organisms belonging to the normal oropharyngeal flora. A moderate growth of alpha-streptococci was observed from a further five pieces. Four of these had not been cleaned after the latest **inhalation** occasion, and one was visibly dirty. Pseudomonads were observed from three pieces; two of these had been disinfected by boiling water and one by acetic acid, followed by rinsing in tap water. All three had been inadequately dried. Pseudomonads could not be cultured simultaneously from the sputum of these three patients. In conclusion, most patients comply with our cleaning and disinfection recommendations and these recommendations appear satisfactory in preventing bacterial contamination.

10/7/6 (Item 4 from file: 5)  
DIALOG(R)File 5: BIOSIS Previews(R)  
(c) 2000 BIOSIS. All rts. reserv.

10709301 BIOSIS NO.: 199799306446  
An outbreak of *Burkholderia cepacia* lower respiratory tract infection associated with contaminated albuterol nebulization solution.  
AUTHOR: Feboli A C(a); Koshinski R; Arias K; Marks-Austin K; Stull D  
Stieritzand T L  
AUTHOR ADDRESS: (a)Cooper Hosp./Univ. Med. Cent., Div. Infectious Dis., 401

Haddon Ave., Camden, NJ 08103\*\*USA  
JOURNAL: Infection Control and Hospital Epidemiology (11):p741-743 1996  
ISSN: 0899-823X  
RECORD TYPE: Abstract  
LANGUAGE: English

ABSTRACT: An outbreak of *Burkholderia cepacia* lower respiratory tract colonization and infection occurred in the adult intensive-care units in various geographic locations throughout our hospital. Forty-four patients became colonized or infected over an 11-month period, whereas *B. cepacia* had been isolated from only 13 patients in the preceding 48 months. Environmental cultures revealed the source to be extrinsically contaminated albuterol nebulization solution. Polymerase chain reaction-ribotyping confirmed the genetic relatedness of the *B. cepacia* patient isolates and the contaminated albuterol. After extensive infection control training for the respiratory therapy staff, including attention to nebulization technique, washing and drying the **nebulizer** cup, and good handwashing, there have not been any new cases.

10/7/7 (Item 5 from file: 5)  
DIALOG(R)File 5:BIOSIS Previews(R)  
(c) 2000 BIOSIS. All rts. reserv.

10425532 BIOSIS NO.: 199699046677  
Outbreak of severe *Pseudomonas aeruginosa* respiratory infections due to contaminated nebulizers.  
AUTHOR: Cobben N A M; Drent M(a); Jonkers M; Wouters E F M; Vaneechoutte M; Stokkeringh E E  
AUTHOR ADDRESS: (a)Dep. Pulmonary, Univ. Hospital Maastricht, P.O. Box 5500, 6200 AZ Maastricht\*\*Netherlands  
JOURNAL: Journal of Hospital Infection 33 (1):p63-70 1996  
ISSN: 0195-6701  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

ABSTRACT: During the six months from January-June 1994, 10 cases of severe and 11 of less severe **pulmonary** infection caused by *Pseudomonas aeruginosa* were diagnosed in patients with chronic obstructive airways disease. possible sources were evaluated. *P. aeruginosa* was isolated from four of the 22 nebulizers tested. The relationship of isolates from the patients and nebulizers was confirmed by sero- and phage-typing, and by arbitrarily-primed polymerase chain reaction (AP-PCR). Three types were identified and the distribution of types in patients with severe infection was as follows (one patient had a multiple infection). Type I was isolated from two nebulizers and from sputa, and/or blood and/or bronchial protected specimen brush samples or bronchial lavage fluid from four patients. Type II came from the sputa of three patients and a third **nebulizer**; and type III from sputa and/or blood of four further patients and another **nebulizer**. The data provided evidence for the relation between *P. aeruginosa* as a cause of infection and the contamination of the nebulizers. When **nebulizer** mouthpieces were changed every 24 h and sterilized between patients, no more contamination occurred, and the outbreak ceased.

10/7/8 (Item 6 from file: 5)  
DIALOG(R)File 5:BIOSIS Previews(R)  
(c) 2000 BIOSIS. All rts. reserv.

09318263 BIOSIS NO.: 199497366633  
Studies on the survival of aerosolized bovine rotavirus (UK) and a murine rotavirus.

AUTHOR: Ijaz M K(a); Soltan S A; Alkarmi T; Dar F K; Bhatti A R; Elhag K M  
AUTHOR ADDRESS: (a)Dep. Med. Microbiol., Fac. Med. and Health Sci., United  
Arab Emirates Univ., P.O. Box 17666, Al \*United Arab Emirates  
JOURNAL: Comparative Immunology Microbiology and Infectious Diseases 17 (2  
):p91-98 1994  
ISSN: 0147-9571  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English  
SUMMARY LANGUAGE: English; French

ABSTRACT: The effect of relative humidity (RH) and temperature on the survival of airborne bovine rotavirus UK isolate (BRV-UK) and a murine rotavirus (MRV) was studied. In any one experiment, the virus under test was suspended in tryptose phosphate broth (TPB) supplemented with uranine (physical tracer) and an antifoam, was aerosolized using a Collision **nebulizer** into the rotating drum with the RH at either low (30 +/- 5%), medium (50 +/- 5%) or high (80 +/- 5%) level at 20 +/- 1 degree C. Following a 15-min period of viral **aerosol** stabilization, sequential samples of drum air were collected using an All-Glass Impinger (AGI) for 24 h post-aerosolization. Both of the rotavirus isolates were found to survive best at medium RH level and high RH was found least favorable for the survival of these aerosolized rotaviruses. The survival pattern of aerosolized MRV was found to be the best when compared with survival pattern of all animal and human rotavirus isolates studies performed under aerosolized conditions in our laboratory. The findings of these experiments confirm and extend our previous reports on the survival of other animal and human aerosolized rotaviruses and emphasize the fact that air may be one of the vehicles for their dissemination and could explain why it is difficult to control nosocomial outbreaks of rotavirus gastroenteritis and to keep animal colonies rotavirus-free.

10/7/9 (Item 7 from file: 5)  
DIALOG(R)File 5:BIOSIS Previews(R)  
(c) 1990 BIOSIS. All rts. reserv.

08939698 BIOSIS NO.: 199395125049  
Case-control and **vector** studies on nosocomial acquisition of  
Pseudomonas cepacia in adult patients with cystic fibrosis.  
AUTHOR: Burdge David R(a); Nakielna E M; Noble M A  
AUTHOR ADDRESS: (a)Div. Infectious Dis., Univ. Hosp., Shaughnessy Site,  
3611 4560 Oak St., Vancouver, British Colum  
JOURNAL: Infection Control and Hospital Epidemiology 14 (3):p127-130 1993  
ISSN: 0899-823X  
DOCUMENT TYPE: Article  
RECORD TYPE: Abstract  
LANGUAGE: English

ABSTRACT: Objective: To examine factors associated with nosocomial acquisition of Pseudomonas cepacia in adult patients with cystic fibrosis. Design: A retrospective case-control study of 5 patients with nosocomial acquisition of P. cepacia versus 20 matched controls who failed to develop P. cepacia infection. Selective handwashing, air sampling, and respiratory equipment sampling also were performed. Setting: A university hospital providing tertiary care to 95 adult cystic fibrosis patients. Patients: All patients are adults with known cystic fibrosis. Case definition required multiple negative sputum cultures for P. cepacia prior to and during admission, with a positive sputum culture prior to discharge. Controls had negative sputum cultures for P. cepacia prior to and throughout hospitalization. Controls were matched for age, gender, disease severity, and frequency of hospitalizations. Results: Factors associated with increased risk of nosocomial acquisition of P. cepacia included receiving humidifier or nebulized treatments (50% versus 5%, p=.016, odds ratio=28.5, 95% confidence interval=1.93 to 420.58).



Factors without significance included ward, room, teaching versus nonteaching status, use of steroids, sharing a hospital room with another cystic fibrosis patient, antibiotic use, presence of portocath in situ, or socializing with another individual with cystic fibrosis known to be *P. cepacia*-positive. Air sampling studies failed to demonstrate aerosolization of *P. cepacia* by coughing cystic fibrosis patients over a 1-hour sampling time. Handwashing studies failed to demonstrate *P. cepacia* on hands of cystic fibrosis patients, nurses, or physiotherapists (before or after physiotherapy). Reservoirs from nebulizers consistently grew *P. cepacia* following therapy. Conclusions: Respiratory equipment may be an important source of nosocomial acquisition of *P. cepacia* in adult cystic fibrosis patients.

10/7/10 (Item 1 from file: 399)  
DIALOG(R) File 399:CA SEARCH(R)  
(c) 2000 American Chemical Society. All rts. reserv.

180187193 CA: 130(14)187193h PATENT  
Aqueous aerosol preparations containing biologically active macromolecules and method for their production  
INVENTOR(AUTHOR): Lamche, Herbert; Meade, Christopher John Montague; Zierenberg, Bernd  
LOCATION: Germany,  
ASSIGNEE: Boehringer Ingelheim Pharma KG  
PATENT: PCT International ; WO 9907340 A1 DATE: 19990218  
APPLICATION: WO 98EP4803 (19980731) \*DE 19733651 (19970804)  
PAGES: 39 pp. CODEN: PIXXD2 LANGUAGE: German CLASS: A61K-009/00A;  
A61K-038/28B DESIGNATED COUNTRIES: AU; BG; BR; BY; CA; CN; CZ; EE; HU; ID; IL; JP; KR; KZ; LT; LV; MX; NO; NZ; PL; RO; RU; SG; SI; SK; TR; UA; US; UZ; VN; YU; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: AT; BE; CH ; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE  
SECTION:  
CA263006 Pharmaceuticals  
IDENTIFIERS: biol macromol aerosol nebulizer, protein aerosol nebulizer, insulin aerosol nebulizer, interferon aerosol nebulizer  
DESCRIPTORS:  
Inhalants(drug delivery systems)...  
aerosols; aq. aerosol preps. contg. biol. active macromols.  
Amino acids,biological studies... Annexins... Antisense DNA... Antisense oligonucleotides... Antisense PNA... Biological macromolecules...  
Interferons... Interleukin 10... Interleukin 12... Interleukin 2...  
Interleukins... Lymphotoxin... Peptides,biological studies...  
Proteins(general),biological studies... Spray atomizers... Transcription factors... Tumor necrosis factor .alpha.... Tumor-associated antigen...  
Vaccines... Viscosity...  
aq. aerosol preps. contg. biol. active macromols.  
Cytokines...  
endothelial monocyte-activating polypeptide II; aq. aerosol preps. contg. biol. active macromols.  
Genes(animal)...  
for tumor-assocd. antigens; aq. aerosol preps. contg. biol. active macromols.  
Interferons...  
interferon .omega.; aq. aerosol preps. contg. biol. active macromols.  
Viral infection...  
measles, vaccine for; aq. aerosol preps. contg. biol. active macromols.  
Propellants(sprays and foams)...  
nebulization without use of; aq. aerosol preps. contg. biol. active macromols.  
Hypothalamic hormones...  
orexins; aq. aerosol preps. contg. biol. active macromols.  
Cell adhesion molecules... Interleukin receptors...  
sol.; aq. aerosol preps. contg. biol. active macromols.

Hepatitis...

vaccine for; aq. aerosol preps. contg. biol. active macromols.

CAS REGISTRY NUMBERS:

58-82-2 antagonists, peptides; aq. aerosol preps. contg. biol. active macromols.

9032-64-6 9002-72-6 9007-12-9 9015-71-8 9034-39-3 9054-89-1

11096-26-7 51110-01-1 83869-56-1 115966-23-9 139639-23-9

143011-72-7 169494-85-3 191588-94-0 aq. aerosol preps. contg. biol. active macromols.

56-84-8 56-86-0 147-85-3 9004-10-8 9005-49-6 biological studies, aq. aerosol preps. contg. biol. active macromols.

1377/11 (Item 1 from file: 357)

DIALOG(R) File 357:Derwent Biotechnology Aks

© 2000 Derwent Publ Ltd. All rts. reserv.

0249853 DBA Accession No.: 2000-03143 PATENT

Composition for **pulmonary** delivery useful for treating and diagnosing

**pulmonary** diseases such as asthma, tuberculosis, etc. -

aerosolized nucleic acid used for diagnosis, therapy and gene therapy of **lung** disease, e.g. tuberculosis, bronchitis, pneumonia,

**lung** cancer

AUTHOR: Bennett C F; Ecker D J; Cook P D

CORPORATE SOURCE: Carlsbad, CA, USA.

PATENT ASSIGNEE: Isis-Pharm. 1999

PATENT NUMBER: WO 9960010 PATENT DATE: 19991125 WPI ACCESSION NO.:

2000-062437 (2005)

PRIORITY APPLIC. NO.: US 83585 APPLIC. DATE: 19980521

NATIONAL APPLIC. NO.: WO 99US11214 APPLIC. DATE: 19990520

LANGUAGE: English

ABSTRACT: A pharmaceutical composition used for **pulmonary** delivery of an **oligonucleotide**, is claimed. Also claimed is a means of administering a nucleic acid composition, used for diagnosis or therapy, by aerosolizing the nucleic acid, and introducing it into the **lung** of a mammal. The claims also cover a medical device used to deliver an aerosolized nucleic acid composition. This can be used in gene therapy, and to investigate the role of a gene in the lungs. It can also be used to regulate expression of a gene, and to diagnose and treat asthma, **lung** cancer, tuberculosis, virus infection, **pulmonary** fibrosis, bronchitis and pneumonia. **Pulmonary** delivery of the desired **oligonucleotide** overcomes complications and expense associated with other routes, such as nuclease activity, particularly when using **antisense** oligonucleotides. The **oligonucleotide** preferably has one of the given DNA sequences. The composition is preferably a powder contained in an aqueous medium. It is administered to the lungs using a **nebulizer**. (85pp)

1 ds

Set	Items	Description
S1	6596	(PULMONARY OR LUNG OR AEROSOL OR AEROSOLIZE OF INHALATE OR INHALATION) AND (OLIGONUCLEOTIDE OR VECTOR OR ANTISENSE OR RI-BOZYME)
S2	13	AU="BENNETT, CLARENCE F." OR AU="BENNETT, CLARENCE FRANK"
S3	116	AU="BENNETT, C. F." OR AU="BENNETT, C. FRANK"
S4	129	S2 OR S3
S5	123	RD (unique items)
S6	17	S1 AND S5
S7	17	RD (unique items)
S8	13	S1 AND NEBULIZER
S9	11	RD (unique items)
S10	11	S9 NOT S6
? s s1 and oligonucleotide		

6596 S1  
 67566 OLIGONUCLEOTIDE  
 S11 1308 S1 AND OLIGONUCLEOTIDE  
 ? s s1 and (antisense or ribozyme)  
 6596 S1  
 37681 ANTISENSE  
 7274 RIBOZYME  
 S12 1289 S1 AND (ANTISENSE OR RIBOZYME)  
 ? s s11 and s12

1308 S11  
 1289 S12  
 S13 308 S11 AND S12  
 ? rd

...examined 50 records (50)  
 ...examined 50 records (100)  
 ...examined 50 records (150)  
 ...examined 50 records (200)  
 ...examined 50 records (250)  
 ...examined 50 records (300)  
 ...completed examining records  
 S14 234 PD (unique items)  
 ? ds

Set	Items	Description
S1	6596	(PULMONARY OR LUNG OR AEROSOL OR AEROSOLIZE OR INHALATE OR INHALATION) AND (OLIGONUCLEOTIDE OR VECTOR OR ANTISENSE OR RIBOZYME)
S2	13	AU="BENNETT, CLARENCE F." OR AU="BENNETT, CLARENCE FRANK"
S3	116	AU="BENNETT, C. F." OF AU="BENNETT, C. FRANK"
S4	129	S2 OR S3
S5	123	PD (unique items)
S6	17	S1 AND S5
S7	17	PD (unique items)
S8	13	S1 AND NEBULIZER
S9	11	PD (unique items)
S10	11	S9 NOT S6
S11	1308	S1 AND OLIGONUCLEOTIDE
S12	1289	S1 AND (ANTISENSE OR RIBOZYME)
S13	308	S11 AND S12
S14	234	PD (unique items)

? s s1 and alkoxyalkoxy

6596 S1  
 63 ALKOXYALKOXY  
 S15 0 S1 AND ALKOXYALKOXY  
 ? s s1 and dialkylaminooxyalkyl

6596 S1  
 0 DIALKYLAMINOOXYALKYL  
 S16 0 S1 AND DIALKYLAMINOOXYALKYL  
 ? s s1 and methylenephosphonate

6596 S1  
 325 METHYLENEPHOSPHONATE  
 S17 0 S1 AND METHYLENEPHOSPHONATE  
 ? t s14/5/1-134

14/5/1 (Item 1 from file: 155)  
 DIALOG(R)File 155:MEDLINE(R)  
 (c) format only 2000 Dialog Corporation. All rts. reserv.

10314068 20142210

Lithium activates mammalian Na<sup>+</sup>/H<sup>+</sup> exchangers: isoform specificity and inhibition by genistein.

Kobayashi Y; Pang T; Iwamoto T; Wakabayashi S; Shigekawa M

Department of Molecular Physiology, National Cardiovascular Center Research Institute, Suita, Osaka, Japan.

Pflügers Archiv (GERMANY) Feb 2000, 439 (4) p455-62, ISSN 0031-6768

Journal Code: OZX

Languages: ENGLISH

Document type: JOURNAL ARTICLE

JOURNAL ANNOUNCEMENT: 0005

Subfile: INDEX MEDICUS

Replacement of external NaCl with LiCl induced cytoplasmic alkalinization in OCL-39 cells and rat L6 myoblasts expressing the endogenous Na<sup>+</sup>/H<sup>+</sup> exchanger isoform NHE1. This Li<sup>+</sup>-induced alkalinization is due to activation of the Na<sup>+</sup>/H<sup>+</sup> exchanger because it was completely inhibited by 100 microM ethylisopropylamiloride (apparent K<sub>d</sub>=1 microM) and because it did not occur in exchanger-deficient PS120 cells. The effect of Li<sup>+</sup> was not mimicked by Na<sup>+</sup>, K<sup>+</sup>, Cs<sup>+</sup> and choline<sup>+</sup>. Li<sup>+</sup> caused cytoplasmic alkalinization in PS120 cells expressing NHE1 or NHE2, but not NHE3, when Li<sup>+</sup> was added to cells at a concentration high enough to saturate their external transport sites as predicted from Li<sup>+</sup> affinities. Li<sup>+</sup> did not induce phosphatidylinositol (PI) turnover or intracellular Ca<sup>2+</sup> mobilization. Li<sup>+</sup>-induced alkalinization was not affected by protein kinase C down-regulation, loss of glycogen synthase kinase 3beta caused by antisense oligonucleotide treatment, or pretreatment with calphostin C, pertussis toxin, MEK inhibitor PD98059 and PI3-kinase inhibitor LY294002. However, it was markedly suppressed by the tyrosine kinase inhibitor genistein (10 microM). Thus, externally added Li<sup>+</sup> activates NHE1 and NHE2 via a mechanism possibly involving a tyrosine kinase, causing an increase in cytoplasmic pH that could potentially affect various cell functions.

Tags: Animal; Human; Support, Non-U.S. Gov't

Descriptors: \*Enzyme Inhibitors--Pharmacology--PD; \*Genistein --Pharmacology--PD; \*Isoenzymes--Metabolism--ME; \*Lithium--Pharmacology--PD; \*Sodium-Hydrogen Antiporter--Metabolism--ME; Alkalies--Metabolism--ME; Cells, Cultured; Cricetulus; Cytoplasm--Enzymology--EN; Enzyme Activation --Physiology--PH; Fibroblasts--Cytology--CY; Fibroblasts--Enzymology--EN; Hamsters; Hydrogen--Metabolism--ME; Hydrogen-Ion Concentration; Isoenzymes --Antagonists and Inhibitors--AI; Lung--Cytology--CY; Muscle Fibers --Cytology--CY; Muscle Fibers--Enzymology--EN; Protein-Tyrosine Kinase --Antagonists and Inhibitors--AI; Protein-Tyrosine Kinase--Metabolism--ME; Rats; Skin--Cytology--CY; Sodium--Metabolism--ME; Sodium-Hydrogen Antiporter--Antagonists and Inhibitors--AI; Substrate Specificity CAS Registry No.: 0 (Alkalies); 0 (Enzyme Inhibitors); 0 (Isoenzymes); 0 (Sodium-Hydrogen Antiporter); 1333-74-0 (Hydrogen); 446-72-0 (Genistein); 7439-93-2 (Lithium); 7440-23-5 (Sodium) Enzyme No.: EC 2.7.1.112 (Protein-Tyrosine Kinase)

14/5/2 (Item 2 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(S) format only 2000 Dialog Corporation. All rts. reserv.

10288057 20134519

**Antisense** intercellular adhesion molecule-1 (ICAM-1) oligodeoxynucleotide delivered during organ preservation inhibits posttransplant ICAM-1 expression and reduces primary lung isograft failure.

Toda K; Kayano K; Karimova A; Naka Y; Fujita T; Minamoto K; Wang CY; Pinsky DJ

Columbia University College of Physicians and Surgeons, New York, NY 10032, USA.

Circulation research (UNITED STATES) Feb 4 2000, 86 (2) p166-74,

ISSN 0009-7330 Journal Code: DAJ

Contract/Grant No.: HL55397, HL, NHLBI; R01 HL609 HL, NHLBI

Languages: ENGLISH

Document type: JOURNAL ARTICLE

JOURNAL ANNOUNCEMENT: 0004

Subfile: INDEX MEDICUS

Transiently increased expression of leukocyte adhesion receptors after lung preservation contributes to early graft demise by recruiting leukocytes, activating complement, and causing microcirculatory stasis. We hypothesized that inhibiting intercellular adhesion molecule-1 (ICAM-1) expression even briefly may significantly improve lung graft function and that the preservation period might provide a unique window to deliver a therapeutic pulse of antisense oligonucleotide ICAM-1 to inhibit ICAM-1 expression after transplantation. Interleukin-1beta-treated rat pulmonary endothelial cells given a 20-mer phosphorothioate oligonucleotide comprising an antisense span targeted to the 3'-untranslated region of rat ICAM-1 demonstrated an oligonucleotide dose-dependent reduction in ICAM-1 expression. Using a cationic liposomal carrier, this same antisense oligonucleotide (but not the sense control) instilled into the pulmonary vasculature at the time of preservation reduced subsequent graft ICAM-1 expression and graft leukostasis and markedly improved oxygenation, pulmonary blood flow, and graft survival. These experiments demonstrate that the preservation period presents a window during which to target an anti-ICAM-1 expression strategy to inhibit early adhesion receptor expression and improve functional outcome after lung transplantation.

Tags: Animal; Male; Support, U.S. Gov't, P.H.S.

Descriptors: Graft Survival; \*Intercellular Adhesion Molecule-1--Genetics--GE; \*Lung Transplantation; \*Oligonucleotides, Antisense--Pharmacology--PD; \*Organ Preservation--Methods--MT; Cells, Cultured; Endothelium, Vascular--Cytology--CY; Gene Expression--Genetics--GE; Gene Expression--Physiology--PH; Lung--Cytology--CY; Lung--Enzymology--EN; Lung--Immunology--IM; Microcirculation; Neutrophils--Cytology--CY; Peroxidase--Analysis--AN; Pulmonary Circulation; Rats; Rats, Inbred Lew; RNA, Messenger--Metabolism--ME  
CAS Registry No.: 0 (Oligonucleotides, Antisense); 0 (RNA, Messenger); 136947-89-5 (Intercellular Adhesion Molecule-1)  
Enzyme No.: EC 1.11.1.7 (Peroxidase)

14/5/3 (Item 3 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

© format only 2000 Dialog Corporation. All rts. reserv.

10068610 20025529

Bronchial smooth muscle hypoplasia in mouse embryonic lungs exposed to a laminin beta1 chain antisense oligonucleotide.

Zhang J; O'Shea S; Liu J; Schuger L

Department of Pathology, Wayne State University School of Medicine, Detroit 48201, USA.

Mechanisms of development (IRELAND) Dec 1999, 89 (1-2) p15-23, ISSN 0923-4773 Journal Code: AXF

Contract/Grant No.: HL-48730, HL, NHLBI; NS-21108, NS, NINDS

Languages: ENGLISH

Document type: JOURNAL ARTICLE

JOURNAL ANNOUNCEMENT: 0004

Subfile: INDEX MEDICUS

We used an antisense oligonucleotide (ODN) to inhibit laminin (LM) beta1 chain synthesis in mouse embryonic lung explants and cell cultures. The ODN spanned 17 bases located 13 bases downstream the initiation codon and contained phosphorothioate and C-5 propynyl pyrimidine modifications. Penetration of the ODN into the lung explants was confirmed by fluorescein isothiocyanate (FITC) tagg

<-----User Break----->

ing. 50 microm of

**antisense** ODN decreased LM betal chain synthesis by 82+/-6.9% with no significant changes in the u!  
Oct 14/6/1-134

14/6/1 (Item 1 from file: 155)  
10314068 20142210  
Lithium activates mammalian Na<sup>+</sup>/H<sup>+</sup> exchangers: isoform specificity and inhibition by genistein.  
Feb 2000

14/6/2 (Item 2 from file: 155)  
10383057 20134519  
**Antisense** intercellular adhesion molecule-1 (ICAM-1) oligodeoxynucleotide delivered during organ preservation inhibits posttransplant ICAM-1 expression and reduces primary **lung** isograft failure.  
Feb 4 2000

14/6/3 (Item 3 from file: 155)  
10363610 20025529  
Bronchial smooth muscle hypoplasia in mouse embryonic lungs exposed to a laminin betal chain **antisense oligonucleotide**.  
Dec 1999

14/6/4 (Item 4 from file: 155)  
10328167 20040664  
Antitumor activity and pharmacokinetics of a mixed-backbone **antisense oligonucleotide** targeted to the RIalpha subunit of protein kinase A after oral administration.  
Nov 23 1999

14/6/5 (Item 5 from file: 155)  
10320058 20019523  
Distribution of a 20-mer phosphorothioate **oligonucleotide**, PSP69846A (ISIS 5132), into airway leukocytes and epithelial cells following intratracheal delivery to brown-norway rats.  
Oct 1999

14/6/6 (Item 6 from file: 155)  
10318942 99454783  
Decreasing oncoprotein 18/stathmin levels reduces microtubule catastrophes and increases microtubule polymer in vivo.  
Nov 1999

14/6/7 (Item 7 from file: 155)  
10157114 99429805  
Submucosal gland development in the airway is controlled by lymphoid enhancer binding factor 1 (LEF1).  
Oct 1999

14/6/8 (Item 8 from file: 155)  
10141706 99433900  
Tumor necrosis factor-alpha mediates lipopolysaccharide-induced macrophage inflammatory protein-2 release from alveolar epithelial cells. Autoregulation in host defense.  
Oct 1999

14/6/9 (Item 9 from file: 155)  
10102733 99220912

**Antisense** oligonucleotides to the epidermal growth factor receptor.  
Jan 1999

14/6/10 (Item 10 from file: 155)  
10122173 99111046

Antitumor activity of a C-raf **antisense oligonucleotide** in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice.  
Jul 1997

14/6/11 (Item 11 from file: 155)  
10122110 99108639

Role of protein kinase C in the deficient gap junctional intercellular communication of K-ras-transformed murine **lung** epithelial cells.  
Nov-Dec 1998

14/6/12 (Item 12 from file: 155)  
10116115 99009240

Interleukin-1 beta and reactive oxygen species mediate activation of c-Jun NH2-terminal kinases, in human epithelial cells, by two independent pathways.  
Oct 9 1998

14/6/13 (Item 13 from file: 155)  
10112944 98412956

A new non-viral DNA delivery **vector**: the terplex system.  
Apr 30 1998

14/6/14 (Item 14 from file: 155)  
10062700 99414366

PKCbetaI mediates the inhibition of P2Y receptor-induced inositol phosphate formation in endothelial cells.  
Aug 1999

14/6/15 (Item 15 from file: 155)  
10054510 99431210

Histological localization of acetyltransferases in human tissue.  
Sep 1 1999

14/6/16 (Item 16 from file: 155)  
10040367 99382313

**Oligonucleotide** therapy of allergic asthma.  
Aug 1999

14/6/17 (Item 17 from file: 155)  
09978171 99328945

Adoptively transferred late allergic response is inhibited by IL-4, but not IL-5, **antisense oligonucleotide**.  
Jul 1999

14/6/18 (Item 18 from file: 155)  
09973179 99292452

**Antisense** oligonucleotides against the alpha-subunit of ENaC

decrease **lung** epithelial cation-channel activity.  
Jun 1999

14/6/19 (Item 19 from file: 155)  
09943171 99272474

Expression of nerve growth factor-induced clone B subfamily and pro-opiomelanocortin gene in **lung** cancer cell lines.  
Jun 1999

14/6/20 (Item 20 from file: 155)  
09910074 99231967

**Antisense** bcl-2 treatment increases programmed cell death in non-small cell **lung** cancer cell lines.  
Feb 1999

14/6/21 (Item 21 from file: 155)  
09887014 99144489

Types of purinoceptors and phospholipase A2 involved in the activation of the platelet-activating factor-dependent transacetylase activity and arachidonate release by ATP in endothelial cells.  
Aug 1998

14/6/22 (Item 22 from file: 155)  
09871854 99150456

Mitogen-activated protein kinase **antisense oligonucleotide** inhibits the growth of human **lung** cancer cells.  
Mar 1999

14/6/23 (Item 23 from file: 155)  
09854859 99175483

Conserved function of mSpry-2, a murine homolog of Drosophila sprouty, which negatively modulates respiratory organogenesis.  
Feb 25 1999

14/6/24 (Item 24 from file: 155)  
09777726 99098918

Characterization of a potent and specific class of **antisense oligonucleotide** inhibitor of human protein kinase C-alpha expression.  
Jan 15 1999

14/6/25 (Item 25 from file: 155)  
09622670 98393772

Effects of **antisense oligonucleotide** to iNOS on hemodynamic and vascular changes induced by LPS.  
Sep 1998

14/6/26 (Item 26 from file: 155)  
09550663 98249554

**Pulmonary** bioavailability of a phosphorothioate **oligonucleotide** (CGP 64128A): comparison with other delivery routes.  
Apr 1998

14/6/27 (Item 27 from file: 155)  
09540246 98314902

Human melanoma metastasis is inhibited following ex vivo treatment with an **antisense oligonucleotide** to protein kinase C-alpha.



Jun 5 1998

14/6/28 (Item 28 from file: 155)  
09500765 98186845  
Phosphorothioate oligodeoxyribonucleotides dissociate from cationic lipids before entering the nucleus.  
Apr 15 1998

14/6/29 (Item 29 from file: 155)  
09436117 98243046  
Abrogation of c-Raf expression induces apoptosis in tumor cells.  
Apr 9 1998

14/6/30 (Item 30 from file: 155)  
09434786 98233712  
Monocyte chemoattractant protein-1 synthesis by murine lung fibroblasts modulates CD4+ T cell activation.  
May 1 1998

14/6/31 (Item 31 from file: 155)  
09433921 98175560  
Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production.  
Mar 15 1998

14/6/32 (Item 32 from file: 155)  
09426377 98173032  
Enhanced metastasis of B16 melanoma cells by unexpected elevated expression of the metastasis-associated TI-241 (LRF-1-, Jun-Fos-related) gene treated with **antisense oligonucleotide**.  
Feb 1998

14/6/33 (Item 33 from file: 155)  
09412451 98150982  
Identification of a novel cis-element in the 3'-untranslated region of mammalian peptidylglycine alpha-amidating monooxygenase messenger ribonucleic acid.  
Mar 1998

14/6/34 (Item 34 from file: 155)  
09403180 98134516  
Antitumor activity of a PKC-alpha **antisense oligonucleotide** in combination with standard chemotherapeutic agents against various human tumors transplanted into nude mice.  
Jan 1998

14/6/35 (Item 35 from file: 155)  
09384196 98016240  
Pharmacokinetics and metabolism in mice of a phosphorothioate **oligonucleotide antisense** inhibitor of C-raf-1 kinase expression.  
Nov 1997

14/6/36 (Item 36 from file: 155)  
09358941 98070911

Involvement of hepatocyte growth factor in formation of bronchoalveolar structures in embryonic rat lung in primary culture.  
Dec 8 1997

14/6/37 (Item 37 from file: 155)  
09321362 98027999

Evaluation of the toxicity of ISIS 2302, a phosphorothioate **oligonucleotide**, in a 4-week study in CD-1 mice.  
Oct 1997

14/6/38 (Item 38 from file: 155)  
09221788 97404242

Pharmacokinetics and tissue distribution of a DNA-methyltransferase **antisense** (MT-AS) **oligonucleotide** and its catabolites in tumor-bearing nude mice.  
Aug 1997

14/6/39 (Item 39 from file: 155)  
09220605 97392782

Cloning and sequence analysis of a cDNA for the beta subunit of chicken thyroid-stimulating hormone.  
Aug 1997

14/6/40 (Item 40 from file: 155)  
09176344 97347286

**Antisense** oligonucleotides targeting human protein kinase C-alpha inhibit phorbol ester-induced reduction of bradykinin-evoked calcium mobilization in A549 cells.  
Feb 1997

14/6/41 (Item 41 from file: 155)  
09117379 97272033

Receptor mediation in cannabinoid stimulated arachidonic acid mobilization and anandamide synthesis.  
1997

14/6/42 (Item 42 from file: 155)  
09106586 97256584

Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide **antisense** to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice.  
Apr 1997

14/6/43 (Item 43 from file: 155)  
09075209 97175661

An ICAM-1 **antisense oligonucleotide** prevents and reverses dextran sulfate sodium-induced colitis in mice.  
Feb 1997

14/6/44 (Item 44 from file: 155)  
09074591 97197596

Contiguous four-guanosine sequence in c-myc **antisense** phosphorothioate oligonucleotides inhibits cell growth on human lung cancer cells: possible involvement of cell adhesion inhibition.  
Jan 1997

14/6/45 (Item 45 from file: 155)  
09073970 97190191

Human beta-defensin-1 is a salt-sensitive antitoxic in **lung** that is inactivated in cystic fibrosis.

Feb 21 1997

14/6/46 (Item 46 from file: 155)  
08364777 97194778

Reversible inhibition of IL-8 receptor B mRNA expression and proliferation in non-small cell **lung** cancer by **antisense** oligonucleotides.

Nov-Dec 1996

14/6/47 (Item 47 from file: 155)  
08764184 96357173

Inhibition of growth of human tumor cell lines in nude mice by an **antisense** of **oligonucleotide** inhibitor of protein kinase C-alpha expression.

Aug 1 1996

14/6/48 (Item 48 from file: 155)  
08709324 96215305

Involvement of G protein-coupled receptor kinase 5 in homologous desensitization of the thyrotropin receptor.

Apr 26 1996

14/6/49 (Item 49 from file: 155)  
08696681 95382112

**Antisense** oligonucleotides for PDGF-B and its receptor inhibit mechanical strain-induced fetal **lung** cell growth.

Aug 1995

14/6/50 (Item 50 from file: 155)  
08636339 96191303

Reduction of expression of the multidrug resistance protein (MRP) in human tumor cells by **antisense** phosphorothioate oligonucleotides.

Feb 23 1996

14/6/51 (Item 51 from file: 155)  
08627652 96181716

Mucin mRNA expression in **lung** adenocarcinoma cell lines and tissues.

Mar-Apr 1996

14/6/52 (Item 52 from file: 155)  
08513992 96109328

TTF-1 regulates **lung** epithelial morphogenesis.

Dec 1995

14/6/53 (Item 53 from file: 155)  
08418929 96032511

Expression of transforming growth factor-beta type II receptor in rat **lung** is regulated during development.

Sep 1995

14/6/54 (Item 54 from file: 155)

08394919 95356364

Inhibition of tumor cell metastasis in chick embryo by beta 1 integrin  
antisense oligonucleotide]  
Jul 1995

14/6/55 (Item 55 from file: 155)  
08372669 95328608

Cell and tissue distribution of synthetic oligonucleotides in healthy and tumor-bearing nude mice. An autoradiographic, immunohistological, and direct fluorescence microscopy study.  
Jul 1995

14/6/56 (Item 56 from file: 155)  
03161699 94252235

Expression of high density lipoprotein-binding protein messenger ribonucleic acid in the rat ovary and its regulation by gonadotropin.  
Jun 1994

14/6/57 (Item 57 from file: 155)  
03129661 95190687

Incidence of latent infection of Epstein-Barr virus in lung cancers--an analysis of EBER1 expression in lung cancers by in situ hybridization.  
Dec 1994

14/6/58 (Item 58 from file: 155)  
03012962 94364423

Enhanced metastatic ability of TNF-alpha-treated malignant melanoma cells is reduced by intercellular adhesion molecule-1 (ICAM-1, CD54) antisense oligonucleotides.  
Sep 1994

14/6/59 (Item 59 from file: 155)  
08079908 94266339

Inhibition of protein kinase C-alpha expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters.  
Jun 10 1994

14/6/60 (Item 60 from file: 155)  
07563909 94139576

Differential expression of neurotrophin receptors during renal development.  
Dec 1993

14/6/61 (Item 61 from file: 155)  
07802156 93353620

Endonucleolytic cleavages and DNA-joining activities of the integration protein of human foamy virus.  
Sep 1993

14/6/62 (Item 62 from file: 155)  
07777155 93107074

Molecular cloning of a cDNA encoding the "61-kDa" calmodulin-stimulated cyclic nucleotide phosphodiesterase. Tissue-specific expression of structurally related isoforms.  
Jan 5 1993

14/6/63 (Item 63 from file: 155)  
07676075 94058078

The myc family of oncogenes and their presence and importance in small-cell **lung** carcinoma and other tumour types.  
Sep-Oct 1993

14/6/64 (Item 64 from file: 155)  
07596393 93352845

Glycosylation-dependent cell adhesion molecule 1 (GlyCAM 1) mucin is expressed by lactating mammary gland epithelial cells and is present in milk.  
Aug 1993

14/6/65 (Item 65 from file: 155)  
07933261 93236012

Expression of vascular permeability factor/vascular endothelial growth factor in normal rat tissues.  
Apr 1993

14/6/66 (Item 66 from file: 155)  
0793425 92363936

Molecular cloning of amphiglycan, a novel integral membrane heparan sulfate proteoglycan expressed by epithelial and fibroblastic cells.  
Aug 1992

14/6/67 (Item 67 from file: 155)  
0793158 91107740

Systematic analysis of the ability of stromal cell lines derived from different murine adult tissues to support maintenance of hematopoietic stem cells in vitro.  
Dec 1990

14/6/68 (Item 68 from file: 155)  
0738924 91406290

In vitro effects of drugs on production of mucins in rabbit tracheal epithelial cells expressing mucin gene: a model system for studying upper airway respiratory diseases.  
Aug 1992

14/6/69 (Item 69 from file: 155)  
07279799 93135990

Multiple drug-resistance in variant of a human non-small cell **lung** carcinoma cell line, DLKP-A.  
1992

14/6/70 (Item 70 from file: 155)  
07232477 93357967

Synthetic **antisense oligonucleotide** probes the essentiality of metallothionein gene.  
Nov-Dec 1992

14/6/71 (Item 71 from file: 155)  
07151205 93042476

Synthesis of TGF-beta 1 by vascular endothelial cells is correlated with cell spreading.

Sep-Oct 1992

14/6/72 (Item 72 from file: 155)  
07101109 92378735  
Influence on metastasis of the reduction of major histocompatibility complex (MHC) class I gene with an **antisense oligonucleotide**.  
Aug 1992

14/6/73 (Item 73 from file: 155)  
07052000 92293057  
Cellular expression of tropoelastin mRNA splice variants.  
Apr 1992

14/6/74 (Item 74 from file: 155)  
07020097 92228508  
Stimulation of cell division and fibroblast focus formation by **antisense** repression of retinoblastoma protein synthesis.  
Apr 1992

14/6/75 (Item 75 from file: 155)  
06849828 92011548  
**Antisense** oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms.  
Sep 25 1991

14/6/76 (Item 76 from file: 155)  
06914919 91139683  
The mRNAs encoding the two angiotensin-converting isozymes are transcribed from the same gene by a tissue-specific choice of alternative transcription initiation sites.  
Feb 25 1991

14/6/77 (Item 77 from file: 155)  
06584840 91205766  
A novel point mutation at codon 146 of the K-ras gene in a human colorectal cancer identified by the polymerase chain reaction.  
Jan 1991

14/6/78 (Item 78 from file: 155)  
06342154 89306185  
Localization of epidermal growth factor precursor in tooth and lung during embryonic mouse development.  
Aug 1989

14/6/79 (Item 1 from file: 5)  
12168347 BIOSIS NO.: 200000021849  
Clinical development of G3139 **antisense** drug (**oligonucleotide**) targeting BCL-2.  
1993

14/6/80 (Item 2 from file: 5)  
12327713 BIOSIS NO.: 199900522562  
ICAM-1 **antisense oligonucleotide** delivered during lung preservation inhibits early ICAM-1 expression and improves graft function after transplantation.  
1993

14/6/81 (Item 3 from file: 5)  
12107756 BIOSIS NO.: 199900402605  
Spongelike alginate nanoparticles as a new potential system for the  
delivery of **antisense** oligonucleotides.  
1999

14/6/82 (Item 4 from file: 5)  
11780015 BIOSIS NO.: 199900026124  
Galphai-2 is required for carbachol-induced stress fiber formation in human  
airway smooth muscle cells.  
1999

14/6/83 (Item 5 from file: 5)  
11780006 BIOSIS NO.: 199900026115  
**Antisense oligonucleotide** to PKC-epsilon alters cAMP-dependent  
stimulation of CFTR in Calu-3 cells.  
1998

14/6/84 (Item 6 from file: 5)  
11789460 BIOSIS NO.: 199900015569  
Effects of a laminin beta1-**antisense oligonucleotide** on the  
mouse developing lung.  
1998

14/6/85 (Item 7 from file: 5)  
11416928 BIOSIS NO.: 199800198260  
Down regulation by **antisense** oligonucleotides of the class III  
beta-tubulin gene in Taxol-resistant human lung cancer cells.  
1998

14/6/86 (Item 8 from file: 5)  
11415372 BIOSIS NO.: 199800196704  
In vitro tumor growth inhibition by telomerase **antisense** and  
anticancer agents.  
1998

14/6/87 (Item 9 from file: 5)  
11322945 BIOSIS NO.: 199800104277  
In vivo modulation of silica-induced **pulmonary** fibrosis by  
**antisense** oligonucleotides.  
1997

14/6/88 (Item 10 from file: 5)  
10873763 BIOSIS NO.: 199799594913  
Essays of modern molecular genetics. Essay 6. Gene therapy and medicine of  
the XXI century.  
1997

14/6/89 (Item 11 from file: 5)  
10415485 BIOSIS NO.: 199799536630  
**Antisense oligonucleotide** (ON) inhibits proliferation of  
cultured neonatal lung fibroblast.  
1997

14/6/90 (Item 12 from file: 5)  
10909162 BIOSIS NO.: 9799530307

An **antisense** bcl-2 **oligonucleotide** alters cell proliferation,  
viability and programmed cell death in non-small cell **lung** cancer  
cell lines.  
1997

14/6/91 (Item 13 from file: 5)  
10796319 BIOSIS NO.: 199799417464

Comparison of the toxicity profiles of ISIS 1082 and ISIS 2105,  
phosphorothioate oligonucleotides, following subacute intradermal  
administration in Sprague-Dawley rats.  
1997

14/6/92 (Item 14 from file: 5)  
10686449 BIOSIS NO.: 199799307594

Selective **antisense** inhibition of **pulmonary** fibrogenic cytokine  
gene expression.  
1996

14/6/93 (Item 15 from file: 5)  
10685974 BIOSIS NO.: 199799307119

Selectivity of **antisense** action against point mutated Ki-ras oncogene  
in human **lung** carcinoma cells.  
1996

14/6/94 (Item 16 from file: 5)  
10685967 BIOSIS NO.: 199799307112

Suppression of proliferation of human neonatal **lung** fibroblasts using  
**antisense** oligonucleotides in vitro.  
1996

14/6/95 (Item 17 from file: 5)  
10679837 BIOSIS NO.: 199799300982

**Antisense oligonucleotide** effects on MRP-expressing **lung**  
tumour cells.  
1996

14/6/96 (Item 18 from file: 5)  
10675756 BIOSIS NO.: 199699196901

P53 **antisense oligonucleotide** inhibits growth of human colon  
tumor and normal cell lines.  
1996

14/6/97 (Item 19 from file: 5)  
10471530 BIOSIS NO.: 199699092725

Fate of cationic liposomes and their complex with **oligonucleotide** in  
vivo.  
1996

14/6/98 (Item 20 from file: 5)  
10357845 BIOSIS NO.: 199698812763

Pharmacokinetics and tissue distribution of a methyltransferase  
**antisense oligonucleotide** (MT-AS) in nude mice bearing human  
**lung** cancer.  
1996



14/6/99 (Item 21 from file: 5)  
10356370 BIOSIS NO.: 199698811288  
Effect of **antisense oligonucleotide** inhibition of human  
FEC-alpha, delta, epsilon, eta, and zeta on c-fos and c-jun expression in  
A549 **lung** carcinoma cells.  
1996

14/6/100 (Item 22 from file: 5)  
10326019 BIOSIS NO.: 199698780937  
**Oligonucleotide** targeting to alveolar macrophages by mannose  
receptor-mediated endocytosis.  
1996

14/6/101 (Item 23 from file: 5)  
09670115 BIOSIS NO.: 199598125033  
Carcinoma cells express IL-8 and the IL-8 receptor: Their inhibition  
attenuates the growth of carcinoma cells.  
1995

14/6/102 (Item 24 from file: 5)  
09624189 BIOSIS NO.: 199598079107  
Detection of Mycobacterium leprae by three-primer PCR.  
1994

14/6/103 (Item 25 from file: 5)  
09196075 BIOSIS NO.: 199497304445  
Inhibition of c-myc oncogene expression with a c-myc **antisense**  
**oligonucleotide** and its effects on proliferation and drug  
sensitivity in drug sensitive and resistant human small cell **lung**  
cancer cells.  
1994

14/6/104 (Item 26 from file: 5)  
08962522 BIOSIS NO.: 199396114023  
Diffuse malignant mesothelioma of the pleura: A clinicopathological study  
of six patients with a prolonged symptom-free interval or extended  
survival after biopsy and a review of the literature of long-term  
survival.  
1993

14/6/105 (Item 27 from file: 5)  
08926114 BIOSIS NO.: 199396077615  
Immunohistochemical and in situ hybridization analysis of p53 in human  
endometrial carcinoma of the uterus.  
1993

14/6/106 (Item 28 from file: 5)  
08757687 BIOSIS NO.: 199395047038  
Synthesis of TGF-beta-1 by vascular endothelial cells is correlated with  
cells is correlated with cell spreading.  
1992

14/6/107 (Item 29 from file: 5)  
07543444 BIOSIS NO.: 000091095522  
THE MESSENGER RNAs ENCODING THE TWO ANGIOTENSIN-CONVERTING ISOZYMES ARE  
TRANSCRIBED FROM THE SAME GENE BY A TISSUE-SPECIFIC CHOICE OF ALTERNATIVE

14/6/108 (Item 1 from file: 399)  
DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Low-adenosine antisense oligonucleotide agents, compositions, kits and treatments for respiratory disorders

14/6/109 (Item 2 from file: 399)  
DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Treatment of tumors with oligonucleotides directed to insulin-like growth factor-I receptor

14/6/110 (Item 3 from file: 399)  
DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Anti-adenosine receptor antisense oligonucleotide composition, kit and method for treatment of disorders associated with bronchoconstriction and lung inflammation

14/6/111 (Item 4 from file: 399)  
DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Inhibition of endothelin-1 induced human pulmonary artery smooth muscle cell proliferation by antisense oligodeoxynucleotides targeted against C-myc mRNA

14/6/112 (Item 5 from file: 399)  
DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Antisense oligonucleotide-based compositions and methods for reducing radiation and drug resistance in cells

14/6/113 (Item 6 from file: 399)  
DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Effects of endothelin-1 antisense oligonucleotide on pulmonary hemodynamics in normoxic and hypoxic rats

14/6/114 (Item 7 from file: 399)  
DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Inhibiting the growth of p53-deficient tumor cells by administering the p53 gene

14/6/115 (Item 8 from file: 399)  
DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Oligonucleotide inhibitors of bcl-xL for antitumor therapy

14/6/116 (Item 9 from file: 399)  
DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Method for synthesizing complexes of platinum with iminoethers and their

use as antitumor drugs and nucleotide-base modifiers

14/6/117 (Item 10 from file: 399)

DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Tumor suppressor-activating MDM2-specific antisense oligonucleotides

14/6/118 (Item 11 from file: 399)

DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Oligonucleotides for enhanced modulation of protein kinase C expression

14/6/119 (Item 12 from file: 399)

DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Antisense modulation of CD71 expression

14/6/120 (Item 13 from file: 399)

DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Compositions and methods for the pulmonary delivery of nucleic acids

14/6/121 (Item 14 from file: 399)

DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Compositions and methods for non-parenteral delivery of oligonucleotides

14/6/122 (Item 15 from file: 399)

DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Neuropilin antisense oligonucleotide sequences and applications to modulate cell growth

14/6/123 (Item 16 from file: 399)

DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Antisense oligonucleotide inhibition of mdm2 gene expression and uses in cancer therapy

14/6/124 (Item 17 from file: 399)

DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Antisense oligonucleotides against human protein kinase C for diagnostic and therapeutic use

14/6/125 (Item 18 from file: 399)

DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Methoxyethoxy oligonucleotides for modulation of protein kinase C expression and therapeutic use

14/6/126 (Item 19 from file: 399)

DIALOG(R)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Antisense oligonucleotide modulation of raf gene expression, and use for

inhibiting cell hyperproliferation

14/6/127 (Item 20 from file: 399)  
DIALOG(F)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Inhibition of fibrogenic TNF-.alpha. gene expression in pulmonary macrophages by antisense oligonucleotides

14/6/128 (Item 21 from file: 399)  
DIALOG(F)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Antisense oligonucleotides complementary to thioredoxin or thioredoxin reductase mRNA and methods of their use to modulate tumor cell growth

14/6/129 (Item 22 from file: 399)  
DIALOG(F)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Oligonucleotide modulation of protein kinase C

14/6/130 (Item 23 from file: 399)  
DIALOG(F)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Antisense oligonucleotides against human protein kinase C, and therapeutic use

14/6/131 (Item 24 from file: 399)  
DIALOG(F)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Antisense oligonucleotide inhibition of epidermal growth factor receptor gene expression

14/6/132 (Item 25 from file: 399)  
DIALOG(F)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Chimeric antisense oligonucleotides for inhibition of TNF-.alpha. expression and therapeutic uses

14/6/133 (Item 26 from file: 399)  
DIALOG(F)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Antisense oligonucleotides capable of binding to multiple targets and their use in the treatment of respiratory disease

14/6/134 (Item 27 from file: 399)  
DIALOG(F)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Antisense oligonucleotide inhibition of protein kinase C

?

PLEASE ENTER A COMMAND OR BE LOGGED OFF IN 5 MINUTES

? ds

Set	Items	Description
S1	6596	PULMONARY OR LUNG OR AEROSOL OR AEROSOLIZE OR INHALATE OR INHALATION) AND (OLIGONUCLEOTIDE OR VECTOR OR ANTISENSE OR RI-BOZYME)
S2	13	AU="BENNETT, CLARENCE F." OR AU="BENNETT, CLARENCE FRANK"

S3 116 AU="BENNETT, C. F." OR AU="BENNETT, C. FRANK"  
 S4 129 S2 OR  
 S5 123 FD (unique items)  
 S6 17 S1 AND S5  
 S7 17 FD (unique items)  
 S8 13 S1 AND NEBULIZER  
 S9 11 FD (unique items)  
 S10 11 S9 NOT S6  
 S11 1308 S1 AND OLIGONUCLEOTIDE  
 S12 1289 S1 AND (ANTISENSE OF RIBOZYME)  
 S13 308 S11 AND S12  
 S14 234 FD (unique items)  
 S15 0 S1 AND ALKOXYALKOXY  
 S16 0 S1 AND DIALKYLAMINOALKYL  
 S17 0 S1 AND METHYLENEDIPHOSPHONATE  
 ? t s14/6/135-234

14/6/135 (Item 28 from file: 399)  
 DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Antisense oligonucleotides against human protein kinase C

14/6/136 (Item 29 from file: 399)  
 DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Antisense inhibition of endothelin-1 gene expression in treatment of pulmonary hypertension

14/6/137 (Item 30 from file: 399)  
 DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Antisense oligonucleotide compositions and methods for the modulation of JNK proteins

14/6/138 (Item 31 from file: 399)  
 DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Delayed progression to AIDS by a missense allele of the CCR2 gene

14/6/139 (Item 32 from file: 399)  
 DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Peptide inhibitors and antisense oligonucleotides of Syk kinase for inhibiting phagocytosis

14/6/140 (Item 33 from file: 399)  
 DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Interleukin-5: a proeosinophil cytokine mediator of inflammation in asthma and a target for antisense therapy

14/6/141 (Item 34 from file: 399)  
 DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Antisense oligonucleotides for IL-8 and IL-8 receptor, and use in treatment of cancer

14/6/142 (Item 35 from file: 399)  
DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Antisense oligonucleotide modulation of multidrug resistance-associated protein

14/6/143 (Item 36 from file: 399)  
DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Transgenic animals with disrupted expression of growth differentiation factor-8 or animals administered with antibodies to GDF-8

14/6/144 (Item 37 from file: 399)  
DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Antisense inhibition of human adhesion molecules

14/6/145 (Item 38 from file: 399)  
DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Agent and method of treatment for diseases and conditions associated with respiratory ailments and lung inflammation

14/6/146 (Item 39 from file: 399)  
DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Antisense oligonucleotides for inhibiting expression of erbB-2 oncogene

14/6/147 (Item 40 from file: 399)  
DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Antisense oligonucleotide modulation of raf gene expression

14/6/148 (Item 41 from file: 399)  
DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Methods for prevention of cellular proliferation and restenosis

14/6/149 (Item 42 from file: 399)  
DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Cationic virosomes as transfer system for genetic material

14/6/150 (Item 43 from file: 399)  
DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Antisense oligonucleotides for inhibiting the expression of platelet-derived growth factor for treating lung fibrosis

14/6/151 (Item 44 from file: 399)  
DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Therapeutic oligonucleotides targeting the human MDR1 and MRP genes

14/6/152 (Item 45 from file: 399)

DIALOG(F)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Respirable antisense oligonucleotides as novel therapeutic agents for asthma and other pulmonary diseases

14/6/153 (Item 46 from file: 399)

DIALOG(F)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Combinations of drugs with antisense oligonucleotides for treatment of proliferative diseases

14/6/154 (Item 47 from file: 399)

DIALOG(F)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Antiproliferative combinations, containing raf-targeted oligonucleotides and chemotherapeutic compounds

14/6/155 (Item 48 from file: 399)

DIALOG(F)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Methoxyethoxy-derivatized oligonucleotides for modulation of protein kinase C (PKC) expression

14/6/156 (Item 49 from file: 399)

DIALOG(F)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Cloning of cDNA for a human leptin receptor variant and methods for detecting variants and regulating obesity

14/6/157 (Item 50 from file: 399)

DIALOG(F)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Inhibition of tumor growth by antisense oligonucleotides for interleukin-8 (IL-8) and IL-8 receptor

14/6/158 (Item 51 from file: 399)

DIALOG(F)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Antisense oligonucleotides to p53 tumor suppressor suppress the induction of apoptosis by epidermal growth factor in NCI-H 598 human lung cancer cells

14/6/159 (Item 52 from file: 399)

DIALOG(F)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Control of CD44 gene expression for therapeutic use

14/6/160 (Item 53 from file: 399)

DIALOG(F)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Method of treatment for lung diseases using antisense oligonucleotides

14/6/161 (Item 54 from file: 399)

DIALOG(F)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Antisense oligonucleotides demonstrate a dominant role of c-Ki-RAS

proteins in regulating the proliferation of diploid human fibroblasts

14/6/162 (Item 55 from file: 399)

DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Targeted delivery of antisense oligonucleotides for selective inhibition of pulmonary fibrotic cytokines

14/6/163 (Item 56 from file: 399)

DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Targeted delivery of antisense oligonucleotides for selective inhibition of pulmonary fibrotic cytokines

14/6/164 (Item 57 from file: 399)

DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Method of inducing resistance to tumor growth in mammals with diffusion chamber containing tumor cells and apoptosis-inducing agents

14/6/165 (Item 58 from file: 399)

DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Antisense oligonucleotides for inhibition of cell proliferation by inhibition of E2F-1 gene expression

14/6/166 (Item 59 from file: 399)

DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Antisense oligonucleotides inhibiting DNA methyltransferase expression and having tumorigenicity-inhibiting activity

14/6/167 (Item 60 from file: 399)

DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Oligonucleotide inhibitors of the expression of protein kinase C isoenzyme genes and their therapeutic uses

14/6/168 (Item 61 from file: 399)

DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Oligonucleotide modulation of multidrug resistance-associated protein

14/6/169 (Item 62 from file: 399)

DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Monoclonal antibody to and peptide analogs of T cell receptor V.alpha.2.3 chain for diagnosis and therapy of sarcoidosis

14/6/170 (Item 63 from file: 399)

DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Oligonucleotide modulation of cell adhesion

14/6/171 (Item 64 from file: 399)



DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Method for inducing tumor immunity using tumor cells treated to have altered levels of a molecular factor

14/6/172 (Item 65 from file: 399)

DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

The use of phosphorus-33-labeled oligonucleotides for in situ hybridization of vertebrate embryo frozen sections

14/6/173 (Item 66 from file: 399)

DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Role of epidermal growth factor expression in early mouse embryo lung branching morphogenesis in culture: antisense oligodeoxynucleotide inhibitory strategy

14/6/174 (Item 67 from file: 399)

DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Localized oligonucleotide therapy

14/6/175 (Item 68 from file: 399)

DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

antisense oligonucleotides and methods for treatment of Epstein-Barr virus-associated diseases

14/6/176 (Item 69 from file: 399)

DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Oligonucleotides for treatment of tumors with neurotrophin activity

14/6/177 (Item 70 from file: 399)

DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Methods and compositions using oligonucleotides useful in autologous bone marrow transplantation and for cancer treatment

14/6/178 (Item 1 from file: 357)

0250992 DBA Accession No.: 2000-05482

Composition containing engineered adeno virus, useful for treating cystic fibrosis or deficiency of alpha-antitrypsin, delivered directly to the **lung** - cystic fibrosis transmembrane conductance regulator, alpha-1-antitrypsin or **antisense oligonucleotide** expression in **lung** using **vector** produced by 293 cell packaging cell culture 2000

14/6/179 (Item 2 from file: 357)

0250455 DBA Accession No.: 2000-04945

New **antisense** oligonucleotides inhibiting the anti-apoptotic protein bcl-xL, useful for reducing bcl-xL production in tumor cells to treat cancer - or in vascular cells to promote the regression of vascular lesions; **vector**-mediated **antisense oligonucleotide** gene transfer for cancer gene therapy 2000

14/6/180 (Item 3 from file: 357)  
0250294 DBA Accession No.: 2000-04784  
Polynucleotide library used to determine cancerous states of mammalian cells - DNA library used to produce recombinant protein and as DNA probe array for diagnosis of cancer 1999

14/6/181 (Item 4 from file: 357)  
0249200 DBA Accession No.: 2000-03690  
**Antisense** intercellular adhesion molecule-1 (ICAM-1) oligodeoxyribonucleotide delivered during organ preservation inhibits posttransplant ICAM-1 expression and reduces primary lung isograft failure - cationic liposome-mediated **antisense oligonucleotide** gene transfer and expression in rat lung endothelium cell culture for lung transplant gene therapy 2000

14/6/182 (Item 5 from file: 357)  
0249094 DBA Accession No.: 2000-03584  
New isolated serine/threonine kinase, used for developing products for the diagnosis and treatment of cancers - plasmid pSDNA3.1.BUB1-mediated protein-kinase expression in 293T cell, monoclonal antibody, hybridoma, DNA probe and **antisense oligonucleotide** for cancer, neurodegenerative or immune disorder therapy 1999

14/6/183 (Item 6 from file: 357)  
0248659 DBA Accession No.: 2000-03149  
New pharmaceutical composition useful for **pulmonary** delivery of **oligonucleotide** for treating asthma, lung cancer and pulmonary fibrosis - **antisense** therapy and DNA diagnostic delivery 1999

14/6/184 (Item 7 from file: 357)  
0248653 DBA Accession No.: 2000-03143  
Composition for **pulmonary** delivery useful for treating and diagnosing **pulmonary** diseases such as asthma, tuberculosis, etc. - aerosolized nucleic acid used for diagnosis, therapy and gene therapy of lung disease, e.g. tuberculosis, bronchitis, pneumonia, lung cancer 1999

14/6/185 (Item 8 from file: 357)  
0248465 DBA Accession No.: 2000-02955  
Differentiation-associated sequences, methods for inhibiting cell growth and inducing differentiation - expression in host cell, **antisense oligonucleotide** and monoclonal antibody for cancer therapy and recombinant vaccine 1999

14/6/186 (Item 9 from file: 357)  
0248444 DBA Accession No.: 2000-02934  
Novel human potassium channel subunit useful for diagnosis, prevention and treatment of **pulmonary** disorders, cancer, autoimmune diseases, neurological disorders - expression in CHO, HEK-293, COS or Spodoptera frugiperda Sf9 insect cell and **antisense oligonucleotide** 1999

14/6/187 (Item 10 from file: 357)  
0247927 DBA Accession No.: 2000-02417  
Oligonucleotides that bind nuclear protein present in lung cells, used in vectors for delivering therapeutic genes to lung tissue,

e.g. for treating cystic fibrosis - recombinant adenovirus or retrovirus **vector**-mediated sense or **antisense** gene transfer and expression in human for e.g. cystic fibrosis or emphysema prevention and gene therapy 1999

14/6/188 (Item 11 from file: 357)  
0247132 DBA Accession No.: 2000-01622  
Human aflatoxin-B1 aldehyde-reductase enzymes useful for treating gastrointestinal and neoplastic disorders - recombinant protein and **antisense oligonucleotide** for use in tumor therapy 1999

14/6/189 (Item 12 from file: 357)  
0246737 DBA Accession No.: 2000-01227  
Inhibiting the expression of human epidermal growth factor receptor in the treatment of diseases such as cancer - **vector**-mediated **antisense oligonucleotide** administration for therapy 1999

14/6/190 (Item 13 from file: 357)  
0246613 DBA Accession No.: 2000-01103  
New isolated interleukin-1 receptor binding proteins, used to treat e.g. sepsis, shock, arthritis, pancreatitis, graft-versus-host disease, inflammatory disease, autoimmune disease or proliferative disease - expression in host cell and antibody 1999

14/6/191 (Item 14 from file: 357)  
0246106 DBA Accession No.: 2000-00596  
New polypeptides and polynucleotides, useful in diagnosis and treatment of metastatic cancer - mouse recombinant semaphorin-H and -Hv production via **vector**-mediated gene transfer and expression in host cell and **antisense oligonucleotide** for gene therapy 1999

14/6/192 (Item 15 from file: 357)  
0244434 DBA Accession No.: 1999-12581  
Differentiation-associated proteins, useful in vaccines and pharmaceuticals to inhibit cell growth - mda8-A and mda8-B expression in host cell and antibody, used for cancer diagnosis, therapy and drug screening 1999

14/6/193 (Item 16 from file: 357)  
0243678 DBA Accession No.: 1999-14443  
New inhibitors of serine protease useful for treating inflammation - enzyme-inhibitor production and **antisense oligonucleotide** and antibody for diagnosis, prevention and gene therapy 1999

14/6/194 (Item 17 from file: 357)  
0242966 DBA Accession No.: 1999-12167  
New isolated human polynucleotides - DNA probe for use in diagnosis and polynucleotide associated with differential gene expression for use in gene therapy 1999

14/6/195 (Item 18 from file: 357)  
0241916 DBA Accession No.: 1999-12017  
Nucleotide sequences encoding mammalian EDG-5 receptor - human and mouse recombinant EDG-5 receptor, useful for the therapy of e.g. cigarette smoke, silica and asbestos-induced **lung** damage, asthma and infection 1999

14/6/196 (Item 19 from file: 357)  
0241483 DBA Accession No.: 1999-11584  
Inhibiting tumor cell proliferation using ribozymes - replication-deficient recombinant adeno virus **vector**-mediated **ribozyme** sense and **antisense oligonucleotide** transfer for use in lung, mamma and ovary cancer gene therapy 1999

14/6/197 (Item 20 from file: 357)  
0240942 DBA Accession No.: 99-10516  
Chimeric **antisense** oligonucleotides against tumor necrosis factor-alpha useful for treating inflammatory skin disorders - bacterium or phage **vector**-mediated expression 9999

14/6/198 (Item 21 from file: 357)  
0239371 DBA Accession No.: 99-05472  
Preventing and treating acute lung injury and pulmonary fibrosis - using fibronectin receptor-antagonist and tenascin receptor integrin-alpha-v-beta-6-antagonist monoclonal antibody or **antisense oligonucleotide** with antimetastatic activity 1999

14/6/199 (Item 22 from file: 357)  
0232781 DBA Accession No.: 99-02882  
New DNA-methyltransferase nucleotide sequences - **vector** plasmid pBluescript-SK+-mediated gene transfer and expression in human lung carcinoma cell, **antisense oligonucleotide**, for cancer diagnosis and gene therapy 1998

14/6/200 (Item 23 from file: 357)  
0231755 DBA Accession No.: 99-02856  
New isolated promoter sequences of human involucrin gene - **vector**-mediated human papilloma virus oncogene transfer and tissue-specific gene expression in suprabasal epithelial cell or transgenic animal, used for cancer gene therapy or drug screening 1998

14/6/201 (Item 24 from file: 357)  
0229277 DBA Accession No.: 98-10874  
**Antisense oligonucleotide** inhibiting multidrug-resistance protein expression - used for small-cell lung cancer or inflammatory disorder therapy or multi-drug resistance prevention in chemotherapy, etc. 1998

14/6/202 (Item 25 from file: 357)  
0228910 DBA Accession No.: 98-10507  
Inducing apoptosis in proliferative mammal cells with inhibitor of IAP or NAIP polypeptide - **vector**-mediated apoptosis-inhibitor gene transfer and expression in transgenic animal, DNA probe and **antisense oligonucleotide** for cancer diagnosis or gene therapy, etc. 1998

14/6/203 (Item 26 from file: 357)  
0229378 DBA Accession No.: 98-09975  
Novel human dosage compensation-associated protein - useful in the treatment of developmental disorders and or cancers 1998

14/6/204 (Item 27 from file: 357)  
0228340 DBA Accession No.: 98-09937

New isolated human anion channel protein - ion channel protein used to develop products for the diagnosis and therapy of developmental disorder or cancer 1998

14/6/205 (Item 28 from file: 357)  
0226422 DBA Accession No.: 98-08019  
Smooth muscle cell transcription factor - recombinant protein and **antisense oligonucleotide** for use in arteriosclerosis, Crohn disease, etc., therapy 1998

14/6/206 (Item 29 from file: 357)  
0225983 DBA Accession No.: 98-07580  
New human glutathione-S-transferase variants - glutathione-transferase mutant enzymes for use in cancer diagnosis, prevention and therapy 1998

14/6/207 (Item 30 from file: 357)  
0225197 DBA Accession No.: 98-06794  
Human and cattle deoxyribonuclease-II enzyme and encoding cDNA - recombinant DNA-ase-II preparation by **vector** expression in host cell, **antisense oligonucleotide** and antibody, used for cancer or autoimmune disease diagnosis or therapy, etc. 1998

14/6/208 (Item 31 from file: 357)  
0225161 DBA Accession No.: 98-06758  
New isolated monocyte chemoattractant protein MCP-4 and MCP-5 - human recombinant protein preparation, **antisense oligonucleotide** and transgenic animal, for e.g. cancer therapy, etc. 1998

14/6/209 (Item 32 from file: 357)  
0225152 DBA Accession No.: 98-06749  
New isolated epithelial protein as early marker of cancer and related DNA, vectors - recombinant epithelium cell protein production, DNA probes and **antisense oligonucleotides** for diagnosis and therapy of cancer 1998

14/6/210 (Item 33 from file: 357)  
0225346 DBA Accession No.: 98-04443  
Inducing p53-mediated apoptosis by treatment with an agent that inhibits DNA repair - **antisense oligonucleotide** and tumor suppressor gene transfer for use in cancer and leukemia therapy and gene therapy 1998

14/6/211 (Item 34 from file: 357)  
0222218 DBA Accession No.: 98-03815  
New isolated retinoid metabolising proteins - recombinant protein, DNA probe and **antisense oligonucleotide** for use in disease diagnosis, therapy and drug screening 1997

14/6/212 (Item 35 from file: 357)  
0218596 DBA Accession No.: 98-00193  
New multi-tumor aberrant growth gene PSAFP-1 and derived proteins, RNA, **antisense** sequences, etc. - DNA probe, DNA primer, **ribozyme** and **antisense oligonucleotide** for cancer diagnosis and therapy 1997

14/6/213 (Item 36 from file: 357)  
0216045 DBA Accession No.: 97-11166  
Cancer antigen peptide derived from the tyrosinase-related protein-1 or -2  
- recombinant vaccine and nucleic acid vaccine for cancer 1997

14/6/214 (Item 37 from file: 357)  
0216015 DBA Accession No.: 97-11136  
Fhit proteins and related nucleic acids - for use as an antitumor or  
diagnostic agent, or in cancer gene therapy, etc. 1997

14/6/215 (Item 38 from file: 357)  
0216708 DBA Accession No.: 97-10829  
Human OB-R or leptin receptor variant for obesity diagnosis and treatment  
- obesity protein receptor variant DNA sequence, DNA probe, **antisense**  
, **ribozyme** and triple helix-forming agent for use in obesity  
diagnosis, therapy or gene therapy 1997

14/6/216 (Item 39 from file: 357)  
0216705 DBA Accession No.: 97-10826  
Detecting defective leptin receptor by hybridization assay - obesity  
protein receptor variant DNA sequence, DNA probe, **antisense**,  
**ribozyme** and triple helix-forming agent for use in obesity  
diagnosis, therapy or gene therapy 1997

14/6/217 (Item 40 from file: 357)  
0216896 DBA Accession No.: 97-10817  
Detecting defective form of leptin receptor by probing cellular RNA -  
obesity protein receptor variant detection by DNA probe hybridization,  
and obesity therapy by gene therapy, or **antisense**  
**oligonucleotide**, antigen or **ribozyme** therapy 1997

14/6/218 (Item 41 from file: 357)  
0216920 DBA Accession No.: 97-06041  
**Antisense oligonucleotide** to vav proto-oncogene - artificial  
gene construction for use in gene therapy of acute or chronic  
myelogenous leukemia or **lung** tumor 1997

14/6/219 (Item 42 from file: 357)  
0208419 DBA Accession No.: 97-04540  
Biotechnology down under - (conference report) 1997

14/6/220 (Item 43 from file: 357)  
0208901 DBA Accession No.: 97-01922  
Nucleic acid encoding human prostaglandin-H-synthase-2 - gene cloning and  
fusion protein expression, for prostaglandin-antagonist drug screening;  
**antisense**, **ribozyme** or triple helix-forming  
**oligonucleotide** for use in therapy 1996

14/6/221 (Item 44 from file: 357)  
0208350 DBA Accession No.: 97-01471  
A **vector** containing a gene able to attenuate fibroblasts under  
control of FSP1 gene promoter - for collagen or transforming growth  
factor-beta-1 **antisense oligonucleotide** delivery or  
thymidine-kinase gene transfer and ganciclovir or aciclovir prodrug  
activation 1996

14/6/222 (Item 45 from file: 357)

0182621 DBA Accession No.: 96-02814

New adeno viral vectors - multiply-deficient adeno virus **vector** for cystic fibrosis transmembrane conductance regulator, **antisense** RNA or immunogen gene transfer, for gene therapy or genetic immunization 1995

14/6/223 (Item 46 from file: 357)

0188212 DBA Accession No.: 95-15747

Suppression of 40-kDa laminin binding protein expression reduces tumorigenicity of murine **lung** cancer cells - (conference abstract) 1995

14/6/224 (Item 47 from file: 357)

0137056 DBA Accession No.: 95-14571

Method for detecting 12-lipoxygenase or the DNA or RNA encoding it - by reverse transcription or DNA probe hybridization, for tumor metastasis diagnosis 1995

14/6/225 (Item 48 from file: 357)

0137044 DBA Accession No.: 95-14559

New **antisense** oligonucleotides against the E2F-1 gene - and artificial gene construct for cancer therapy 1995

14/6/226 (Item 49 from file: 357)

0135234 DBA Accession No.: 95-12055

Novel deltex protein and related nucleic acids and antibodies - **antisense oligonucleotide** application in cancer therapy and recombinant protein application in tumor diagnosis 1995

14/6/227 (Item 50 from file: 357)

0177697 DBA Accession No.: 95-04518

Oncoprotein protein-kinase JNK - recombinant c-Jun N-terminal protein-kinase, monoclonal antibody, diagnostic DNA probe, **antisense oligonucleotide** and c-Jun oncoprotein-glutathione-transferase fusion protein production 1995

14/6/228 (Item 51 from file: 357)

0177171 DBA Accession No.: 95-03992

Modulation of protein-kinase-C expression - **antisense oligonucleotide** and DNA probe, for application in psoriasis, colorectal carcinoma, **lung** carcinoma, mamma carcinoma and skin cancer diagnosis and therapy 1995

14/6/229 (Item 52 from file: 357)

0174150 DBA Accession No.: 95-00971

Targeting gastrin-releasing peptide receptors with **antisense** oligodeoxynucleotides in human small cell **lung** cancer - gastrin-releasing peptide receptor **antisense oligonucleotide** for use in small cell **lung** carcinoma therapy (conference abstract) 1994

14/6/230 (Item 53 from file: 357)

0172741 DBA Accession No.: 94-15292

**Antisense** oligonucleotides to human lipocortin-1 inhibit glucocorticoid-induced inhibition of A549 cell growth and eicosanoid release - **antisense oligonucleotide** against **lung**

14/6/231 (Item 54 from file: 357)  
 0160689 DBA Accession No.: 94-09240  
 Mutant or native collagen gene **antisense** DNA sequence for mutant collagen gene expression inhibition - potential e.g. osteogenesis imperfecta, chondrodysplasi, certain forms of osteoporosis, etc. gene therapy 1994

14/6/232 (Item 55 from file: 357)  
 0157727 DBA Accession No.: 94-00278  
 Immunogenic tumor cell with reduced intracellular level of molecular factor - used with **antisense** RNA **oligonucleotide**, episomal **vector**, **ribozyme** or triplex-DNA for application in tumor therapy 1993

14/6/233 (Item 56 from file: 357)  
 0145830 DBA Accession No.: 93-03982  
 Treatment of tumors expressing brain-derived neurotrophic factor - gene expression in MBx cell line and therapy using **antisense** DNA; diagnosis 1993

14/6/234 (Item 57 from file: 357)  
 0144688 DBA Accession No.: 93-02740  
**Antisense oligonucleotide** hybridizing with human ras gene - oncogene **antisense** DNA for use in cancer therapy or as a diagnostic DNA probe 1992  
 ? ds

Set	Items	Description
S1	6596	(PULMONARY OR LUNG OR AEROSOL OR AEROSOLIZE OR INHALATE OR INHALATION) AND (OLIGONUCLEOTIDE OR VECTOR OR ANTISENSE OR RIBOZYME)
S2	13	AU="BENNETT, CLARENCE F." OR AU="BENNETT, CLARENCE FRANK"
S3	116	AU="BENNETT, C. F." OR AU="BENNETT, C. FRANK"
S4	129	S2 OR S3
S5	123	PD (unique items)
S6	17	S1 AND S5
S7	17	PD (unique items)
S8	13	S1 AND NEBULIZER
S9	11	PD (unique items)
S10	11	S9 NOT S6
S11	1309	S1 AND OLIGONUCLEOTIDE
S12	1289	S1 AND (ANTISENSE OR RIBOZYME)
S13	308	S11 AND S12
S14	234	PD (unique items)
S15	0	S1 AND ALKOXYALKOXY
S16	0	S1 AND DIALKYLAMINOXYALKYL
S17	0	S1 AND METHYLENEPHOSPHONATE
? s s1 and (modified or modification)		

	6596	S1
	369166	MODIFIED
	229970	MODIFICATION
S18	291	S1 AND (MODIFIED OR MODIFICATION)
? s s18 not s14		
	291	S18
	234	S14
S19	262	S18 NOT S14



...examined 50 records (50)  
 ...examined 50 records (100)  
 ...examined 50 records (150)  
 ...examined 50 records (200)  
 ...examined 50 records (250)  
 ...completed examining records  
     S20      205    RD (unique items)  
 t s14/7/26,108,110,120,125,133,136,145,150,152,160,162

14/7/26      (Item 26 from file: 155)  
 DIALOG(R)File 155:MEDLINE(P)  
 (c) format only 2000 Dialog Corporation. All rts. reserv.

09550663    98249554

**Pulmonary** bioavailability of a phosphorothioate  
**oligonucleotide** (CGP 64128A): comparison with other delivery routes.  
 Nicklin PL; Bayley D; Giddings J; Craig SJ; Cummins LL; Hastewell JG;  
 Phillips JA  
 Novartis Horsham Research Centre, Horsham, West Sussex, UK.  
 paul.nicklin@pharma.novartis.com  
 Pharmaceutical research (UNITED STATES) Apr 1998, 15 (4) p583-91,  
 ISSN: 0724-8741 Journal Code: PHS  
 Languages: ENGLISH  
 Document type: JOURNAL ARTICLE

**PURPOSE:** Phosphorothioate **antisense** oligodeoxynucleotides are promising therapeutic candidates. When given systemically in clinical trials they are administered via slow intravenous infusion to avoid their putative plasma concentration-dependent haemodynamic side-effects. In this study, we have evaluated alternative parenteral and non-parenteral administration routes which have the potential to enhance the therapeutic and commercial potential of these agents. **METHODS:** The delivery of CGP 64128A by intravenous, subcutaneous, intra-peritoneal, oral and intra-tracheal (**pulmonary**) routes was investigated in rats using radiolabelled compound and supported by more specific capillary gel electrophoretic analyses. **RESULTS:** Intravenously administered CGP 64128A exhibited the rapid blood clearance and distinctive tissue distribution which are typical for phosphorothioate oligodeoxynucleotides. Subcutaneous and intraperitoneal administration resulted in significant bioavailabilities (30.9% and 28.1% over 360 min, respectively) and reduced peak plasma levels when compared with intravenous dosing. Administration via the gastrointestinal tract gave negligible bioavailability (< 2%). Intra-tracheal administration resulted in significant but dose-dependent bioavailabilities of 3.2, 16.5 and 39.8% at 0.06, 0.6 and 6.0 mg/kg, respectively. **CONCLUSIONS:** Significant bioavailabilities of CGP 64128A were achieved following subcutaneous, intra-peritoneal and intra-tracheal administration. **Pulmonary** delivery represents a promising mode of non-parenteral dosing for **antisense** oligonucleotides. The dose-dependent increase in **pulmonary** bioavailability suggests that low doses may be retained in the lungs for local effects whereas higher doses may be suitable for the treatment of a broader spectrum of systemic diseases.

14/7/108      (Item 1 from file: 399)  
 DIALOG(R)File 399:CA SEARCH(R)  
 (c) 2000 American Chemical Society. All rts. reserv.

132203144    CA: 132(16)203144s    PATENT  
 Low-adenosine antisense oligonucleotide agents, compositions, kits and treatments for respiratory disorders  
 INVENTOR(AUTHOR): Nyce, Jonathan W.  
 LOCATION: USA

ASSIGNEE: East Carolina University  
PATENT: PCT International ; WO 200009525 A2 DATE: 200009224  
APPLICATION: WO 99US17712 (19990803) \*US 95212 (19980803)  
PAGES: 1343 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C07H-000/A  
DESIGNATED COUNTRIES: AU; CA; CN; MX; RU; US DESIGNATED REGIONAL: AT; BE  
; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE  
SECTION:  
CA201009 Pharmacology  
IDENTIFIERS: antisense oligonucleotide respiratory disorder, lung airway  
obstruction antisense oligonucleotide, asthma treatment antisense  
oligonucleotide, inflammation treatment antisense oligonucleotide, allergy  
treatment antisense oligonucleotide, cancer treatment antisense  
oligonucleotide  
DESCRIPTORS:  
Drug delivery systems...  
aerosols; low-adenosine antisense oligonucleotide agents, compns., kits  
and treatments for respiratory disorders  
Integrins...  
.alpha.4.beta.1, target; low-adenosine antisense oligonucleotide  
agents, compns., kits and treatments for respiratory disorders  
Integrins...  
antigens Mac-1 (macrophage 1), target; low-adenosine antisense  
oligonucleotide agents, compns., kits and treatments for respiratory  
disorders  
Transcription factors...  
AP-1 (activator protein 1), target; low-adenosine antisense  
oligonucleotide agents, compns., kits and treatments for respiratory  
disorders  
Sialoglycoproteins...  
asialoglycoproteins, drug uptake enhancer; low-adenosine antisense  
oligonucleotide agents, compns., kits and treatments for respiratory  
disorders  
Adenosine receptors...  
A1, target; low-adenosine antisense oligonucleotide agents, compns.,  
kits and treatments for respiratory disorders  
Purinoceptor agonists... Purinoceptor antagonists...  
A1; low-adenosine antisense oligonucleotide agents, compns., kits and  
treatments for respiratory disorders  
Purinoceptor agonists... Purinoceptor antagonists...  
A2; low-adenosine antisense oligonucleotide agents, compns., kits and  
treatments for respiratory disorders  
Adenosine receptors...  
A2a, target; low-adenosine antisense oligonucleotide agents, compns.,  
kits and treatments for respiratory disorders  
Adenosine receptors...  
A1b, target; low-adenosine antisense oligonucleotide agents, compns.,  
kits and treatments for respiratory disorders  
Adenosine receptors...  
A3, target; low-adenosine antisense oligonucleotide agents, compns.,  
kits and treatments for respiratory disorders  
Chemokine receptors...  
.beta. chemokine receptor CCR3, target; low-adenosine antisense  
oligonucleotide agents, compns., kits and treatments for respiratory  
disorders  
Cytokine receptors...  
.beta. chemokine receptor CCR5, target; low-adenosine antisense  
oligonucleotide agents, compns., kits and treatments for respiratory  
disorders  
Chemokines...  
.beta., receptor CCR5, target; low-adenosine antisense oligonucleotide  
agents, compns., kits and treatments for respiratory disorders  
Interleukin 1 receptors...  
.beta., target; low-adenosine antisense oligonucleotide agents,  
compns., kits and treatments for respiratory disorders  
Proteins, specific or class...

binding, target; low-adenosine antisense oligonucleotide agents, compns., kits and treatments for respiratory disorders

Bradykinin receptors...

B2, target; low-adenosine antisense oligonucleotide agents, compns., kits and treatments for respiratory disorders

Chemokines...

C-C, .beta., receptor CCR2, target; low-adenosine antisense oligonucleotide agents, compns., kits and treatments for respiratory disorders

Chemokines...

C-C, receptors, CCR3, target; low-adenosine antisense oligonucleotide agents, compns., kits and treatments for respiratory disorders

Drug delivery systems...

capsules; low-adenosine antisense oligonucleotide agents, compns., kits and treatments for respiratory disorders

Diglycerides...

CDP-deriv., surfactant for drug delivery; low-adenosine antisense oligonucleotide agents, compns., kits and treatments for respiratory disorders

Cytokine receptors...

chemokine, fusin, target; low-adenosine antisense oligonucleotide agents, compns., kits and treatments for respiratory disorders

Proteins, specific or class...

cyclosporin A-binding, target; low-adenosine antisense oligonucleotide agents, compns., kits and treatments for respiratory disorders

(etc.)...

CAS REGISTRY NUMBERS:

158492-48-9 186470-20-2 186676-07-3 188704-72-5 208884-01-9

222024-49-9 222024-50-2 222024-51-3 222024-52-4 222024-53-5

222024-54-6 222024-55-7 222024-56-8 222024-57-9 222024-60-4

222024-63-7 222024-64-8 222024-65-9 222024-66-0 222024-67-1

222024-69-3 222024-71-7 222024-72-8 222024-73-9 222024-74-0

222024-75-1 222024-76-2 222024-77-3 222024-78-4 222024-79-5

222024-80-8 222024-81-9 222024-83-1 222024-84-2 222024-85-3

222024-86-4 222024-87-5 222024-88-6 222024-89-7 222024-90-0

222024-91-1 222024-92-2 222024-93-3 222024-94-4 222024-95-5

222024-96-6 222024-97-7 222025-02-7 222025-03-8 222025-04-9

222025-06-1 222025-07-2 222025-08-3 222025-09-4 222025-10-7

222025-11-8 222025-12-9 222025-13-0 222025-14-1 222025-15-2

222025-16-3 222025-17-4 222025-18-5 222025-19-6 222025-21-0

222025-23-2 222025-30-1 222025-33-4 222025-35-6 222025-38-9

222025-39-0 222025-40-3 222025-41-4 222025-42-5 222025-43-6

222025-44-7 222025-45-8 222025-46-9 222025-47-0 222025-48-1

222025-49-2 222025-52-7 222025-53-3 222025-54-9 222025-55-0

222025-56-1 222025-57-2 222025-58-3 222025-59-4 222025-60-7

222025-61-8 222025-62-9 222025-63-0 222025-64-1 222025-65-2

222025-66-3 222025-67-4 222025-68-5 222025-69-6 222025-70-9

222025-71-0 222025-72-1 222025-73-2 222025-75-4 222025-77-6

222025-78-7 222025-79-8 222025-80-1 222025-83-4 222025-86-7

222025-87-8 222025-88-9 222025-89-0 222025-90-3 222025-91-4

222025-92-5 222026-02-0 222026-03-1 222026-07-5 222026-09-7

222026-13-3 222026-18-8 222026-19-9 222026-20-2 222026-21-3

222026-22-4 222026-23-5 222026-24-6 222026-25-7 222026-26-9

222026-27-9 222026-31-5 222026-32-6 222026-33-7 222026-34-8

222026-37-1 222026-40-6 222026-42-8 222026-45-1 222026-47-2

222026-51-9 222026-54-2 222026-57-5 222026-59-7 222026-64-4

222026-65-5 222026-66-6 222026-67-7 222026-68-3 222026-69-9

222026-70-2 222026-72-4 222026-74-6 222026-75-7 222026-77-9

222026-79-1 222026-80-4 222026-82-6 222026-83-7 222026-84-8

222026-85-9 222026-86-0 222026-87-1 222026-88-2 222026-90-6

222026-92-8 222026-94-0 222026-96-2 222026-98-4 222027-01-2

222027-04-5 222027-05-6 222027-07-9 222027-10-3 222027-24-9

222027-27-2 222027-30-7 222027-32-9 222027-34-1 222027-36-3

222027-38-5 222027-41-0 222027-43-2 222027-45-4 222027-47-6

222027-48-7 222027-49-8 222027-50-1 222027-51-2 222027-53-4

222027-55-6	222027-57-8	222027-60-3	222027-61-4	222027-62-5
222027-63-6	222027-64-7	222028-22-0	222028-24-2	222028-26-4
222028-27-5	222028-28-6	222028-29-7	222028-30-0	222028-31-1
222028-39-9	222028-42-4	222028-45-7	222028-47-9	222028-51-5
222028-52-6	222028-53-7	222028-54-8	222028-55-9	222028-56-0
222028-57-1	222028-60-6	222028-62-8	222028-63-9	222028-64-0
222028-67-3	222028-71-9	222028-75-3	222028-78-6	222028-81-1
222028-84-4	222028-89-9	222028-92-4	222028-93-5	222028-94-6
222028-96-8	222028-97-9	222028-98-0	222028-99-1	222029-00-7
222029-02-9	222029-04-1	222029-05-2	222029-07-4	222029-08-5
222029-09-6	222029-10-9	222029-11-0	222029-12-1	222029-13-2
222029-14-3	222029-15-4	222029-17-6	222029-20-1	222029-23-4
222029-25-6	222029-29-0	222029-32-5	222029-33-6	222029-34-7
222029-36-9	222029-37-0	222029-38-1	222029-39-2	222029-41-6
222029-42-7	222029-43-8	222029-46-1	222029-47-2	222029-48-3
222029-49-4	222029-50-7	222029-51-8	222029-52-9	222029-53-0
222029-54-1	222029-55-2	222029-56-3	222029-57-4	222029-58-5
222029-60-9	222029-62-1	222029-64-3	222029-65-4	222029-66-5
222029-68-7	222029-69-8	222029-70-1	222029-71-2	222029-72-3
222029-73-4	222029-74-5	222029-75-6	222029-76-7	222029-77-8
222029-78-9	222029-79-0	222029-80-3	222029-81-4	222029-82-5
222029-83-6	222029-84-7	222029-85-8	222029-86-9	222029-87-0
222029-88-1	222029-89-2	222029-90-5	222029-91-6	222029-92-7
222029-93-8	222029-94-9	222029-95-0	222029-97-2	222029-98-3
222030-00-4	222030-02-6	222030-04-8	222030-06-0	222030-09-3
222030-11-7	222030-13-9	222030-16-2	222030-18-4	222030-19-5
222030-20-8	222030-21-9	222030-24-2	222030-25-3	222030-26-4
222030-27-5	222030-28-6	222030-29-7	222030-30-0	222030-31-1
222030-32-2	222030-33-3	222030-34-4	222030-35-5	222030-36-6
222030-37-7	222030-38-8	222030-39-9	222030-42-4	222030-46-8
222030-54-8	222030-62-8	222030-64-0	222030-65-1	222030-68-2
222030-67-3	222030-68-4	222030-69-5	222030-70-8	222030-71-9
222030-72-0	222030-73-1	222030-74-2	222030-75-3	222030-76-4
222030-77-5	222030-78-6	222030-81-1	222030-85-5	222030-87-7
222030-88-8	222030-89-9	222030-90-2	222030-91-3	222030-92-4
222030-93-5	222030-94-6	222030-95-7	222030-96-8	222030-97-9
222030-98-0	222030-99-1	222031-00-7	222031-01-8	222031-03-0
222031-04-1	222031-05-2	222031-06-3	222031-07-4	222031-08-5
222031-09-6	222031-10-9	222031-11-0	222031-12-1	222031-13-2
222031-14-3	222031-15-4	222031-16-5	222031-17-6	222031-18-7
222031-19-8	222031-20-1	222031-21-2	222031-22-3	222031-24-5
222031-25-6	222031-26-7	222031-27-8	222031-28-9	222031-29-0
222031-30-3	222031-31-4	222031-32-5	222031-34-7	222031-36-9
222031-37-0	222031-38-1	222031-41-6	222031-44-9	222031-45-0
222031-46-1	222031-47-2	222031-48-3	222031-49-4	222031-50-7
222031-51-9	222031-52-9	222031-53-0	222031-54-1	222031-55-2
222031-56-3	222031-57-4	222031-58-5	222031-59-6	222031-60-9
222031-61-0	222031-62-1	222031-65-4	222031-66-5	222031-67-6
222031-68-7	222031-69-8	222031-70-1	222031-71-2	222031-72-3
222031-73-4	222031-74-5	222031-75-6	222031-76-7	222031-77-8
222031-78-9	222031-79-0	222031-80-3	222031-81-4	222031-82-5
222031-83-6	222031-86-9	222031-90-5	222031-94-9	222032-00-0
222032-02-2	222032-03-3	222032-04-4	222032-06-6	222032-07-7
222032-09-9	222032-10-2	222032-11-3	222032-12-4	222032-13-5
222032-14-6	222032-15-7	222032-16-8	222032-17-9	222032-18-0
222032-19-1	222032-20-4	222032-22-6	222032-23-7	222034-04-0
222034-05-1	222034-06-2	222034-07-3	222034-08-4	222034-09-5
222034-10-8	222034-11-9	222034-13-1	222034-14-2	222034-15-3
222034-16-4	222034-17-5	222034-18-6	222034-19-7	222034-21-1
222034-22-2	222034-23-3	222034-24-4	222034-25-5	222034-26-6
222034-27-7	222034-28-8	222034-31-3	222034-32-4	222034-33-5
222034-34-6	222034-35-7	222034-36-8	222034-37-9	222034-38-0
222034-39-1	222034-40-4	222034-41-5	222034-42-6	222034-43-7
222034-44-8	222034-45-9	222034-46-0	222034-47-1	222034-48-2
222034-49-3	222034-50-6	222034-51-7	222034-56-2	222034-60-8

222034-63-1	222034-65-3	222034-66-4	222034-68-6	222034-69-7
222034-70-0	222034-71-1	222034-72-2	222034-73-3	222034-76-6
222034-80-2	222034-84-6	222034-88-0	222034-91-5	222034-98-2
222035-03-2	222035-09-8	222035-19-0	222035-23-6	222035-27-0
222035-31-6	222035-35-0	222035-41-8	222035-45-2	222035-49-6
222035-53-2	222035-56-5	222035-59-8	222035-62-3	222035-65-6
222035-69-0	222035-73-6	222035-77-0	222035-82-7	222035-85-0
222035-89-4	222035-94-1	222035-96-3	222036-00-2	222036-03-5
222036-07-9	222036-11-5	222036-15-9	222036-25-1	222036-29-5
222036-32-0	222036-35-3	222036-42-2	222036-44-4	222036-48-8
222036-52-4	222036-88-6	222036-93-3	222036-97-7	222037-02-7
222037-04-9	222037-07-2	222037-08-3	222037-11-8	222037-15-2
222037-16-3	222037-17-4	222037-18-5	222037-19-6	222037-20-9
222037-21-0	222037-22-1	222037-24-3	222037-28-7	222037-29-8
222037-30-1	222037-31-2	222037-32-3	222037-33-4	222037-34-5
222037-35-6	222037-36-7	222037-37-8	222037-38-9	222037-39-0
222037-40-3	222037-41-4	222037-42-5	222037-43-6	222037-44-7
222037-45-8	222037-46-9	222037-47-0	222037-48-1	222037-49-2
222037-50-5	222037-51-6	222037-52-7	222037-53-8	222037-54-9
222037-55-0	222037-59-4	222037-63-0	222037-67-4	222037-69-6
222037-72-1	222037-74-3	222037-82-3	222037-83-4	222037-84-5
222037-85-6	222037-88-9	222037-89-0	222037-90-3	222037-91-4
222037-92-5	222037-93-6	222037-94-7	222037-95-8	222037-96-9
222037-97-0	222037-98-1	222037-99-2	222038-00-8	222038-01-9
222038-02-0	222038-03-1	222038-05-3	222038-06-4	222038-17-7
222038-24-6	222038-25-7	222038-26-8	222038-27-9	222038-28-0
222038-29-1	222038-30-4	222038-31-5	222038-33-7	222038-34-8
222038-35-9	222038-36-0	222038-37-1	222038-38-2	222038-39-3
222038-40-6	222038-41-7	222038-42-8	222038-43-9	222038-44-0
222038-45-1	222038-46-2	222038-47-3	222038-48-4	222038-49-5
222038-50-8	222038-51-9	222038-52-0	222038-53-1	222038-54-2
222038-55-3	222038-56-4	222038-57-5	222038-58-6	222038-60-0
222038-61-1	222038-62-2	222038-63-3	222038-64-4	222038-65-5
222038-66-6	222038-67-7	222038-68-8	222038-69-9	222038-70-0
222038-71-3	222038-72-4	222038-73-5	222038-74-6	222038-75-7
222038-76-8	222038-77-9	222038-78-0	222038-79-1	222038-80-4
222038-82-6	222038-83-7	222038-84-8	222038-85-9	222038-86-0
222038-87-1	222038-88-2	222038-89-3	222038-90-6	222038-91-7
222038-92-8	222038-93-9	222038-94-0	222038-95-1	222038-96-2
222038-97-3	222038-98-4	222038-99-5	222039-00-1	222039-01-2
222039-02-3	222039-03-4	222039-04-5	222039-05-6	222039-06-7
222039-08-9	222039-09-0	222039-10-3	222039-11-4	222039-12-5
222039-13-6	222039-15-8	222039-16-9	222039-17-0	222039-18-1
222039-19-2	222039-20-5	222039-21-6	222039-22-7	222039-23-8
222039-24-9	222039-25-0	222039-26-1	222039-27-2	222039-28-3
222039-29-4	222039-30-7	222039-31-8	222039-32-9	222039-33-0
222039-34-1	222039-35-2	222039-36-3	222039-37-4	222039-38-5
222039-39-6	222039-40-9	222039-41-0	222039-42-1	222039-43-2
222039-47-6	222039-48-7	222039-50-1	222039-51-2	222039-52-3
222039-53-4	222039-54-5	222039-55-6	222039-56-7	222039-57-8
222039-58-9	222039-59-0	222039-60-3	222039-61-4	222039-62-5
222039-63-6	222039-64-7	222039-65-8	222039-66-9	222039-67-0
222039-68-1	222039-69-2	222039-70-5	222039-71-6	222039-72-7
222039-73-8	222039-74-9	222039-75-0	222039-76-1	222039-77-2
222039-78-3	222039-79-4	222039-80-7	222039-81-8	222039-82-9
222039-83-0	222039-84-1	222039-85-2	222039-86-3	222039-87-4
222039-88-5	222039-89-6	222039-90-9	222039-91-0	222039-92-1
222039-93-2	222039-94-3	222039-95-4	222039-96-5	222039-97-6
222039-98-7	222039-99-8	222040-00-8	222040-01-9	222040-02-0
222040-03-1	222040-04-2	222040-05-3	222040-06-4	222040-07-5
222040-08-6	222040-09-7	222040-10-0	222040-11-1	222040-12-2
222040-13-3	222040-14-4	222040-15-5	222040-16-6	222040-17-7
222040-18-8	222040-19-9	222040-20-2	222040-21-3	222040-22-4
222040-34-8	222040-37-1	222040-38-2	222040-40-6	222040-41-7
222040-42-8	222040-43-9	222040-44-0	222040-47-3	222040-49-5

222040-50-8 222040-51-9 222040-53-1 222040-54-2 222040-55-3  
 222040-56-4 222040-57-5 222040-58-6 222040-59-7 222040-60-0  
 222040-61-1 222040-62-2 222040-63-3 222040-64-4 222040-65-5  
 222040-66-6 222040-67-7 222040-68-8 222040-69-9 222040-70-2  
 222040-71-3 222040-72-4 222040-73-5 222040-74-6 222040-75-7  
 222040-76-8 222040-77-9 222040-78-0 222040-79-1 222040-80-4  
 222040-81-5 222040-82-6 222040-84-8 222040-85-9 222040-86-0  
 222040-88-2 222040-89-3 222040-91-7 222040-93-9 222040-95-1  
 222040-97-3 222040-99-5 222041-00-1 222041-01-2 222041-02-3  
 222041-03-4 222041-06-7 222041-09-0 222041-14-7 222186-46-1  
 222186-54-1 222186-55-2 222186-60-9 222186-63-2 222186-71-2  
 222186-73-4 222186-74-5 222186-75-6 222186-76-7 222186-81-4  
 222186-82-5 222186-83-6 222186-84-7 222186-86-9 222186-87-0  
 222186-89-2 222186-91-6 222533-35-9 259119-10-3 260044-11-9  
 260048-14-4 adenosine A1 receptor-specific; low-adenosine antisense  
 oligonucleotide agents, compns., kits and treatments for respiratory  
 disorders  
 186556-26-3 222041-34-1 222041-35-2 222041-36-3 222041-37-4  
 222041-38-5 222041-39-6 222041-40-9 222041-41-0 222041-42-1  
 222041-43-2 222041-44-3 222041-45-4 222041-46-5 adenosine A2a  
 receptor-specific; low-adenosine antisense oligonucleotide agents,  
 compns., kits and treatments for respiratory disorders  
 186556-27-4 222041-47-6 222041-48-7 222041-49-8 222041-50-1  
 222041-51-2 222041-52-3 222041-53-4 222041-54-5 222186-96-1  
 adenosine A2b receptor-specific; low-adenosine antisense  
 oligonucleotide agents, compns., kits and treatments for respiratory  
 disorders  
 186470-21-3 186470-22-4 186676-08-4 186676-09-5 222041-56-7  
 222041-57-8 222041-58-9 222041-59-0 222041-60-3 222186-93-8  
 222186-95-0 adenosine A3 receptor-specific; low-adenosine antisense  
 oligonucleotide agents, compns., kits and treatments for respiratory  
 disorders  
 56-81-5 57-10-3 biological studies, surfactant for drug delivery;  
 low-adenosine antisense oligonucleotide agents, compns., kits and  
 treatments for respiratory disorders  
 9013-20-1 drug uptake enhancer; low-adenosine antisense oligonucleotide  
 agents, compns., kits and treatments for respiratory disorders  
 186619-39-6 222041-92-1 222041-93-2 human .beta.-tryptase-specific;  
 low-adenosine antisense oligonucleotide agents, compns., kits and  
 treatments for respiratory disorders  
 186556-46-7 222042-61-7 222042-62-8 human cathepsin G-specific;  
 low-adenosine antisense oligonucleotide agents, compns., kits and  
 treatments for respiratory disorders  
 222177-19-7 222177-20-0 222177-21-1 222177-22-2 222177-23-3  
 222177-24-4 222177-25-5 222177-28-8 222177-34-6 222177-37-9  
 222177-38-0 222177-40-4 222177-41-5 222177-42-6 222177-43-7  
 222177-44-8 222177-46-0 222177-47-1 222177-48-2 222177-49-3  
 222177-50-6 human chymase-specific; low-adenosine antisense  
 oligonucleotide agents, compns., kits and treatments for respiratory  
 disorders  
 222042-63-9 222042-64-0 222042-65-1 222042-66-2 human defensin  
 1-specific; low-adenosine antisense oligonucleotide agents, compns.,  
 kits and treatments for respiratory disorders  
 222042-67-3 222042-68-4 human defensin 3-specific; low-adenosine  
 antisense oligonucleotide agents, compns., kits and treatments for  
 respiratory disorders  
 186556-37-6 222174-68-7 222174-69-8 222174-70-1 222174-73-4  
 259239-95-7 human ELAM-1-specific; low-adenosine antisense  
 oligonucleotide agents, compns., kits and treatments for respiratory  
 disorders  
 222177-52-8 222177-53-9 222177-54-0 222177-57-3 222177-63-1  
 222177-68-6 222177-70-0 222177-73-3 222177-74-4 222177-76-6  
 222177-77-7 222177-78-8 (etc.) human endothelial nitric oxide  
 synthase-specific; low-adenosine antisense oligonucleotide agents,  
 compns., kits and treatments for respiratory disorders

14/7/110 (Item 3 from file: 399)  
DIALOG(R) File 399:CA SEARCH(R)  
(c) 2000 American Chemical Society. All rts. reserv.

132185414 CA: 132(14)185414y PATENT  
Anti-adenosine receptor antisense oligonucleotide composition, kit and  
method for treatment of disorders associated with bronchoconstriction and  
lung inflammation  
INVENTOR(AUTHOR): Nyce, Jonathan W.  
LOCATION: USA  
ASSIGNEE: East Carolina University  
PATENT: United States ; US 6025339 A DATE: 20000215  
APPLICATION: US 757024 (19961126) \*US 472527 (19950607)  
PAGES: 43 pp., Cont.-in-part of U.S. Ser. No. 472,527. CODEN: USXXAM  
LANGUAGE: English CLASS: 514044000; A61K-048/00A; C12N-015/11B;  
C12N-015/09B  
SECTION:  
CA268005 Pharmaceuticals  
CA201XXX Pharmacology  
IDENTIFIERS: antisense oligonucleotide antiasthmatic bronchodilator  
adenosine receptor  
DESCRIPTORS:  
Gene, animal... mRNA...  
adenosine receptor-encoding, oligonucleotides antisense to;  
anti-adenosine receptor antisense oligonucleotide compn. for treatment  
of disorders assocd. with bronchoconstriction and lung inflammation  
Drug delivery systems...  
aerosols; anti-adenosine receptor antisense oligonucleotide compn.,  
kit, and method for treatment of disorders assocd. with  
bronchoconstriction and lung inflammation  
Antioxidants... Buffers... Dispersing agents... DNA sequences... Essential  
oils... Flavoring materials... Oligodeoxyribonucleotides...  
Oligonucleotides... Phosphorothioate oligonucleotides... Preservatives...  
Propellants(sprays and foams)... Solvents... Surfactants...  
anti-adenosine receptor antisense oligonucleotide compn. for treatment  
of disorders assocd. with bronchoconstriction and lung inflammation  
Antiasthmatics... Antisense oligonucleotides... Anti-inflammatory agents...  
Asthma... Bronchodilators...  
anti-adenosine receptor antisense oligonucleotide compn., kit, and  
method for treatment of disorders assocd. with bronchoconstriction and  
lung inflammation  
Adenosine receptors...  
A1, gene encoding; anti-adenosine receptor antisense oligonucleotide  
compn. for treatment of disorders assocd. with bronchoconstriction and  
lung inflammation  
Bronchi...  
bronchoconstriction; anti-adenosine receptor antisense oligonucleotide  
compn., kit, and method for treatment of disorders assocd. with  
bronchoconstriction and lung inflammation  
Drug delivery systems...  
capsules; anti-adenosine receptor antisense oligonucleotide compn. for  
treatment of disorders assocd. with bronchoconstriction and lung  
inflammation  
Drug delivery systems...  
carriers; anti-adenosine receptor antisense oligonucleotide compn. for  
treatment of disorders assocd. with bronchoconstriction and lung  
inflammation  
Drug delivery systems...  
cartridges; anti-adenosine receptor antisense oligonucleotide compn.  
for treatment of disorders assocd. with bronchoconstriction and lung  
inflammation  
Microcrystallites...  
drug delivery systems; anti-adenosine receptor antisense

oligonucleotide compn. for treatment of disorders assocd. with  
bronchoconstriction and lung inflammation

Lung, disease...

inflammation; anti-adenosine receptor antisense oligonucleotide compn.,  
kit, and method for treatment of disorders assocd. with  
bronchoconstriction and lung inflammation

Drug delivery systems...

inhalants; anti-adenosine receptor antisense oligonucleotide compn. for  
treatment of disorders assocd. with bronchoconstriction and lung  
inflammation

Codons...

initiation, oligonucleotides antisense to; anti-adenosine receptor  
antisense oligonucleotide compn. for treatment of disorders assocd.  
with bronchoconstriction and lung inflammation

Drug delivery systems...

liposomes; anti-adenosine receptor antisense oligonucleotide compn. for  
treatment of disorders assocd. with bronchoconstriction and lung  
inflammation

Oligodeoxyribonucleotides...

methylphosphonate-linked; anti-adenosine receptor antisense  
oligonucleotide compn. for treatment of disorders assocd. with  
bronchoconstriction and lung inflammation

Phosphorothioate oligonucleotides...

phosphorodithioate; anti-adenosine receptor antisense oligonucleotide  
compn. for treatment of disorders assocd. with bronchoconstriction and  
lung inflammation

#### CAS REGISTRY NUMBERS:

144189-73-1 anti-adenosine receptor antisense oligonucleotide compn. for  
treatment of disorders assocd. with bronchoconstriction and lung  
inflammation

259115-35-0D	259115-36-1D	259115-37-2D	259115-38-3D	259115-39-4D
259115-40-7D	259115-41-8D	259115-42-9D	259115-43-0D	259115-44-1D
259115-45-2D	259115-46-3D	259115-47-4D	259115-48-5D	259115-49-6D
259115-50-9D	259115-51-0D	259115-52-1D	259115-53-2D	259115-54-3D
259115-55-4D	259115-56-5D	259115-57-6D	259115-58-7D	259115-59-8D
259115-60-1D	259115-61-2D	259115-62-3D	259115-63-4D	259115-64-5D
259115-65-6D	259115-66-7D	259115-67-8D	259115-68-9D	259115-69-0D
259115-70-3D	259115-71-4D	259115-72-5D	259115-73-6D	259115-74-7D
259115-75-8D	259115-76-9D	259115-77-0D	259115-78-1D	259115-79-2D
259115-80-5D	259115-81-6D	259115-82-7D	259115-83-8D	259115-84-9D
259115-85-0D	259115-86-1D	259115-87-2D	259115-88-3D	259115-89-4D
259115-90-7D	259115-91-8D	259115-92-9D	259115-93-0D	259115-94-1D
259115-95-2D	259115-96-3D	259115-97-4D	259115-98-5D	259115-99-6D
259116-00-2D	259116-01-3D	259116-02-4D	259116-03-5D	259116-04-6D
259116-05-7D	259116-06-8D	259116-07-9D	259116-08-0D	259116-09-1D
259116-10-4D	259116-11-5D	259116-12-6D	259116-13-7D	259116-14-8D
259116-15-9D	259116-16-0D	259116-17-1D	259116-18-2D	259116-19-3D
259116-20-6D	259116-21-7D	259116-22-8D	259116-23-9D	259116-24-0D
259116-25-1D	259116-26-2D	259116-27-3D	259116-28-4D	259116-29-5D
259116-30-8D	259116-31-9D	259116-32-0D	259116-33-1D	259116-34-2D
259116-35-3D	259116-36-4D	259116-37-5D	259116-38-6D	259116-39-7D
259116-40-0D	259116-41-1D	259116-42-2D	259116-43-3D	259116-44-4D
259116-45-5D	259116-46-6D	259116-47-7D	259116-48-8D	259116-49-9D
259116-50-2D	259116-51-3D	259116-52-4D	259116-53-5D	259116-54-6D
259116-55-7D	259116-56-8D	259116-57-9D	259116-58-0D	259116-59-1D
259116-60-4D	259116-61-5D	259116-62-6D	259116-63-7D	259116-64-8D
259116-65-9D	259116-66-0D	259116-67-1D	259116-68-2D	259116-69-3D
259116-70-6D	259116-71-7D	259116-72-8D	259116-73-9D	259116-74-0D
259116-75-1D	259116-76-2D	259116-77-3D	259116-78-4D	259116-79-5D
259116-80-8D	259116-81-9D	259116-82-0D	259116-83-1D	259116-84-2D
259116-85-3D	259116-86-4D	259116-87-5D	259116-88-6D	259116-89-7D
259116-90-0D	259116-91-1D	259116-92-2D	259116-93-3D	259116-94-4D
259116-95-5D	259116-96-6D	259116-97-7D	259116-98-8D	259116-99-9D
259117-00-5D	259117-01-6D	259117-02-7D	259117-03-8D	259117-04-9D
259117-05-0D	259117-06-1D	259117-07-2D	259117-08-3D	259117-09-4D



259117-10-7D	259117-11-8D	259117-12-9D	259117-13-0D	259117-14-1D
259117-15-2D	259117-16-3D	259117-17-4D	259117-18-5D	259117-19-6D
259117-20-9D	259117-21-0D	259117-22-1D	259117-23-2D	259117-24-3D
259117-25-4D	259117-26-5D	259117-27-6D	259117-28-7D	259117-29-8D
259117-30-1D	259117-31-2D	259117-32-3D	259117-33-4D	259117-34-5D
259117-35-6D	259117-36-7D	259117-37-8D	259117-38-9D	259117-39-0D
259117-40-3D	259117-41-4D	259117-42-5D	259117-43-6D	259117-44-7D
259117-45-8D	259117-46-9D	259117-47-0D	259117-48-1D	259117-49-2D
259117-50-5D	259117-51-6D	259117-52-7D	259117-53-8D	259117-54-9D
259117-55-0D	259117-56-1D	259117-57-2D	259117-58-3D	259117-59-4D
259117-60-7D	259117-61-8D	259117-62-9D	259117-63-0D	259117-64-1D
259117-65-2D	259117-66-3D	259117-67-4D	259117-68-5D	259117-69-6D
259117-70-9D	259117-71-0D	259117-72-1D	259117-73-2D	259117-74-3D
259117-75-4D	259117-76-5D	259117-77-6D	259117-78-7D	259117-79-8D
259117-80-1D	259117-81-2D	259117-82-3D	259117-83-4D	259117-84-5D
259117-85-6D	259117-86-7D	259117-87-8D	259117-88-9D	259117-89-0D
259117-90-3D	259117-91-4D	259117-92-5D	259117-93-6D	259117-94-7D
259117-95-8D	259117-96-9D	259117-97-0D	259117-98-1D	259117-99-2D
259118-00-8D	259118-01-9D	259118-02-0D	259118-03-1D	259118-04-2D
259118-05-3D	259118-06-4D	259118-07-5D	259118-08-6D	259118-09-7D
259118-10-0D	259118-11-1D	259118-12-2D	259118-13-3D	259118-14-4D
259118-15-5D	259118-16-6D	259118-17-7D	259118-18-8D	259118-19-9D
259118-20-2D	259118-21-3D	259118-22-4D	259118-23-5D	259118-24-6D
259118-25-7D	259118-26-8D	259118-27-9D	259118-28-0D	259118-29-1D
259118-30-4D	259118-31-5D	259118-32-6D	259118-33-7D	259118-34-8D
259118-35-9D	259118-36-0D	259118-37-1D	259118-38-2D	259118-39-3D
259118-40-6D	259118-41-7D	259118-42-8D	259118-43-9D	259118-44-0D
259118-45-1D	259118-46-2D	259118-47-3D	259118-48-4D	259118-49-5D
259118-50-8D	259118-51-9D	259118-52-0D	259118-53-1D	259118-54-2D
259118-55-3D	259118-56-4D	259118-57-5D	259118-58-6D	259118-59-7D
259118-60-0D	259118-61-1D	259118-62-2D	259118-63-3D	259118-64-4D
259118-65-5D	259118-66-6D	259118-67-7D	259118-68-8D	259118-69-9D
259118-70-2D	259118-71-3D	259118-72-4D	259118-73-5D	259118-74-6D
259118-75-7D	259118-76-8D	259118-77-9D	259118-78-0D	259118-79-1D
259118-80-4D	259118-81-5D	259118-82-6D	259118-83-7D	259118-84-8D
259118-85-9D	259118-86-0D	259118-87-1D	259118-88-2D	259118-89-3D
259118-90-6D	259118-91-7D	259118-92-8D	259118-93-9D	259118-94-0D
259118-95-1D	259118-96-2D	259118-97-3D	259118-98-4D	259118-99-5D
259119-00-1D	259119-01-2D	259119-02-3D	259119-03-4D	259119-04-5D
259119-05-6D	259119-06-7D	259119-07-8D	259119-08-9D	259119-09-0D
259119-10-3D	259119-11-4D	259119-12-5D	259119-13-6D	259119-14-7D
259119-15-8D	259119-16-9D	259119-17-0D	259119-18-1D	259119-19-2D
259119-20-5D	259119-21-6D	259119-22-7D	259119-23-8D	259119-24-9D
259119-25-0D	259119-26-1D	259119-27-2D	259119-28-3D	259119-29-4D
259119-30-7D	259119-31-8D	259119-32-9D	259119-33-0D	259119-34-1D
259119-35-2D	259119-36-3D	259119-37-4D	259119-38-5D	259119-39-6D
259119-40-9D	259119-41-0D	259119-42-1D	259119-43-2D	259119-44-3D
259119-45-4D	259119-46-5D	259119-47-6D	259119-48-7D	259119-49-8D
259119-50-1D	259119-51-2D	259119-52-3D	259119-53-4D	259119-54-5D
259119-55-6D	259119-56-7D	259119-57-8D	259119-58-9D	259119-59-0D
259119-60-3D	259119-61-4D	259119-62-5D	259119-63-6D	259119-64-7D
259119-65-8D	259119-66-9D	259119-67-0D	259119-68-1D	259119-69-2D
259119-70-5D	259119-71-6D	259119-72-7D	259119-73-8D	259119-74-9D
259119-75-0D	259119-76-1D	259119-77-2D	259119-78-3D	259119-79-4D
259119-80-7D	259119-81-8D	259119-82-9D	259119-83-0D	259119-84-1D
259119-85-2D	259119-86-3D	259119-87-4D	259119-88-5D	259119-89-6D
259119-90-9D	259119-91-0D	259119-92-1D	259119-93-2D	259119-94-3D
259119-95-4D	259119-96-5D	259119-97-6D	259119-98-7D	259119-99-8D
259120-00-8D	259120-01-9D	259120-02-0D	259120-03-1D	259120-04-2D
259120-05-3D	259120-06-4D	259120-07-5D	259120-08-6D	259120-09-7D
259120-10-0D	259120-11-1D	259120-12-2D	259120-13-3D	259120-14-4D
259120-15-5D	259120-16-6D	259120-17-7D	259120-18-8D	259120-19-9D
259120-20-2D	259120-21-3D	259120-22-4D	259120-23-5D	259120-24-6D
259120-25-7D	259120-26-8D	259120-27-9D	259120-28-0D	259120-29-1D
259120-30-4D	259120-31-5D	259120-32-6D	259120-33-7D	259120-34-8D

259120-35-9D	259120-36-0D	259120-37-1D	259120-38-2D	259120-39-3D
259120-40-6D	259120-41-7D	259120-42-8D	259120-43-9D	259120-44-0D
259120-45-1D	259120-46-2D	259120-47-3D	259120-48-4D	259120-49-5D
259120-50-8D	259120-51-9D	259120-52-0D	259120-53-1D	259120-54-2D
259120-55-3D	259120-56-4D	259120-57-5D	259120-58-6D	259120-59-7D
259120-60-0D	259120-61-1D	259120-62-2D	259120-63-3D	259120-64-4D
259120-65-5D	259120-66-6D	259120-67-7D	259120-68-8D	259120-69-9D
259120-70-2D	259120-71-3D	259120-72-4D	259120-73-5D	259120-74-6D
259120-75-7D	259120-76-8D	259120-77-9D	259120-78-0D	259120-79-1D
259120-80-4D	259120-81-5D	259120-82-6D	259120-83-7D	259120-84-8D
259120-85-9D	259120-86-0D	259120-87-1D	259120-88-2D	259120-89-3D
259120-90-6D	259120-91-7D	259120-92-8D	259120-93-9D	259120-94-0D
259120-95-1D	259120-96-2D	259120-97-3D	259120-98-4D	259120-99-5D
259121-00-1D	259121-01-2D	259121-02-3D	259121-03-4D	259121-04-5D
259121-05-6D	259121-06-7D	259121-07-8D	259121-08-9D	259121-09-0D
259121-10-3D	259121-11-4D	259121-12-5D	259121-13-6D	259121-14-7D
259121-15-8D	259121-16-9D	259121-17-0D	259121-18-1D	259121-19-2D
259121-20-5D	259121-21-6D	259121-22-7D	259121-23-8D	259121-24-9D
259121-25-0D	259121-26-1D	259121-27-2D	259121-28-3D	259121-29-4D
259121-30-7D	259121-31-8D	259121-32-9D	259121-33-0D	259121-34-1D
259121-35-2D	259121-36-3D	259121-37-4D	259121-38-5D	259121-39-6D
259121-40-9D	259121-41-0D	259121-42-1D	259121-43-2D	259121-44-3D
259121-45-4D	259121-46-5D	259121-47-6D	259121-48-7D	259121-49-8D
259121-50-1D	259121-51-2D	259121-52-3D	259121-53-4D	259121-54-5D
259121-55-6D	259121-56-7D	259121-57-8D	259121-58-9D	259121-59-0D
259121-60-3D	259121-61-4D	259121-62-5D	259121-63-6D	259121-64-7D
259121-65-8D	259121-66-9D	259121-67-0D	259121-68-1D	259121-69-2D
259121-70-5D	259121-71-6D	259121-72-7D	259121-73-8D	259121-74-9D
259121-75-0D	259121-76-1D	259121-77-2D	259121-78-3D	259121-79-4D
259121-80-7D	259121-81-8D	259121-82-9D	259121-83-0D	259121-84-1D
259121-85-2D	259121-86-3D	259121-87-4D	259121-88-5D	259121-89-6D
259121-90-9D	259121-91-0D	259121-92-1D	259121-93-2D	259121-94-3D
259121-95-4D	259121-96-5D	259121-97-6D	259121-98-7D	259121-99-8D
259122-00-4D	259122-01-5D	259122-02-6D	259122-03-7D	259122-04-8D
259122-05-9D	259122-06-0D	259122-07-1D	259122-08-2D	259122-09-3D
259122-10-6D	259122-11-7D	259122-12-8D	259122-13-9D	259122-14-0D
259122-15-1D	259122-16-2D	259122-17-3D	259122-18-4D	259122-19-5D
259122-20-8D	259122-21-9D	259122-22-0D	259122-23-1D	259122-24-2D
259122-25-3D	259122-26-4D	259122-27-5D	259122-28-6D	259122-29-7D
259122-30-0D	259122-31-1D	259122-32-2D	259122-33-3D	259122-34-4D
259122-35-5D	259122-36-6D	259122-37-7D	259122-38-8D	259122-39-9D
259122-40-2D	259122-41-3D	259122-42-4D	259122-43-5D	259122-44-6D
259122-45-7D	259122-46-8D	259122-47-9D	259122-48-0D	259122-49-1D
259122-50-4D	259122-51-5D	259122-52-6D	259122-53-7D	259122-54-8D
259122-55-9D	259122-56-0D	259122-57-1D	259122-58-2D	259122-59-3D
259122-60-6D	259122-61-7D	259122-62-8D	259122-63-9D	259122-64-0D
259122-65-1D	259122-66-2D	259122-67-3D	259122-68-4D	259122-69-5D
259122-70-8D	259122-71-9D	259122-72-0D	259122-73-1D	259122-74-2D
259122-75-3D	259122-76-4D	259122-77-5D	259122-78-6D	259122-79-7D
259122-80-0D	259122-81-1D	259122-82-2D	259122-83-3D	259122-84-4D
259122-85-5D	259122-86-6D	259122-87-7D	259122-88-8D	259122-89-9D
259122-90-2D	259122-91-3D	259122-92-4D	259122-93-5D	259122-94-6D
259122-95-7D	259122-96-8D	259122-97-9D	259122-98-0D	259122-99-1D
259123-00-7D	259123-01-8D	259123-02-9D	259123-03-0D	259123-04-1D
259123-05-2D	259123-06-3D	259123-07-4D	259123-08-5D	259123-09-6D
259123-10-9D	259123-11-0D	259123-12-1D	259123-13-2D	259123-14-3D
259123-15-4D	259123-16-5D	259123-17-6D	259123-18-7D	259123-19-8D
259123-20-1D	259123-21-2D	259123-22-3D	259123-23-4D	259123-24-5D
259123-25-6D	259123-26-7D	259123-27-8D	259123-28-9D	259123-29-0D
259123-30-3D	259123-31-4D	259123-32-5D	259123-33-6D	259123-34-7D
259123-35-8D	259123-36-9D	259123-37-0D	259123-38-1D	259123-39-2D
259123-40-5D	259123-41-6D	259123-42-7D	259123-43-8D	259123-44-9D
259123-45-0D	259123-46-1D	259123-47-2D	259123-48-3D	259123-49-4D
259123-50-7D	259123-51-8D	259123-52-9D	259123-53-0D	259123-54-1D
259123-55-2D	259123-56-3D	259123-57-4D	259123-58-5D	259123-59-6D

259123-60-9D 259123-61-0D 259123-62-1D 259123-63-2D 259123-64-3D  
 259123-65-4D 259123-66-5D 259123-67-6D 259123-68-7D 259123-69-8D  
 259123-70-1D 259123-71-2D 259123-72-3D 259123-73-4D 259123-74-5D  
 259123-75-6D 259123-76-7D 259123-77-8D 259123-78-9D 259123-79-0D  
 259123-80-3D 259123-81-4D 259123-82-5D 259123-83-6D 259123-84-7D  
 259123-85-8D 259123-86-9D 259123-87-0D 259123-88-1D 259123-89-2D  
 259123-90-5D 259123-91-6D 259123-92-7D 259123-93-8D 259123-94-9D  
 259123-95-0D 259123-96-1D 259123-97-2D 259123-98-3D 259123-99-4D  
 259124-00-0D 259124-01-1D 259124-02-2D 259124-03-3D 259124-04-4D  
 259124-05-5D 259124-06-6D 259124-07-7D 259124-08-8D 259124-09-9D  
 259124-10-2D 259124-11-3D 259124-12-4D 259124-13-5D 259124-14-6D  
 259124-15-7D 259124-16-8D 259124-17-9D 259124-18-0D 259124-19-1D  
 259124-20-4D 259124-21-5D 259124-22-6D 259124-23-7D 259124-24-8D  
 259124-25-9D 259124-26-0D 259124-27-1D 259124-28-2D 259124-29-3D  
 259124-30-6D 259124-31-7D 259124-32-8D 259124-33-9D 259124-34-0D  
 259124-35-1D 259124-36-2D 259124-37-3D 259124-38-4D 259124-39-5D  
 259124-40-8D derivs., nucleotide sequence; anti-adenosine receptor  
 antisense oligonucleotide compn. for treatment of disorders assocd.  
 with bronchoconstriction and lung inflammation  
 259125-16-1 259125-17-2 259125-18-3 unclaimed nucleotide sequence;  
 anti-adenosine receptor antisense oligonucleotide compn., kit and  
 method for treatment of disorders assocd. with bronchoconstriction and  
 lung inflammation

14/7/120 (Item 13 from file: 399)  
 DIALOG(R) File 399:CA SEARCH(R)  
 (c) 2000 American Chemical Society. All rts. reserv.

132015684 CA: 132(2)15684u PATENT  
 Compositions and methods for the pulmonary delivery of nucleic acids  
 INVENTOR(AUTHOR): Bennett, Clarence Frank; Ecker, David J.; Cook, Phillip  
 Dan

LOCATION: USA  
 ASSIGNEE: Isis Pharmaceuticals, Inc.  
 PATENT: PCT International ; WO 9960166 A1 DATE: 19991125  
 APPLICATION: WO 99US11141 (19990520) \*US 83586 (19980521)  
 PAGES: 90 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12Q-001/68A;  
 C12N-015/00B; C12N-015/85B; C12N-015/63B; C12N-015/11B; C12P-019/34B;  
 C07H-001/04B; A61K-048/00B DESIGNATED COUNTRIES: AE; AL; AM; AT; AU; AZ;  
 BA; BB; BG; BP; BY; CA; CH; CN; CU; CZ; DE; DK; EE; ES; FI; GB; GD; GE; GH;  
 GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU;  
 LV; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL;  
 TJ; TM; TR; TT; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU;  
 TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; SD; SL; SZ; UG; ZW; AT; BE  
 ; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ;  
 CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

SECTION:  
 CA263006 Pharmaceuticals  
 IDENTIFIERS: nucleic acid pulmonary delivery aerosol nebulization, lung  
 delivery antisense oligonucleotide aerosol  
 DESCRIPTORS:  
 Drug delivery systems...  
 aerosols; compns. and methods for the pulmonary delivery of nucleic  
 acids  
 Nucleic acids... Peptide nucleic acids... Phosphorothioate  
 oligodeoxyribonucleotides...  
 antisense; compns. and methods for the pulmonary delivery of nucleic  
 acids  
 Antisense RNA...  
 aptamers or mol. decoys; compns. and methods for the pulmonary delivery  
 of nucleic acids  
 Bronchi...  
 bronchitis, treatment with antisense oligonucleotides; compns. and  
 methods for the pulmonary delivery of nucleic acids

Gene, animal...  
 c-Ha-ras, oligonucleotides antisense to; compns. and methods for the  
 pulmonary delivery of nucleic acids

Gene, animal...  
 c-Ki-ras, oligonucleotides antisense to; compns. and methods for the  
 pulmonary delivery of nucleic acids

Antiasthmatics... Antisense oligonucleotides... Drug delivery systems...  
 Lung... Pharmacokinetics... Ribozymes... Tuberculostatics...  
 compns. and methods for the pulmonary delivery of nucleic acids

Selectins...  
 E-, oligonucleotides antisense to; compns. and methods for the  
 pulmonary delivery of nucleic acids

Lung, disease...  
 fibrosis, treatment with antisense oligonucleotides; compns. and  
 methods for the pulmonary delivery of nucleic acids

RNA...  
 guide, antisense; compns. and methods for the pulmonary delivery of  
 nucleic acids

Cell adhesion molecules...  
 ICAM-1 (intercellular adhesion mol. 1), oligonucleotides antisense to;  
 compns. and methods for the pulmonary delivery of nucleic acids

Medical goods...  
 inhalers; compns. and methods for the pulmonary delivery of nucleic  
 acids

Lung, neoplasm...  
 inhibitors; compns. and methods for the pulmonary delivery of nucleic  
 acids

Antitumor agents...  
 lung; compns. and methods for the pulmonary delivery of nucleic acids

CD40(antigen)... CD80(antigen)... CD86(antigen)... Cell adhesion molecules  
 ... LFA-3(antigen)... Mycobacterium bovis... Mycobacterium tuberculosis...  
 Streptococcus pneumoniae...  
 oligonucleotides antisense to; compns. and methods for the pulmonary  
 delivery of nucleic acids

Cell adhesion molecules...  
 PECAM-1, oligonucleotides antisense to; compns. and methods for the  
 pulmonary delivery of nucleic acids

Gene, animal...  
 ras, oligonucleotides antisense to; compns. and methods for the  
 pulmonary delivery of nucleic acids

Pneumonia... Rhinovirus...  
 treatment with antisense oligonucleotides; compns. and methods for the  
 pulmonary delivery of nucleic acids

Cell adhesion molecules...  
 VCAM-1, oligonucleotides antisense to; compns. and methods for the  
 pulmonary delivery of nucleic acids

CAS REGISTRY NUMBERS:  
 138330-98-0 195397-89-8 195397-90-1 214841-85-7 215860-95-0  
 246519-46-0 250705-05-6 250705-06-7 250705-07-8 250705-62-5  
 250755-32-9 compns. and methods for the pulmonary delivery of nucleic  
 acids

141436-78-4 176023-60-2 oligonucleotides antisense to; compns. and  
 methods for the pulmonary delivery of nucleic acids

1463-10-1 22423-26-3P 163759-49-7P 163759-50-0P 163759-94-2P  
 182495-93-3P 182495-99-4P 182496-00-0P 182496-01-1P synthesis of  
 antisense oligonucleotides; compns. and methods for the pulmonary  
 delivery of nucleic acids

14/7/125 (Item 18 from file: 399)  
 DIALOG(R) File 399:CA SEARCH(R)  
 (c) 2000 American Chemical Society. All rts. reserv.

131209115 CA: 131(16)209115j PATENT  
 Methoxyethoxy oligonucleotides for modulation of protein kinase C

expression and therapeutic use

INVENTOR(AUTHOR): De Nicholas M.; Martin, Pierre; Mann, Karl-Heinz

LOCATION: USA

ASSIGNEE: Isis Pharmaceuticals, Inc.; Ciba-Geigy AG

PATENT: United States ; US 5948898 A DATE: 19990907

APPLICATION: US 601269 (19960214) \*US 852852 (19920316) \*US 89996  
(19930709) \*US 478178 (19950607)

PAGES: 18 pp., Cont.-in-part of U.S. Ser. No. 478,178. CODEN: USXXAM

LANGUAGE: English CLASS: 536023500; C07H-021/04A

SECTION:

CA201006 Pharmacology

CA233XXX Carbohydrates

IDENTIFIERS: protein kinase C inhibitor methoxyethoxy oligonucleotide,  
cancer treatment methoxyethoxy oligonucleotide

DESCRIPTORS:

Antisense oligonucleotides... Bladder carcinoma inhibitors... Breast  
carcinoma inhibitors... Colon carcinoma inhibitors... Glioblastoma  
inhibitors... Lung carcinoma inhibitors... mRNA... Oligonucleotides...  
methoxyethoxy oligonucleotides for modulation of protein kinase C  
expression and therapeutic use

CAS REGISTRY NUMBERS:

141436-78-4 160676-03-9 195397-89-8P 195397-90-1P 195397-91-2P  
methoxyethoxy oligonucleotides for modulation of protein kinase C  
expression and therapeutic use  
151379-73-1LP 163665-40-5D methoxyethoxy-modified, methoxyethoxy  
oligonucleotides for modulation of protein kinase C expression and  
therapeutic use  
90146-10-4P 163759-49-7P 163759-50-0P 163759-94-2P 182495-98-3P  
182496-00-0P 182496-01-1P prepn. and reaction; methoxyethoxy  
oligonucleotides for modulation of protein kinase C expression and  
therapeutic use  
93-97-0 103-24-7 109-86-4 1463-10-1 37306-44-8 40615-36-9 102691-36-1  
reaction; methoxyethoxy oligonucleotides for modulation of protein  
kinase C expression and therapeutic use

14/7/133 (Item 26 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2000 American Chemical Society. All rts. reserv.

130306599 CA: 130(23)306599g PATENT

Antisense oligonucleotides capable of binding to multiple targets and  
their use in the treatment of respiratory disease

INVENTOR(AUTHOR): Nyce, Jonathan W.

LOCATION: USA

ASSIGNEE: East Carolina University

PATENT: PCT International ; WO 9913886 A1 DATE: 19990325

APPLICATION: WO 98US19419 (19980917) \*US 59160 (19970917) \*US 93972  
(19980609)

PAGES: 120 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-031/70A;  
A61K-048/00B; C07H-021/00B; C07H-021/04B; C12N-005/10B

DESIGNATED COUNTRIES: AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN;  
CU; CZ; DE; DK; EE; ES; FI; GB; GE; GH; GM; HR; HU; ID; IL; IS; JP; KE; KG;  
KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MD; MG; MK; MN; MW; MX; NO; NZ; PL;  
PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; UA; UG; US; UZ; VN; YU;  
ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS  
; MW; SD; SZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT;  
LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD;  
TG

SECTION:

CA201009 Pharmacology

CA203XXX Biochemical Genetics

IDENTIFIERS: antisense oligonucleotide multiple target respiratory  
disease, bronchorestriction antisense oligonucleotide multiple target,  
inflammation antisense oligonucleotide multiple target, allergy antisense

oligonucleotide multiple target, asthma antisense oligonucleotide multiple target, adenosine receptor antisense oligonucleotide respiratory disease

DESCRIPTORS:

Adenosine receptors... Adrenoceptors... Allergy inhibitors... Androgen receptors... Anterior pituitary hormone receptors... Antiasthmatics... Anti-inflammatory drugs... A1 receptor(adenosine)... A2a receptor(adenosine)... A2b receptor(adenosine)... bcl-2 gene(animal)... Bradykinin receptors... Bronchoconstriction... B2 receptor(bradykinin)... Capsules(drug delivery systems)... CD11b(antigen)... CD34(antigen)... Cell adhesion molecules... Chemokine receptors... Chemokines... Cholinergic receptors... Cyclophilins... c-myc gene(animal)... c-src gene(animal)... Dopamine receptors... Drug delivery systems... Enzymes,biological studies... Eosinophil cationic protein... Estrogen receptors... ETA receptors... ETB receptors... E-selectin... Fc receptors... Fc.epsilon. receptors... Fc.epsilon.RII receptors... Fibronectins... FKBP(protein)... GABA receptors... Glucagon receptors... Growth factors(animal)... Histamine receptors... ICAM-1(cell adhesion molecule)... ICAM-2(cell adhesion molecule)... ICAM-3(cell adhesion molecule)... Immunoglobulins... Insulin receptors... Integrin .alpha.4.beta.1... Integrin .beta.2... Interleukin receptors... Interleukin 1 receptors... Interleukin 1.beta.... Interleukin 11... Interleukin 1... Interleukin 3 receptors... Interleukin 3... Interleukin 4... Interleukin 5 receptors... Interleukin 5... Interleukin 6 receptors... Interleukin 6... Interleukin 8 receptors... Interleukin 8... Interleukin 9... Interleukins... Lecithins... Leukotriene B4 receptors... LFA-1(antigen)... L-selectin... Macrophage inflammatory protein 1.alpha.... Mac-1 antigen... Major basic protein... Monocyte chemoattractant protein-1... Muscarinic receptors... M1 receptor(muscarinic)... M3 receptor(muscarinic)... Neuropeptide receptors... Neuropeptides... Neurotransmitters... NF-.kappa.B... NK1 receptor... NK3 receptor... Omega-3 fatty acids... PECAM-1(cell adhesion molecule)... Polyoxyalkylenes,biological studies... Polyunsaturated fatty acids... Progesterone receptors... Prostanoid receptors... p150,95 antigen... P-selectin... RANTES(chemokine)... ras gene(animal)... Respiratory tract diseases... Sprays(drug delivery systems)... Surfactants... Tachykinin receptors... Thyroid hormone receptors... Transcription factor AP-1... Transcription factor GATA-1... Transcription factor NF-IL6... Transcription factors... Transforming proteins... Tumor necrosis factor .alpha.... VCAM-1(cell adhesion molecule)... .beta.2-Adrenoceptors... 5-HT receptors...

antisense oligonucleotides capable of binding to multiple targets and their use in treatment of respiratory disease

Sialoglycoproteins...

asialoglycoproteins, cell internalization agents; antisense oligonucleotides capable of binding to multiple targets and their use in treatment of respiratory disease

Adenosine receptors...

A3; antisense oligonucleotides capable of binding to multiple targets and their use in treatment of respiratory disease

Interleukin 1 receptors...

.beta.; antisense oligonucleotides capable of binding to multiple targets and their use in treatment of respiratory disease

Chemokine receptors...

.beta. chemokine receptor CCR1; antisense oligonucleotides capable of binding to multiple targets and their use in treatment of respiratory disease

(etc.)...

CAS REGISTRY NUMBERS:

196470-20-2 adenosine A1 receptor-specific; antisense oligonucleotides capable of binding to multiple targets and their use in treatment of respiratory disease

222186-96-1 adenosine A2b receptor-specific; antisense oligonucleotides capable of binding to multiple targets and their use in treatment of respiratory disease

186470-21-3 186470-22-4 222186-91-6 222186-93-8 222186-95-0 adenosine A3 receptor-specific; antisense oligonucleotides capable of binding to multiple targets and their use in treatment of respiratory disease

62-49-7 107-73-3 987-58-0 9001-62-1 9001-84-7 9001-82-7 9002-03-3  
 9002-06-6 9002-93-1 9002-93-1 9003-99-0 9004-06-2 9013-05-2  
 9013-79-0 9024-61-7 9031-44-1 9031-56-5 9031-61-2 9035-73-8  
 9036-21-9 9037-80-3 9039-45-6 9040-57-7 9075-53-0 25322-68-3  
 25322-69-4 33507-63-0 39391-18-9 56626-18-7 65154-06-5 65802-85-9  
 80295-54-1 80619-02-9 80804-53-1 81669-70-7 83682-98-8 83869-56-1  
 90698-32-1 95233-18-4 97501-92-3 97501-93-4 99732-49-7 103220-14-0  
 106096-93-9 106392-12-5 108778-82-1 122653-71-8 123626-67-5  
 141436-78-4 142243-02-5 143011-72-7 144189-73-1 165245-96-5  
 222300-73-4 222300-75-6 222300-76-7 222300-77-8 222300-78-9  
 222300-79-0 222300-80-3 222300-81-4 222300-82-5 222300-83-6  
 222300-84-7 222300-85-8 222300-86-9 222300-87-0 222300-88-1  
 222300-89-2 222300-90-5 222300-91-6 222300-94-9 222300-98-3  
 222301-05-5 222301-06-6 222301-07-7 222301-10-2 222301-11-3  
 222301-12-4 222301-15-7 222301-16-8 222301-17-9 222301-19-0  
 222301-19-1 222301-20-4 222301-21-5 222301-22-6 222301-23-7  
 222301-24-8 222301-25-9 222301-26-0 222301-27-1 222301-28-2  
 222301-29-3 222301-31-7 222301-32-8 222301-34-0 222301-35-1  
 222301-36-2 222301-37-3 222301-38-4 222301-39-5 222301-40-8  
 222301-41-9 222301-42-0 222301-43-1 222301-44-2 222301-45-3  
 222301-46-4 222301-47-5 222301-48-6 222301-49-7 222301-50-0  
 222301-52-2 222301-53-3 222301-54-4 222301-55-5 222301-56-6  
 222301-57-7 222301-58-8 222301-59-9 222301-62-4 222301-63-5  
 222301-64-6 222301-65-7 222301-66-8 222301-67-9 222301-69-1  
 222301-73-7 222301-74-8 222301-75-9 222301-76-0 222301-77-1  
 222301-78-2 222301-79-3 222301-80-6 222301-81-7 222301-82-8  
 222301-83-9 antisense oligonucleotides capable of binding to multiple  
 targets and their use in treatment of respiratory disease  
 51-55-8 biological studies, receptor; antisense oligonucleotides capable  
 of binding to multiple targets and their use in treatment of  
 respiratory disease  
 56-81-5 biological studies, surfactant; antisense oligonucleotides capable  
 of binding to multiple targets and their use in treatment of  
 respiratory disease  
 9013-20-1 cell internalization agents; antisense oligonucleotides capable  
 of binding to multiple targets and their use in treatment of  
 respiratory disease  
 11029-02-0D compds., surfactant; antisense oligonucleotides capable of  
 binding to multiple targets and their use in treatment of respiratory  
 disease  
 63-38-7D compds. with diacylglycerols, antisense oligonucleotides capable  
 of binding to multiple targets and their use in treatment of  
 respiratory disease  
 136676-07-3 control for adenosine A1 receptor-specific; antisense  
 oligonucleotides capable of binding to multiple targets and their use  
 in treatment of respiratory disease  
 136676-09-5 control for adenosine A3 receptor-specific; antisense  
 oligonucleotides capable of binding to multiple targets and their use  
 in treatment of respiratory disease  
 26330-38-9D dextran and/or alkanoyl side chains, antisense  
 oligonucleotides capable of binding to multiple targets and their use  
 in treatment of respiratory disease  
 158492-48-9 188704-72-5 208884-01-9 222024-49-9 222024-50-2  
 222024-51-3 222024-52-4 222024-53-5 222024-54-6 222024-55-7  
 222024-56-8 222024-57-9 222024-60-4 222024-63-7 222024-64-8  
 222024-65-9 222024-66-0 222024-67-1 222024-69-3 222024-71-7  
 222024-72-8 222024-73-9 222024-74-0 222024-75-1 222024-76-2  
 222024-77-3 222024-78-4 222024-79-5 222024-80-8 222024-81-9  
 222024-83-1 222024-84-2 222024-85-3 222024-86-4 222024-87-5  
 222024-88-6 222024-89-7 222024-90-0 222024-91-1 222024-92-2  
 222024-93-3 222024-94-4 222024-95-5 222024-96-6 222024-97-7  
 222025-02-7 222025-03-8 222025-04-9 222025-05-0 222025-06-1  
 222025-07-2 222025-08-3 222025-09-4 222025-10-7 222025-11-8  
 222025-12-9 222025-13-0 222025-14-1 222025-15-2 222025-16-3  
 222025-17-4 222025-18-5 222025-19-6 222025-21-0 222025-23-2

222025-30-1	222025-33-4	222025-35-6	222025-38-9	222025-39-0
222025-40-3	222025-31-4	222025-42-5	222025-43-6	222025-44-7
222025-45-8	222025-46-9	222025-47-0	222025-48-1	222025-49-2
222025-52-7	222025-53-8	222025-54-9	222025-55-0	222025-56-1
222025-57-2	222025-58-3	222025-59-4	222025-60-7	222025-61-8
222025-62-9	222025-63-0	222025-64-1	222025-65-2	222025-66-3
222025-67-4	222025-68-5	222025-69-6	222025-70-9	222025-71-0
222025-72-1	222025-73-2	222025-75-4	222025-77-6	222025-78-7
222025-79-8	222025-80-1	222025-83-4	222025-86-7	222025-87-8
222025-88-9	222025-89-0	222025-90-3	222025-91-4	222025-92-5
222026-02-0	222026-03-1	222026-07-5	222026-09-7	222026-13-3
222026-18-8	222026-19-9	222026-20-2	222026-21-3	222026-22-4
222026-23-5	222026-24-6	222026-25-7	222026-26-8	222026-27-9
222026-31-5	222026-32-6	222026-33-7	222026-34-8	222026-37-1
222026-40-6	222026-42-8	222026-45-1	222026-47-3	222026-51-9
222026-54-2	222026-57-5	222026-59-7	222026-64-4	222026-65-5
222026-66-6	222026-67-7	222026-68-8	222026-69-9	222026-70-2
222026-72-4	222026-74-6	222026-75-7	222026-77-9	222026-79-1
222026-80-4	222026-82-6	222026-83-7	222026-84-8	222026-85-9
222026-86-0	222026-87-1	222026-88-2	222026-90-6	222026-92-8
222026-94-0	222026-96-2	222026-98-4	222027-01-2	222027-04-5
222027-05-6	222027-07-8	222027-10-3	222027-24-9	222027-27-2
222027-30-7	222027-32-9	222027-34-1	222027-36-3	222027-38-5
222027-41-0	222027-43-2	222027-45-4	222027-47-6	222027-48-7
222027-49-8	222027-50-1	222027-51-2	222027-53-4	222027-55-6
222027-57-8	222027-60-3	222027-61-4	222027-62-5	222027-63-6
222027-64-7	222028-22-0	222028-24-2	222028-26-4	222028-27-5
222028-28-6	222028-29-7	222028-30-0	222028-31-1	222028-39-9
222028-42-4	222028-45-7	222028-47-9	222028-51-5	222028-52-6
222028-53-7	222028-54-8	222028-55-9	222028-56-0	222028-57-1
222028-60-6	222028-62-8	222028-63-9	222028-64-0	222028-67-3
222028-71-9	222028-75-3	222028-78-6	222028-81-1	222028-84-4
222028-89-9	222028-92-4	222028-93-5	222028-94-6	222028-96-8
222028-97-9	222028-98-0	222028-99-1	222029-00-7	222029-02-9
222029-04-1	222029-05-2	222029-07-4	222029-08-5	222029-09-6
222029-10-9	222029-11-0	222029-12-1	222029-13-2	222029-14-3
222029-15-4	222029-17-6	222029-20-1	222029-23-4	222029-25-6
222029-29-0	222029-32-5	222029-33-6	222029-34-7	222029-36-9
222029-37-0	222029-38-1	222029-39-2	222029-41-6	222029-42-7
222029-43-8	222029-46-1	222029-47-2	222029-48-3	222029-49-4
222029-50-7	222029-51-8	222029-52-9	222029-53-0	222029-54-1
222029-55-2	222029-56-3	222029-57-4	222029-58-5	222029-60-9
222029-62-1	222029-64-3	222029-65-4	222029-66-5	222029-68-7
222029-69-8	222029-70-1	222029-71-2	222029-72-3	222029-73-4
222029-74-5	222029-75-6	222029-76-7	222029-77-8	222029-78-9
222029-79-0	222029-80-3	222029-81-4	222029-82-5	222029-83-6
222029-84-7	222029-85-8	222029-86-9	222029-87-0	222029-88-1
222029-89-2	222029-90-5	222029-91-6	222029-92-7	222029-93-8
222029-94-9	222029-95-0	222029-97-2	222029-98-3	222030-00-4
222030-02-6	222030-04-8	222030-06-0	222030-09-3	222030-11-7
222030-13-9	222030-16-2	222030-18-4	222030-19-5	222030-20-8
222030-21-9	222030-24-2	222030-25-3	222030-26-4	222030-27-5
222030-28-6	222030-29-7	222030-30-0	222030-31-1	222030-32-2
222030-33-3	222030-34-4	222030-35-5	222030-36-6	222030-37-7
222030-38-8	222030-39-9	222030-42-4	222030-46-8	222030-50-4
222030-54-8	222030-62-8	222030-64-0	222030-65-1	222030-66-2
222030-67-3	222030-68-4	222030-69-5	222030-70-8	222030-71-9
222030-72-0	222030-73-1	222030-74-2	222030-75-3	222030-76-4
222030-77-5	222030-78-6	222030-81-1	222030-85-5	222030-86-6
222030-87-7	222030-88-8	222030-89-9	222030-90-2	222030-91-3
222030-92-4	222030-93-5	222030-94-6	222030-95-7	222030-96-8
222030-97-9	222030-98-0	222030-99-1	222031-00-7	222031-01-8
222031-02-9	222031-03-0	222031-04-1	222031-05-2	222031-06-3
222031-07-4	222031-08-5	222031-09-6	222031-10-9	222031-11-0
222031-12-1	222031-13-2	222031-14-3	222031-15-4	222031-16-5



222031-17-6	222031-18-7	222031-19-8	222031-20-1	222031-21-2
222031-22-3	222031-23-4	222031-24-5	222031-25-6	222031-26-7
222031-27-8	222031-28-9	222031-29-0	222031-30-3	222031-31-4
222031-32-5	222031-34-7	222031-36-9	222031-37-0	222031-38-1
222031-41-6	222031-44-9	222031-45-0	222031-46-1	222031-47-2
222031-48-3	222031-49-4	222031-50-7	222031-51-8	222031-52-9
222031-53-0	222031-54-1	222031-55-2	222031-56-3	222031-57-4
222031-58-5	222031-59-6	222031-60-9	222031-61-0	222031-62-1
222031-64-3	222031-65-4	222031-66-5	222031-67-6	222031-68-7
222031-69-8	222031-70-1	222031-71-2	222031-72-3	222031-73-4
222031-74-5	222031-75-6	222031-76-7	222031-77-8	222031-78-9
222031-79-0	222031-80-3	222031-81-4	222031-82-5	222031-83-6
222031-86-9	222031-90-5	222031-94-9	222031-98-3	222032-00-0
222032-02-2	222032-03-3	222032-04-4	222032-06-6	222032-07-7
222032-09-9	222032-10-2	222032-11-3	222032-12-4	222032-13-5
222032-14-6	222032-15-7	222032-16-8	222032-17-9	222032-18-0
222032-19-1	222032-20-4	222032-22-6	222032-23-7	222034-04-0
222034-05-1	222034-06-2	222034-07-3	222034-08-4	222034-09-5
222034-10-8	222034-11-9	222034-13-1	222034-14-2	222034-15-3
222034-16-4	222034-17-5	222034-18-6	222034-19-7	222034-21-1
222034-22-2	222034-23-3	222034-24-4	222034-25-5	222034-26-6
222034-27-7	222034-28-8	222034-31-3	222034-32-4	222034-33-5
222034-34-6	222034-35-7	222034-36-8	222034-37-9	222034-38-0
222034-39-1	222034-40-4	222034-41-5	222034-42-6	222034-43-7
222034-44-8	222034-45-9	222034-46-0	222034-47-1	222034-48-2
222034-49-3	222034-50-6	222034-51-7	222034-56-2	222034-60-8
222034-63-1	222034-65-3	222034-66-4	222034-68-6	222034-69-7
222034-70-0	222034-71-1	222034-72-2	222034-73-3	222034-76-6
222034-80-2	222034-84-6	222034-88-0	222034-91-5	222034-98-2
222035-02-2	222035-09-8	222035-19-0	222035-23-6	222035-27-0
222035-31-6	222035-35-0	222035-41-8	222035-45-2	222035-49-6
222035-53-2	222035-56-5	222035-59-8	222035-62-3	222035-65-6
222035-69-0	222035-73-6	222035-77-0	222035-82-7	222035-85-0
222035-89-4	222035-94-1	222035-96-3	222036-00-2	222036-03-5
222036-07-9	222036-11-5	222036-15-9	222036-25-1	222036-29-5
222036-32-0	222036-35-3	222036-38-6	222036-42-2	222036-44-4
222036-48-8	222036-52-4	222036-88-6	222036-93-3	222036-97-7
222037-02-7	222037-04-9	222037-07-2	222037-08-3	222037-11-8
222037-15-2	222037-16-3	222037-17-4	222037-18-5	222037-19-6
222037-20-9	222037-21-0	222037-22-1	222037-24-3	222037-28-7
222037-29-8	222037-30-1	222037-31-2	222037-32-3	222037-33-4
222037-34-5	222037-35-6	222037-36-7	222037-37-8	222037-38-9
222037-39-0	222037-40-3	222037-41-4	222037-42-5	222037-43-6
222037-44-7	222037-45-8	222037-46-9	222037-47-0	222037-48-1
222037-49-2	222037-50-5	222037-51-6	222037-52-7	222037-53-8
222037-54-9	222037-55-0	222037-59-4	222037-63-0	222037-67-4
222037-69-6	222037-72-1	222037-74-3	222037-82-3	222037-88-4
222037-84-5	222037-85-6	222037-88-9	222037-89-0	222037-90-3
222037-91-4	222037-92-5	222037-93-6	222037-94-7	222037-95-8
222037-96-9	222037-97-0	222037-98-1	222037-99-2	222038-00-8
222038-01-9	222038-02-0	222038-03-1	222038-04-2	222038-05-3
222038-06-4	222038-17-7	222038-24-6	222038-25-7	222038-26-8
222038-27-9	222038-28-0	222038-29-1	222038-30-4	222038-31-5
222038-32-6	222038-33-7	222038-34-8	222038-35-9	222038-36-0
222038-37-1	222038-38-2	222038-39-3	222038-40-6	222038-41-7
222038-42-8	222038-43-9	222038-44-0	222038-45-1	222038-46-2
222038-47-3	222038-48-4	222038-49-5	222038-50-8	222038-51-9
222038-52-0	222038-53-1	222038-54-2	222038-55-3	222038-56-4
222038-57-5	222038-58-6	222038-60-0	222038-61-1	222038-62-2
222038-63-3	222038-64-4	222038-65-5	222038-66-6	222038-67-7
222038-68-8	222038-69-9	222038-70-2	222038-71-3	222038-72-4
222038-73-5	222038-74-6	222038-75-7	222038-76-8	222038-77-9
222038-78-0	222038-79-1	222038-80-4	222038-82-6	222038-83-7
222038-84-8	222038-85-9	222038-86-0	222038-87-1	222038-88-2
222038-89-3	222038-90-6	222038-91-7	222038-92-8	222038-93-9

222038-94-0 222038-95-1 222038-96-2 222038-97-3 222038-98-4  
 222038-99-5 222038-100-1 222039-01-2 222039-02-3 222039-03-4  
 222039-04-5 222039-05-6 222039-06-7 222039-08-9 222039-09-0  
 222039-10-3 222039-11-4 222039-12-5 222039-13-6 222039-15-8  
 222039-16-9 222039-17-0 222039-18-1 222039-19-2 222039-20-5  
 222039-21-6 222039-22-7 222039-23-8 222039-24-9 222039-25-0  
 222039-26-1 222039-27-2 222039-28-3 222039-29-4 222039-30-7  
 222039-31-8 222039-32-9 222039-33-0 222039-34-1 222039-35-2  
 222039-36-3 222039-37-4 222039-38-5 222039-39-6 222039-40-9  
 222039-41-0 222039-42-1 222039-43-2 222039-47-6 222039-48-7  
 222039-50-1 222039-51-2 222039-52-3 222039-53-4 222039-54-5  
 222039-55-6 222039-56-7 222039-57-8 222039-58-9 222039-59-0  
 222039-60-3 222039-61-4 222039-62-5 222039-63-6 222039-64-7  
 222039-65-8 222039-66-9 222039-67-0 222039-68-1 222039-69-2  
 222039-70-5 222039-71-6 222039-72-7 222039-73-8 222039-74-9  
 222039-75-0 222039-76-1 222039-77-2 222039-78-3 222039-79-4  
 222039-80-7 222039-81-8 222039-82-9 222039-83-0 222039-84-1  
 222039-85-2 222039-86-3 222039-87-4 222039-88-5 222039-89-6  
 222039-90-9 222039-91-0 222039-92-1 222039-93-2 222039-94-3  
 222039-95-4 222039-96-5 222039-97-6 222039-98-7 222039-99-8  
 222040-00-8 222040-01-9 222040-02-0 222040-03-1 222040-04-2  
 222040-05-3 222040-06-4 222040-07-5 222040-08-6 222040-09-7  
 222040-10-0 222040-11-1 222040-12-2 222040-13-3 222040-14-4  
 222040-15-5 222040-16-6 222040-17-7 222040-18-8 222040-19-9  
 222040-20-2 222040-21-3 222040-22-4 222040-34-8 222040-37-1  
 222040-38-2 222040-40-6 222040-41-7 222040-42-8 222040-43-9  
 222040-44-0 (etc.) human adenosine A1 receptor-specific; antisense  
 oligonucleotides capable of binding to multiple targets and their use  
 in treatment of respiratory disease

14/7/136 (Item 29 from file: 399)  
 DIALOG(F)File 399:CA SEARCH(R)  
 (c) 2000 American Chemical Society. All rts. reserv.

130218305 CA: 130(17)218305c PATENT  
 Antisense inhibition of endothelin-1 gene expression in treatment of  
 pulmonary hypertension  
 INVENTOR(AUTHOR): Higenbottam, Timothy; McCormack, Keith; Smith, Adrian  
 LOCATION: UK,  
 ASSIGNEE: University of Sheffield  
 PATENT: PCT International ; WO 9911778 A1 DATE: 19990311  
 APPLICATION: WO 98GB2584 (19980902) \*GB 9718487 (19970902)  
 PAGES: 35 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-015/11A;  
 A61K-031/70B; A61M-015/00B; A61M-011/00B; B65D-083/14B  
 DESIGNATED COUNTRIES: AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN;  
 CU; DE; DK; EE; ES; FI; GB; GE; GH; GM; HP; HU; ID; IL; IS; JP; KE; KG;  
 KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MD; MG; MK; MN; MW; MX; NO; NZ; PL;  
 PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; UA; UG; US; UZ; VN; YU;  
 ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS  
 ; MW; SD; SZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT;  
 LJ; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD;  
 TG

SECTION:  
 CA201009 Pharmacology  
 IDENTIFIERS: antisense oligonucleotide endothelin gene pulmonary  
 hypertension  
 DESCRIPTORS:  
 Antisense oligonucleotides... Pulmonary hypertension...  
 antisense inhibition of ET-1 gene expression in treatment of pulmonary  
 hypertension  
 Genes(animal)...  
 EDN1; antisense inhibition of ET-1 gene expression in treatment of  
 pulmonary hypertension  
 DNA sequences...

of endothelin-1 gene and antisense oligonucleotides from human  
CAS REGISTRY NUMBERS

123626-67-5 140972-35-6 antisense inhibition of ET-1 gene expression in  
treatment of pulmonary hypertension  
221039-17-4 HsET117; antisense inhibition of ET-1 gene expression in  
treatment of pulmonary hypertension  
221039-20-9 HsET132; antisense inhibition of ET-1 gene expression in  
treatment of pulmonary hypertension  
221039-22-1 HsET318; antisense inhibition of ET-1 gene expression in  
treatment of pulmonary hypertension  
221039-23-2 HsET438; antisense inhibition of ET-1 gene expression in  
treatment of pulmonary hypertension  
221039-24-3 HsET454; antisense inhibition of ET-1 gene expression in  
treatment of pulmonary hypertension  
221039-25-4 HsET779; antisense inhibition of ET-1 gene expression in  
treatment of pulmonary hypertension  
221039-26-5 HsET868; antisense inhibition of ET-1 gene expression in  
treatment of pulmonary hypertension  
221039-32-3 PnET1081; antisense inhibition of ET-1 gene expression in  
treatment of pulmonary hypertension  
221039-27-6 PnET198; antisense inhibition of ET-1 gene expression in  
treatment of pulmonary hypertension  
221039-28-7 PnET294; antisense inhibition of ET-1 gene expression in  
treatment of pulmonary hypertension  
221039-29-8 PnET466; antisense inhibition of ET-1 gene expression in  
treatment of pulmonary hypertension  
221039-30-1 PnET718; antisense inhibition of ET-1 gene expression in  
treatment of pulmonary hypertension  
221039-31-2 PnET795; antisense inhibition of ET-1 gene expression in  
treatment of pulmonary hypertension

14/7/145 (Item 38 from file: 399)  
LIALOG(R)File 399:CA SEARCH(R)  
(c) 2000 American Chemical Society. All rts. reserv.

129072195 CA: 129(6)72195x PATENT  
Agent and method of treatment for diseases and conditions associated with  
respiratory ailments and lung inflammation  
INVENTOR(AUTHOR): Nyce, Jonathan W.  
LOCATION: USA  
ASSIGNEE: East Carolina University; Nyce, Jonathan W.  
PATENT: PCT International ; WO 9823294 A1 DATE: 19980604  
APPLICATION: WO 97US22017 (19971126) \*US 757024 (19961126)  
PAGES: 47 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-048/00A;  
C07H-021/04B; C07H-021/00B; C12N-005/00B; C12N-015/63B; C12N-015/79B;  
C12N-015/09B DESIGNATED COUNTRIES: AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY;  
CA; CH; CN; CU; CZ; DE; DK; EE; ES; FI; GB; GE; HU; ID; IL; IS; JP; KE; KG;  
KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MD; MG; MK; MN; MW; MX; NO; NZ; PL;  
PT; RO; RU; SD; SE; SG; SI; SK; TJ; TM; TR; TT; UA; UG; US; UZ; VN; YU; ZW;  
AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; KE; LS; MW; SD  
; SZ; UG; ZW; AT; BE; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL;  
PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; ML; MR; NE; SN; TD; TG

SECTION:  
CA263005 Pharmaceuticals  
CA201XXX Pharmacology  
IDENTIFIERS: sequence antisense oligonucleotide lung antiinflammatory,  
bronchodilator antisense oligonucleotide sequence  
DESCRIPTORS:  
Genes(animal)...  
adenosine and bradykinin receptors-encoding; antisense oligonucleotides  
for treatment of respiratory ailments and lung inflammation  
Adult respiratory distress syndrome... Allergies... Allergy inhibitors...  
Antiasthmatics... Antioxidants... Antisense oligonucleotides...  
Anti-inflammatory drugs... Bronchoconstriction... Bronchodilators...

Buffers... cDNA sequences... Chronic obstructive pulmonary disease...  
Dispersing agents... Drug carriers(drug delivery systems)... Drug  
delivery systems... Emphysema... Essential oils... Flavoring materials...  
Inhalers(medical)... Liposomes(drug delivery systems)... mRNA... Organic  
solvents... Phosphorothioate oligodeoxyribonucleotides... Preservatives...  
Propellants(fuels)... Pulmonary hypertension... Pulmonary inflammation...  
Respiratory tract diseases... Ribozymes... Sprays(drug delivery systems)...  
Surfactants... Transferrins... Uptake(biological)...

antisense oligonucleotides for treatment of respiratory ailments and  
lung inflammation

Sialoglycoproteins...

asialoglycoproteins; antisense oligonucleotides for treatment of  
respiratory ailments and lung inflammation

Oligodeoxyribonucleotides...

boranophosphate; antisense oligonucleotides for treatment of  
respiratory ailments and lung inflammation

Oligodeoxyribonucleotides...

carbamate; antisense oligonucleotides for treatment of respiratory  
ailments and lung inflammation

Oligodeoxyribonucleotides...

carbonate; antisense oligonucleotides for treatment of respiratory  
ailments and lung inflammation

Oligodeoxyribonucleotides...

formacetal; antisense oligonucleotides for treatment of respiratory  
ailments and lung inflammation

Adenosine receptors... A1 receptor(adenosine)... A2a receptor(adenosine)...

A2b receptor(adenosine)... A3 receptor(adenosine)... Bradykinin receptors

... B2 receptor(bradykinin)...

gene encoding; antisense oligonucleotides for treatment of respiratory  
ailments and lung inflammation

Oligodeoxyribonucleotides...

hydroxylamine; antisense oligonucleotides for treatment of respiratory  
ailments and lung inflammation

Genetic elements...

intron/exon junction; antisense oligonucleotides for treatment of  
respiratory ailments and lung inflammation

Oligodeoxyribonucleotides...

methylene(methylimino); antisense oligonucleotides for treatment of  
respiratory ailments and lung inflammation

Oligodeoxyribonucleotides...

methyleneoxy(methylimino); antisense oligonucleotides for treatment of  
respiratory ailments and lung inflammation

Oligodeoxyribonucleotides...

methylphosphonate; antisense oligonucleotides for treatment of  
respiratory ailments and lung inflammation

Drug delivery systems...

microcrystals; antisense oligonucleotides for treatment of respiratory  
ailments and lung inflammation

Enzymes,biological studies...

mRNA-inactivating; antisense oligonucleotides for treatment of  
respiratory ailments and lung inflammation

Oligodeoxyribonucleotides...

phosphoramidate; antisense oligonucleotides for treatment of  
respiratory ailments and lung inflammation

Oligodeoxyribonucleotides...

phosphorodithioate; antisense oligonucleotides for treatment of  
respiratory ailments and lung inflammation

Oligodeoxyribonucleotides...

phosphotriester; antisense oligonucleotides for treatment of  
respiratory ailments and lung inflammation

Oligodeoxyribonucleotides...

sulfamate; antisense oligonucleotides for treatment of respiratory  
ailments and lung inflammation

Oligodeoxyribonucleotides...

sulfate; antisense oligonucleotides for treatment of respiratory

ailments and lung inflammation  
Oligodeoxyribonucleotides...  
sulfonamide; antisense oligonucleotides for treatment of respiratory  
ailments and lung inflammation  
Oligodeoxyribonucleotides...  
sulfonate; antisense oligonucleotides for treatment of respiratory  
ailments and lung inflammation  
Oligodeoxyribonucleotides...  
sulfone; antisense oligonucleotides for treatment of respiratory  
ailments and lung inflammation  
Oligodeoxyribonucleotides...  
thioether; antisense oligonucleotides for treatment of respiratory  
ailments and lung inflammation  
Oligodeoxyribonucleotides...  
thioformacetal; antisense oligonucleotides for treatment of respiratory  
ailments and lung inflammation  
Oligonucleotides...  
2'-O-Me; antisense oligonucleotides for treatment of respiratory  
ailments and lung inflammation  
CAS REGISTRY NUMBERS:  
9013-20-1 144189-73-1 antisense oligonucleotides for treatment of  
respiratory ailments and lung inflammation  
208882-68-2 208884-01-9 208884-02-0 208884-03-1 nucleotide sequence;  
antisense oligonucleotides for treatment of respiratory ailments and  
lung inflammation

14/7/150 (Item 43 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
© 2000 American Chemical Society. All rts. reserv.

128031092 CA: 128(4)31092x PATENT  
Antisense oligonucleotides for inhibiting the expression of  
platelet-derived growth factor for treating lung fibrosis  
INVENTOR(AUTHOR): Ohta, Ken  
LOCATION: Japan,  
ASSIGNEE: Otsuka Pharmaceutical Co., Ltd.; Ohta, Ken  
PATENT: PCT International ; WO 9744046 A1 DATE: 19971127  
APPLICATION: WO 97JP1637 (19970515) \*JP 96148090 (19960517)  
PAGES: 35 pp. CODEN: PIKXD2 LANGUAGE: Japanese CLASS: A61K-031/70A;  
A61K-048/00B; C12N-015/00B DESIGNATED COUNTRIES: AU; BR; CA; CN; KR; MX;  
US DESIGNATED REGIONAL: AT; BE; CH; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU  
; MC; NL; PT; SE

SECTION:  
CA203001 Biochemical Genetics  
CA201XXX Pharmacology  
CA202XXX Mammalian Hormones  
IDENTIFIERS: antisense oligonucleotide PDGF expression inhibition,  
interstitial pneumonia PDGF expression inhibition, lung fibrosis PDGF  
expression inhibition

DESCRIPTORS:  
Antisense oligonucleotides... Gene therapy... Platelet-derived growth  
factors... Pulmonary fibrosis...  
antisense oligonucleotides for inhibiting expression of  
platelet-derived growth factor for treating lung fibrosis  
Pneumonia...  
interstitial; antisense oligonucleotides for inhibiting expression of  
platelet-derived growth factor for treating lung fibrosis

CAS REGISTRY NUMBERS:  
199687-01-9P 199687-02-0P 199687-03-1P 199687-04-2P 199687-05-3P  
199687-06-4P 199687-07-5P 199687-08-6P 199687-09-7P 199687-10-0P  
oligonucleotide derived from mouse PDGF-B chain; antisense  
oligonucleotides for inhibiting expression of platelet-derived growth  
factor for treating lung fibrosis

14/7/152 (Item 48 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2000 American Chemical Society. All rts. reserv.

127287450 CA: 127(21)287450w JOURNAL  
Respirable antisense oligonucleotides as novel therapeutic agents for  
asthma and other pulmonary diseases  
AUTHOR(S): Nyce, Jonathan W.  
LOCATION: Department of Molecular Pharmacology and Therapeutics,  
EpiGenesis Pharmaceuticals, Inc., Durham, NC, 27707, USA  
JOURNAL: Expert Opin. Invest. Drugs DATE: 1997 VOLUME: 6 NUMBER: 9  
PAGES: 1149-1156 CODEN: EOIDER ISSN: 0967-8298 LANGUAGE: English  
PUBLISHER: Ashley Publications  
SECTION:  
CA261000 Pharmacology  
IDENTIFIERS: review antisense oligonucleotide inhalant lung disease,  
asthma inhibitor antisense oligonucleotide inhalant review  
DESCRIPTORS:  
Antiasthmatics... Antisense oligonucleotides... Inhalants(drug delivery  
systems)... Lung diseases...  
respirable antisense oligonucleotides as novel therapeutic agents for  
asthma and other pulmonary diseases

14/7/160 (Item 53 from file: 399)  
DIALOG(R)File 399:CA SEARCH(R)  
(c) 2000 American Chemical Society. All rts. reserv.

126148487 CA: 126(11)148487e PATENT  
Method of treatment for lung diseases using antisense oligonucleotides  
INVENTOR(AUTHOR): Nyce, Jonathan W.; Metzger, W. James  
LOCATION: USA  
ASSIGNEE: East Carolina University; Nyce, Jonathan W.; Metzger, W. James  
PATENT: PCT International ; WO 9640162 A1 DATE: 19961219  
APPLICATION: WO 96US9306 (19960606) \*US 474497 (19950607)  
PAGES: 71PP CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-031/70A  
DESIGNATED COUNTRIES: AL; AM; AT; AU; AZ; BB; BG; BR; BY; CA; CH; CN;  
CS; DE; DK; EE; ES; FI; GB; GE; HU; IL; IS; JP; KE; KG;  
KP; KR; KZ; LK; LR; LS; LT; LU; LV; MD; MG; MK; MN; MW; MX; NO; NZ; PL  
DESIGNATED REGIONAL: KE; LS; MW; SD; SZ; UG; AT; BE; CH; DE; DK; ES; FI;  
FR; GB; GR; IE; IT; LU; MC; NL; PT; SE  
SECTION:  
CA263005 Pharmaceuticals  
CA201XXX Pharmacology  
CA203XXX Biochemical Genetics  
IDENTIFIERS: lung disease antisense oligonucleotide formulation sequence  
DESCRIPTORS:  
mRNA...  
antisense oligonucleotides for; method of treatment for lung diseases  
using antisense oligonucleotides  
Fc receptors...  
E, .beta., mRNA encoding; method of treatment for lung diseases using  
antisense oligonucleotides  
Cytokines...  
EDN (eosinophil-derived neurotoxin), mRNA encoding; method of treatment  
for lung diseases using antisense oligonucleotides  
Proteins(specific proteins and subclasses)...  
macrophage inflammatory protein 1-.alpha., mRNA encoding; method of  
treatment for lung diseases using antisense oligonucleotides  
Antiasthmatics... Antisense oligonucleotides... Anti-inflammatory drugs...  
Bronchitis... Chronic obstructive pulmonary disease... Cystic fibrosis...  
Liposomes(drug delivery systems)... Lung epithelium... Respiratory tract  
diseases... Sprays(drug delivery systems)... VCAM-1(cell adhesion molecule)  
...

method of treatment for lung diseases using antisense oligonucleotides  
A2a receptor(adenosine)... A2b receptor(adenosine)......ophil cationic  
protein... E-selectin... Fc.epsilon.RII receptors... Fibronectins...  
ICAM-1(cell adhesion molecule)... Interleukin 3... Interleukin 4...  
Interleukin 5... Interleukin 6... Interleukin 8... Major basic protein...  
Muscarinic receptors... P-selectin... Tumor necrosis factor .alpha....  
mRNA encoding; method of treatment for lung diseases using antisense  
oligonucleotides

Phosphates,biological studies...

phosphorodithioates; method of treatment for lung diseases using  
antisense oligonucleotides

Phosphates,biological studies...

phosphorothioates; method of treatment for lung diseases using  
antisense oligonucleotides

IgE...

receptors, .beta., mRNA encoding; method of treatment for lung diseases  
using antisense oligonucleotides

#### CAS REGISTRY NUMBERS:

97501-93-4 .beta., mRNA encoding; method of treatment for lung diseases  
using antisense oligonucleotides

53-61-7 biological studies, oligonucleotides devoid of; method of  
treatment for lung diseases using antisense oligonucleotides

186470-20-2P 186470-21-3P 186470-22-4P 186556-26-3P 186556-27-4P

186556-28-5P 186556-29-6P 186556-30-9P 186556-31-0P 186556-32-1P

186556-33-2P 186556-34-3P 186556-35-4P 186556-36-5P 186556-37-6P

186556-38-7P 186556-39-8P 186556-40-1P 186556-41-2P 186556-42-3P

186556-43-4P 186556-44-5P 186556-45-6P 186556-46-7P 186556-47-8P

186556-48-9P 186556-49-0P 186556-50-3P 186556-51-4P 186556-52-5P

186619-38-5P 186619-39-6P 186676-07-3P 186676-08-4P 186676-09-5P

method of treatment for lung diseases using antisense oligonucleotides

9003-99-0 9024-61-7 39391-18-9 56645-49-9 65302-85-9 83869-56-1

90698-32-1 123626-67-5 mRNA encoding; method of treatment for lung  
diseases using antisense oligonucleotides

9004-06-2 neutrophilic, mRNA encoding; method of treatment for lung  
diseases using antisense oligonucleotides

103220-14-0 1, mRNA encoding; method of treatment for lung diseases using  
antisense oligonucleotides

14/7/162 (Item 55 from file: 399)

DIALOG(F)File 399:CA SEARCH(R)

(c) 2000 American Chemical Society. All rts. reserv.

135230451 CA: 125(18)230451b JOURNAL

Targeted delivery of antisense oligonucleotides for selective inhibition  
of pulmonary fibrotic cytokines

AUTHOR(S): Liang, W.W.; Rojanasakul, Y.

LOCATION: School of Pharmacy, West Virginia University, Morgantown, WV,  
26506, USA

JOURNAL: Proc. Int. Symp. Controlled Release Bioact. Mater. DATE: 1996

VOLUME: 23rd, PAGES: 917-918 CODEN: PCRMEY ISSN: 1022-0178 LANGUAGE:

English

SECTION:

CA263005 Pharmaceuticals

IDENTIFIERS: antisense oligonucleotide targeting lung fibrotic cytokine

DESCRIPTORS:

Nucleotides,oligo-,biological studies...

antisense; targeted delivery of antisense oligonucleotides for  
selective inhibition of pulmonary fibrotic cytokines

Lymphokines and Cytokines...

pulmonary fibrotic; targeted delivery of antisense oligonucleotides for  
selective inhibition of pulmonary fibrotic cytokines

Lymphokines and Cytokines,tumor necrosis factor-.alpha....

targeted delivery of antisense oligonucleotides for selective  
inhibition of pulmonary fibrotic cytokines

## CAS REGISTRY NUMBERS:

25104-18-1D 38000-06- mannosylated, targeted delivery of antisense oligonucleotides for selective inhibition of pulmonary fibrotic cytokines

181629-70-9D reaction products with polylysine, targeted delivery of antisense oligonucleotides for selective inhibition of pulmonary fibrotic cytokines

? ds

Set	Items	Description
S1	6596	(PULMONARY OR LUNG OR AEROSOL OR AEROSOLIZE OR INHALATE OR INHALATION) AND (OLIGONUCLEOTIDE OR VECTOR OR ANTISENSE OR RIBOZYME)
S2	13	AU="BENNETT, CLARENCE F." OR AU="BENNETT, CLARENCE FRANK"
S3	116	AU="BENNETT, C. F." OR AU="BENNETT, C. FRANK"
S4	129	S2 OR S3
S5	123	FD (unique items)
S6	17	S1 AND S5
S7	17	FD (unique items)
S8	13	S1 AND NEBULIZER
S9	11	FD (unique items)
S10	11	S9 NOT S6
S11	1308	S1 AND OLIGONUCLEOTIDE
S12	1229	S1 AND (ANTISENSE OR RIBOZYME)
S13	308	S11 AND S12
S14	234	FD (unique items)
S15	0	S1 AND ALKOXYALKOXY
S16	0	S1 AND DIALKYLAMINOXYALKYL
S17	0	S1 AND METHYLENEPHOSPHONATE
S18	291	S1 AND (MODIFIED OR MODIFICATION)
S19	262	S18 NOT S14
S20	205	FD (unique items)

? t s20/6/1-105

20/6/1 (Item 1 from file: 155)  
 10352936 20203061  
 Efficient adenoviral gene transfer to kidney cortical vasculature utilizing a fiber **modified vector**.  
 Mar-Apr 1999

20/6/2 (Item 2 from file: 155)  
 10349289 20165125  
 Efficient extracellular production of recombinant Escherichia coli heat-labile enterotoxin B subunit by using the expression/secretion system of Bacillus brevis and its mucosal immunoadjuvanticity.  
 Mar 6 2000

20/6/3 (Item 3 from file: 155)  
 10323901 20177745  
 Targeting the urokinase plasminogen activator receptor enhances gene transfer to human airway epithelia.  
 Mar 2000

20/6/4 (Item 4 from file: 155)  
 10272518 20110559  
 Intratumoral administration of adenoviral interleukin 7 gene-**modified** dendritic cells augments specific antitumor immunity and achieves tumor eradication.  
 Jan 1 2000



20/6/5 (Item 5 from file: 155)  
10272512 20110570

Fibroblast growth factor 2-retargeted adenoviral vectors exhibit a **modified** biolocalization pattern and display reduced toxicity relative to native adenoviral vectors.  
Jan 1 2000

20/6/6 (Item 6 from file: 155)  
10217512 20040153

Immunotherapy of disseminated fibrosarcoma in mice using IL-2-producing tumor cells: studies on its mechanism and specificity.  
1999

20/6/7 (Item 7 from file: 155)  
10184109 20031165

**Modification** of an adenoviral **vector** with biologically selected peptides: a novel strategy for gene delivery to cells of choice [see comments]  
Nov 1 1999

20/6/8 (Item 8 from file: 155)  
10170117 99448255

Genetic polymorphism of CYP2A6 in relation to cancer.  
Jul 16 1999

20/6/9 (Item 9 from file: 155)  
10168089 99401797

Fanconi anemia and beta c deficiency-associated **pulmonary** alveolar proteinosis as two hereditary diseases of childhood which are potentially curable by stem cell gene therapy but require different therapeutic approaches.  
Jul-Aug 1999

20/6/10 (Item 10 from file: 155)  
10146141 99408201

Effects of secretable SOD delivered by genetically **modified** cells on xanthine/xanthine oxidase and paraquat-induced cytotoxicity in vitro.  
Aug 1999

20/6/11 (Item 11 from file: 155)  
10137657 99369821

Cellular response to latent TGF-beta1 is facilitated by insulin-like growth factor-II/mannose-6-phosphate receptors on MS-9 cells.  
Aug 25 1999

20/6/12 (Item 12 from file: 155)  
10132867 99288364

Insulin-like growth factor-II/mannose 6 phosphate receptors facilitate the matrix effects of latent transforming growth factor-beta1 released from genetically **modified** keratinocytes in a fibroblast/keratinocyte co-culture system.  
Jul 1999

20/6/13 (Item 13 from file: 155)  
10127876 99206508

Comparison of binding of N3'-->P5' phosphoramidate and phosphorothioate

oligonucleotides to cell surface proteins of cultured cells.  
Feb 1999

20/6/14 (Item 14 from file: 155)  
10047703 99388393

Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically **modified** dendritic cells.  
Aug 1999

20/6/15 (Item 15 from file: 155)  
10014134 99351569

**Ribozyme** -mediated specific gene replacement of the alpha1-antitrypsin gene in human hepatoma cells.  
Jul 1999

20/6/16 (Item 16 from file: 155)  
09996549 99089660

Enhanced in vivo airway gene transfer via transient **modification** of host barrier properties with a surface-active agent.  
Dec 10 1998

20/6/17 (Item 17 from file: 155)  
09996529 99291789

Anti-tumor immunity induced by in vivo adenovirus **vector**-mediated expression of CD40 ligand in tumor cells.  
May 20 1999

20/6/18 (Item 18 from file: 155)  
09996510 99270372

Enhanced therapeutic efficacy of tumor RNA-pulsed dendritic cells after genetic **modification** with lymphotactin.  
May 1 1999

20/6/19 (Item 19 from file: 155)  
09916351 99252437

Interferon (IFN)-beta gene transfer into TS/A adenocarcinoma cells and comparison with IFN-alpha: differential effects on tumorigenicity and host response.  
Apr 1999

20/6/20 (Item 20 from file: 155)  
09910305 99273429

A novel SV40-based **vector** successfully transduces and expresses an alpha 1-antitrypsin **ribozyme** in a human hepatoma-derived cell line.  
Jan 1999

20/6/21 (Item 21 from file: 155)  
09853870 99102396

Selective expansion of alveolar macrophages in vivo by adenovirus-mediated transfer of the murine granulocyte-macrophage colony-stimulating factor cDNA.  
Jan 15 1999

20/6/22 (Item 22 from file: 155)  
09836976 99155237

**Modification** of the genetic program of human alveolar macrophages by adenovirus vectors **in vitro** is feasible but inefficient, limited in part by the low level of expression of the coxsackie/adenovirus receptor.  
Mar 1999

10/6/23 (Item 23 from file: 155)  
09792851 99140410

Monocyte chemoattractant protein-1 gene **modification** of multidrug-resistant human **lung** cancer enhances antimetastatic effect of therapy with anti-P-glycoprotein antibody in SCID mice.  
Mar 1 1999

10/6/24 (Item 24 from file: 155)  
09745011 99077729

**In vivo** evaluation of Fontan pathway flow dynamics by multidimensional phase-velocity magnetic resonance imaging.  
Dec 22-29 1998

10/6/25 (Item 25 from file: 155)  
09714779 99049857

Lymphotactin gene-**modified** bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity.  
Dec 1 1998

10/6/26 (Item 26 from file: 155)  
09609551 98362135

Adenovirus-mediated persistent cystic fibrosis transmembrane conductance regulator expression in mouse airway epithelium.  
Sep 1998

10/6/27 (Item 27 from file: 155)  
09602936 98377920

**Antisense** fosB RNA inhibits thrombin-induced hypertrophy in cultured **pulmonary** arterial smooth muscle cells.  
Aug 11 1998

10/6/28 (Item 28 from file: 155)  
09499434 98239152

Genetically **modified** dermal keratinocytes express high levels of transforming growth factor-beta1.  
May 1998

10/6/29 (Item 29 from file: 155)  
09489990 98192212

Efficient generation of autologous peripheral blood-derived cytotoxic T lymphocytes against poorly immunogenic human tumors using recombinant CD80-adenovirus together with interleukin 12 and interleukin 2.  
Mar 1998

10/6/30 (Item 30 from file: 155)  
09404901 98133163

Multicomponent gene therapy vaccines for **lung** cancer: effective eradication of established murine tumors **in vivo** with interleukin-7/herpes simplex thymidine kinase-transduced autologous tumor and **ex vivo** activated dendritic cells.  
Dec 1997

20/6/31 (Item 31 from file: 155)  
09301994 97477408

Dendritic cells genetically **modified** with an adenovirus **vector** encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity.  
Oct 20 1997

20/6/32 (Item 32 from file: 155)  
09279625 97330947

Determination of **antisense** phosphorothioate oligonucleotides and catabolites in biological fluids and tissue extracts using anion-exchange high-performance liquid chromatography and capillary gel electrophoresis.  
Apr 25 1997

20/6/33 (Item 33 from file: 155)  
09167221 97343935

Isolation and characterization of 2'-fluoro-, 2'-amino-, and 2'-fluoro-/amino-**modified** RNA ligands to human IFN-gamma that inhibit receptor binding.  
Jul 1 1997

20/6/34 (Item 34 from file: 155)  
09162030 97286006

Highly attenuated **modified** vaccinia virus Ankara (MVA) as an effective recombinant **vector**: a murine tumor model.  
Mar 1997

20/6/35 (Item 35 from file: 155)  
09077117 97144164

Interleukin-2 gene transduction into freshly isolated **lung** adenocarcinoma cells with adenoviral vectors.  
Jan 1 1997

20/6/36 (Item 36 from file: 155)  
09042172 96258228

Antitumor effects of an adenovirus expressing **antisense** insulin-like growth factor I receptor on human **lung** cancer cell lines.  
Jul 1 1996

20/6/37 (Item 37 from file: 155)  
08981905 97014003

**Modification** of tumor suppressor gene expression in non-small cell **lung** cancer (NSCLC) with a retroviral **vector** expressing wildtype (normal) p53.  
May 1 1996

20/6/38 (Item 38 from file: 155)  
08950082 97072738

Interaction of oligodeoxynucleotides with mammalian cells.  
Fall 1996

20/6/39 (Item 39 from file: 155)  
08920026 97049952

Regulatable promoters for use in gene therapy applications:

modification of the 5' flanking region of the CFTR gene with multiple cAMP response elements to support basal, low-level gene expression that can be upregulated by exogenous agents that raise intracellular levels of cAMP.  
Oct 1 1996

20/6/40 (Item 40 from file: 155)  
08920025 97049951

Retroviral vectors efficiently transduce basal and secretory airway epithelial cells in vitro resulting in persistent gene expression in organotypic culture.  
Oct 1 1996

20/6/41 (Item 41 from file: 155)  
08908538 97031874

Adenovirus-mediated increase of exogenous and inhibition of endogenous fosB gene expression in cultured **pulmonary** arterial smooth muscle cells.  
Aug 1996

20/6/42 (Item 42 from file: 155)  
08810755 96416734

Pharmacokinetics of a synthetic, chemically **modified** hammerhead **ribozyme** against the rat cytochrome P-450 3A2 mRNA after single intravenous injections.  
Sep 1996

20/6/43 (Item 43 from file: 155)  
08801134 97021499

Humoral and cellular immune responses of nonhuman primates to long-term repeated **lung** exposure to Ad2/CFTR-2.  
Feb 1996

20/6/44 (Item 44 from file: 155)  
08774286 96323654

**Modification** of tumor suppressor gene expression and induction of apoptosis in non-small cell **lung** cancer (NSCLC) with an adenovirus **vector** expressing wildtype p53 and cisplatin.  
May 20 1996

20/6/45 (Item 45 from file: 155)  
08759143 96333338

Localization of a yeast-phase-specific gene product to the cell wall in Histoplasma capsulatum.  
Aug 1996

20/6/46 (Item 46 from file: 155)  
08581109 95367477

Altered MRP is associated with multidrug resistance and reduced drug accumulation in human SW-1573 cells.  
Aug 1995

20/6/47 (Item 47 from file: 155)  
08530376 96238293

[Gene therapy for hereditary and acquired human diseases]  
Therapie genique de maladies humaines hereditaires et acquises.  
1995

20/6/48 (Item 48 from file: 155)

08516987 96192448

A universal method for the mutational analysis of K-ras and p53 gene in non-small-cell **lung** cancer using formalin-fixed paraffin-embedded tissue.

Dec 1995

20/6/49 (Item 49 from file: 155)

08506831 96121561

Characterization of an adenovirus gene transfer **vector** containing an E4 deletion.

Oct 1995

20/6/50 (Item 50 from file: 155)

08496340 96141199

DNA binding of hypothalamic nuclear proteins on estrogen response element and preproenkephalin promoter: **modification** by estrogen.

Nov 1995

20/6/51 (Item 51 from file: 155)

08466731 96051282

Suppression of **lung** cancer cell growth by **ribozyme**-mediated **modification** of p53 pre-mRNA.

Sep 1995

20/6/52 (Item 52 from file: 155)

08440007 96074819

Direct interaction of Gadd45 with PCNA and evidence for competitive interaction of Gadd45 and p21Waf1/Cip1 with PCNA.

Nov 16 1995

20/6/53 (Item 53 from file: 155)

08414315 96003873

Delivery of herpesvirus and adenovirus to nude rat intracerebral tumors after osmotic blood-brain barrier disruption.

Oct 10 1995

20/6/54 (Item 54 from file: 155)

08356810 95363967

Herpes simplex virus immediate-early protein ICP22 is required for viral **modification** of host RNA polymerase II and establishment of the normal viral transcription program.

Sep 1995

20/6/55 (Item 55 from file: 155)

08348810 95352392

**Antisense** oligonucleotides: an experimental strategy to advance a causal analysis of development.

Feb 1995

20/6/56 (Item 56 from file: 155)

08320701 95311330

Macrophage colony-stimulating factor complementary DNA: a candidate for gene therapy in metastatic melanoma [see comments]

Jun 7 1995

20/6/57 (Item 57 from file: 155)  
08165199 94331445

Gene therapy for cystic fibrosis using El-deleted adenovirus: a phase I trial in the nasal cavity. The University of North Carolina at Chapel Hill.  
May 1994

20/6/58 (Item 58 from file: 155)  
08107620 95144543

Human **lung** tumor cell secretion of interleukin-2 for protection against tumor engraftment.  
May 1994

20/6/59 (Item 59 from file: 155)  
08000839 94368492

Suppression of in vivo tumorigenicity of human **lung** cancer cells by retrovirus-mediated transfer of the human tumor necrosis factor-alpha cDNA.  
Sep 1994

20/6/60 (Item 60 from file: 155)  
07967514 94315872

Quantitation of DNA topoisomerase II alpha messenger ribonucleic acid levels in a small cell **lung** cancer cell line and two drug resistant sublines using a polymerase chain reaction-aided transcript titration assay.  
Jul 1994

20/6/61 (Item 61 from file: 155)  
07914535 94231165

Development of a broad spectrum PCR assay for papillomaviruses and its application in screening **lung** cancer biopsies.  
May 1994

20/6/62 (Item 62 from file: 155)  
07875584 94141215

Detection of allergen- and mitogen-induced human cytokine transcripts using a competitive polymerase chain reaction.  
Feb 10 1994

20/6/63 (Item 63 from file: 155)  
07852493 93273482

Evidence for possible involvement of an elastolytic serine protease in aspergillosis.  
Jun 1993

20/6/64 (Item 64 from file: 155)  
07823225 93362171

Continuous systemic secretion of a lysosomal enzyme by genetically **modified** mouse skin fibroblasts.  
Aug 1993

20/6/65 (Item 65 from file: 155)  
07771800 95021166

Expression of cGMP-dependent protein kinase in Escherichia coli [published erratum appears in Mol Cell Biochem 1994 Feb 9;131(1):97]  
Nov 1993

20/6/66 (Item 66 from file: 155)

07610784 93372092

Cytochrome P450 4A4: expression in Escherichia coli, purification, and  
characterization of catalytic properties.

Aug 31 1993

20/6/67 (Item 67 from file: 155)

07489262 93138779

Molecular characterization of a protective outer membrane lipoprotein  
(OmlA) from Actinobacillus pleuropneumoniae serotype 1.

Feb 1993

20/6/68 (Item 68 from file: 155)

07067852 92321186

Gene therapy strategies for **pulmonary** disease.

Jun 22 1992

20/6/69 (Item 69 from file: 155)

06980509 92157865

Intranasal immunization using the B subunit of the Escherichia coli  
heat-labile toxin fused to an epitope of the Bordetella pertussis P.69  
antigen.

Jun 1991

20/6/70 (Item 70 from file: 155)

06975166 92011573

Respiratory tract gene transfer. Transplantation of genetically  
**modified** T-lymphocytes directly to the respiratory epithelial  
surface.

Sep 25 1991

20/6/71 (Item 71 from file: 155)

06631571 90368787

Isolation and characterization of a cDNA clone encoding rat nucleoside  
diphosphate kinase.

Sep 15 1990

20/6/72 (Item 72 from file: 155)

06462778 90262707

Expression of mature **pulmonary** surfactant-associated protein B  
(SP-B) in Escherichia coli using truncated human SP-B cDNAs.

Feb 1990

20/6/73 (Item 73 from file: 155)

05702804 90073668

Production in Escherichia coli of a biologically active subfragment of  
von Willebrand factor corresponding to the platelet glycoprotein Ib,  
collagen and heparin binding domains.

Nov 15 1989

20/6/74 (Item 74 from file: 155)

04383370 85033877

Herpes simplex virus cloned DNA fragments induce coumermycin A1  
resistance in Escherichia coli.

Nov 1984



20/6/75 (Item 1 from file: 5)  
12419145 BIOSIS NO.: 200000172647  
A novel DNA element mediates transcription of Nkx2.1 by Sp1 and Sp3 in  
**pulmonary** epithelial cells.  
2000

20/6/76 (Item 2 from file: 5)  
12351649 BIOSIS NO.: 200000105151  
Bronchial smooth muscle hypoplasia in mouse embryonic lungs exposed to a  
laminin betal chain **antisense oligonucleotide**.  
1999

20/6/77 (Item 3 from file: 5)  
12348373 BIOSIS NO.: 200000101875  
Enhancement of gene transfer efficiency into human cancer cells by  
**modification** of retroviral vectors and addition of chemicals.  
2000

20/6/78 (Item 4 from file: 5)  
12214841 BIOSIS NO.: 199900509690  
Adenoviral vectors **modified** for increased CFTR expression and  
persistence in human ciliated airway epithelia.  
1999

20/6/79 (Item 5 from file: 5)  
12214577 BIOSIS NO.: 199900509426  
Correction of the metabolic defect in Fabry mice through genetic  
**modification** of depot organs.  
1999

20/6/80 (Item 6 from file: 5)  
12181386 BIOSIS NO.: 199900476235  
Tumor DNA circulating in the plasma might play a role in metastasis. The  
hypothesis of the genomestasis.  
1999

20/6/81 (Item 7 from file: 5)  
12061722 BIOSIS NO.: 199900356571  
E4ORF3 requirement for achieving long-term transgene expression from the  
cytomegalovirus promoter in adenovirus vectors.  
1999

20/6/82 (Item 8 from file: 5)  
11973909 BIOSIS NO.: 199900227222  
In vivo targeted gene transfer into liver cells mediated by a novel  
galactosyl-D-lysine/D-serine copolymer.  
1999

20/6/83 (Item 9 from file: 5)  
11962077 BIOSIS NO.: 199900208186  
A novel animal model for the evaluation of the efficacy of drugs directed  
against the ErbB2 receptor on metastasis formation.  
1999

20/6/84 (Item 10 from file: 5)

11888976 BIOSIS NO.: 199900135085

**Modified oligonucleotide** as bona fide antagonists of proteins interacting with DNA. Hairpin antagonists of the human DNA methyltransferase.

1999

20/6/85 (Item 11 from file: 5)

11865739 BIOSIS NO.: 199900111848

Isolation, cloning, and characterization of a new mammalian coronin family member, coroninse, which is regulated within the protein kinase C signaling pathway.

1999

20/6/86 (Item 12 from file: 5)

11851940 BIOSIS NO.: 199900098049

Enhanced in vivo airway gene transfer via transient **modification** of barrier properties with a surface-active agent.

1998

20/6/87 (Item 13 from file: 5)

11845003 BIOSIS NO.: 199900091112

Characterization of a potent and specific class of **antisense oligonucleotide** inhibitor of human protein kinase C-alpha expression.

1999

20/6/88 (Item 14 from file: 5)

11780792 BIOSIS NO.: 199900026901

Characterization of a new intrabody directed against the N-terminal region of human p53.

1998

20/6/89 (Item 15 from file: 5)

11758906 BIOSIS NO.: 199900005015

GDP-L-fucose pyrophosphorylase: Purification, cDNA cloning, and properties of the enzyme.

1998

20/6/90 (Item 16 from file: 5)

11697489 BIOSIS NO.: 199800479220

The major APN transcript of the alveolar type II epithelial cell originates from a unique upstream promoter region.

1998

20/6/91 (Item 17 from file: 5)

11631742 BIOSIS NO.: 199800413473

K-ras **ribozyme** for lung cancer.

BOOK TITLE: Methods in Molecular Medicine; Therapeutic applications of ribozymes

1998

20/6/92 (Item 18 from file: 5)

11326740 BIOSIS NO.: 199800108072

Lymphotactin gene-**modified** bone marrow dendritic cells act as more potent adjuvant for peptide delivery to induce antitumor immunity.

1997

20/6/93 (Item 19 from file: 5)  
10992960 BIOSIS NO.: 199799614105  
Antitumor effect of c-myc **antisense** phosphorothioate  
oligodeoxynucleotides on human melanoma cells in vitro and in mice.  
1996

20/6/94 (Item 20 from file: 5)  
10976618 BIOSIS NO.: 199799597763  
Gene delivery into malignant cells in vivo by a conjugated adenovirus/DNA  
complex.  
1997

20/6/95 (Item 21 from file: 5)  
10535729 BIOSIS NO.: 199699156874  
The validity of some haematological and ELISA methods for the diagnosis of  
canine heartworm disease.  
1996

20/6/96 (Item 22 from file: 5)  
10336387 BIOSIS NO.: 199698791305  
Gene therapy for inherited and acquired human diseases.  
1995

20/6/97 (Item 23 from file: 5)  
10274369 BIOSIS NO.: 199698729287  
Appropriateness of hospitalization of patients with community-acquired  
pneumonia.  
1996

20/6/98 (Item 24 from file: 5)  
10231985 BIOSIS NO.: 199698686903  
Refining a risk model for occupational tuberculosis transmission.  
1996

20/6/99 (Item 25 from file: 5)  
10051577 BIOSIS NO.: 199598506495  
Control of nosocomial infections in an intensive care unit in Guatemala  
City.  
1995

20/6/100 (Item 26 from file: 5)  
09968388 BIOSIS NO.: 199598423306  
Mutation heterogeneity of cystic fibrosis in France: Screening by  
denaturing gradient gel electrophoresis using psoralen-**modified**  
**oligonucleotide**.  
1995

20/6/101 (Item 27 from file: 5)  
09907105 BIOSIS NO.: 199598362023  
Biochemical characterization of human GCF transcription factor in tumor  
cells.  
1995

20/6/102 (Item 28 from file: 5)  
09593988 BIOSIS NO.: 199598048906

Transfer of a constitutive viral promoter-cystic fibrosis transmembrane conductance regulator cDNA to human epithelial cells overcomes resistance to down-regulation of cAMP-regulated Cl-secretion in the presence of inflammatory stimuli.

1994

20/6/103 (Item 29 from file: 5)  
09535331 BIOSIS NO.: 199497543701  
Molecular cloning of a cDNA encoding for the GLP-1 receptor expressed in rat lung.  
1994

20/6/104 (Item 30 from file: 5)  
09364653 BIOSIS NO.: 199497373023  
**Modification** of reagents in the EnviroAmp kit to increase recovery of Legionella organisms in water.  
1994

20/6/105 (Item 31 from file: 5)  
09296043 BIOSIS NO.: 199497304413  
A novel **ribozyme** for **modification** of mutated p53 pre-mRNA in non-small cell lung cancer cell lines.  
1994  
? t s20/6/106-205

20/6/106 (Item 32 from file: 5)  
08809759 BIOSIS NO.: 199395099110  
Multiple drug-resistance in variant of a human non-small cell lung carcinoma cell line, DLKP-A.  
1992

20/6/107 (Item 33 from file: 5)  
08720620 BIOSIS NO.: 199395009971  
Levels of bacteria, fungi and endotoxin in stored timber.  
1992

20/6/108 (Item 34 from file: 5)  
07994429 BIOSIS NO.: 000093050102  
ESCHERICHIA-COLI RECA PROTEIN **MODIFIED** WITH A NUCLEAR LOCATION SIGNAL BINDS TO CHROMOSOMES IN LIVING MAMMALIAN CELLS  
1992

20/6/109 (Item 35 from file: 5)  
07157907 BIOSIS NO.: 000089024548  
PRODUCTION IN ESCHERICHIA-COLI OF A BIOLOGICALLY ACTIVE SUBFRAGMENT OF VON WILLEBRAND FACTOR CORRESPONDING TO THE PLATELET GLYCOPROTEIN 1 IB COLLAGEN AND HEPARIN BINDING DOMAINS  
1989

20/6/110 (Item 36 from file: 5)  
06732092 BIOSIS NO.: 000088041519  
THE USE OF MUCOLYZED INDUCED SPUTUM FOR THE IDENTIFICATION OF **PULMONARY** PATHOGENS ASSOCIATED WITH HUMAN IMMUNODEFICIENCY VIRUS INFECTION  
1989

20/6/111 (Item 37 from file: 5)  
05232173 BIOSIS NO.: 00082072795  
ISOLATION AND CHARACTERIZATION OF COMPLEMENTARY DNA CLONES FOR THE  
35-KILODALTON **PULMONARY** SURFACTANT-ASSOCIATED PROTEIN  
1986

20/6/112 (Item 38 from file: 5)  
05070342 BIOSIS NO.: 000081028466  
STRUCTURE OF CANINE **PULMONARY** SURFACTANT APOPROTEIN COMPLEMENTARY DNA  
AND COMPLETE AMINO-ACID SEQUENCE  
1985

20/6/113 (Item 1 from file: 399)  
DIALOG(R)File 399:(c) 2000 American Chemical Society. All rts. reserv.

CHK1 and ATR cell cycle checkpoint protein kinases for modulating  
differentiation by mitotic spindle and G1 checkpoint control

20/6/114 (Item 2 from file: 399)  
DIALOG(R)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Nucleic acid sequences controlling lung cell-specific gene expression  
with therapeutic applications

20/6/115 (Item 3 from file: 399)  
DIALOG(R)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Methods and modified cells for the treatment of cancer

20/6/116 (Item 4 from file: 399)  
DIALOG(R)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Agent for gene therapy of tumors and neurodegenerative, cardiovascular,  
and autoimmune diseases

20/6/117 (Item 5 from file: 399)  
DIALOG(R)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Effect of host modification and age on airway epithelial gene transfer  
mediated by a murine leukemia virus-derived vector

20/6/118 (Item 6 from file: 399)  
DIALOG(R)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Gene transfer with adenoviruses having modified fiber proteins

20/6/119 (Item 7 from file: 399)  
DIALOG(R)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Human lea-motif developmental protein

20/6/120 (Item 8 from file: 399)  
DIALOG(R)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Methods for optimization of gene therapy by recursive sequence shuffling  
and selection

20/6/121 (Item 9 from file: 399)  
DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Methods for optimization of DNA sequences for use in gene therapy by recursive sequence shuffling and selection

20/6/122 (Item 10 from file: 399)  
DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Oligonucleotides for modulation of protein kinase C

20/6/123 (Item 11 from file: 399)  
DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Strategies to accomplish targeted gene delivery employing tropism-modified adenoviral vectors

20/6/124 (Item 12 from file: 399)  
DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Sugar-modified gapped oligonucleotides for induction of mRNA degradation by RNase H

20/6/125 (Item 13 from file: 399)  
DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Antisense oligonucleotide modulation of raf gene expression

20/6/126 (Item 14 from file: 399)  
DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Selective targeting of human cells by a chimeric adenovirus vector containing a modified fiber protein

20/6/127 (Item 15 from file: 399)  
DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Modification of mutant K-ras gene expression in non-small cell lung cancer (NSCLC)

20/6/128 (Item 16 from file: 399)  
DIALOG(P)File 399:(c) 2000 American Chemical Society. All rts. reserv.

Cholesteryl-modified triple-helix forming oligonucleotides and their uses

20/6/129 (Item 1 from file: 357)  
0249194 DBA Accession No.: 2000-03684  
Real-time monitoring of the hybridization reaction: application to the quantification of oligonucleotides in biological samples - phosphodiester **oligonucleotide** and phosphorothioate **oligonucleotide** analysis method in plasma or liver, lung, kidney or spleen tissue using DNA probe and TRACE technology 2000

20/6/130 (Item 2 from file: 357)

0248440 DBA Accession No.: 2000-02930

**Modified** manganese superoxide dismutase, methods of production and antibodies - recombinant manganese superoxide-dismutase and polyanionic polysaccharide or proteoglycan binding protein fusion protein, used in **lung** disease therapy 1999

20/6/131 (Item 3 from file: 357)

0247902 DBA Accession No.: 2000-02392

Dynein- and microtubule-mediated translocation of adeno virus serotype-5 occurs after endosomal lysis - **vector**-mediated green fluorescent protein or choline-acetyltransferase expression in human **lung** epithelium carcinoma cell for gene therapy 2000

20/6/132 (Item 4 from file: 357)

0247308 DBA Accession No.: 2000-01798

New polynucleotide encoding a variant chemokine receptor - nucleic acid encoding a CXC splice variant with a **modified** tissue distribution, used in inflammatory response suppression 1999

20/6/133 (Item 5 from file: 357)

0247270 DBA Accession No.: 2000-01760

Incorporation of adeno-associated virus in a calcium phosphate coprecipitate improves gene transfer to airway epithelia in vitro and in vivo - coprecipitation of adeno-associated virus and calcium phosphate used to increase airway epithelium transduction efficiency 2000

20/6/134 (Item 6 from file: 357)

0245320 DBA Accession No.: 1999-15421

Production of transgenic swine using spermatozoa as exogenous DNA vectors - transgenic pig construction via sperm **vector**-mediated human inhibitor of complement activation gene transfer (conference abstract) 1999

20/6/135 (Item 7 from file: 357)

0245168 DBA Accession No.: 1999-15269

**Modification** of an adenoviral **vector** with biologically selected peptides to cells of choice - adeno virus **vector** optimization for gene therapy 1999

20/6/136 (Item 8 from file: 357)

0244592 DBA Accession No.: 1999-12739

Adeno virus vectors with **modified** capsid proteins for improved infectious capabilities - improved virus **vector**-mediated beta-galactosidase gene transfer and expression in mouse **lung** for gene therapy 1999

20/6/137 (Item 9 from file: 357)

0242465 DBA Accession No.: 1999-13230

New artificial proteoglycans useful for treating rheumatoid arthritis - expression in host cell, for disease therapy and drug screening 1999

20/6/138 (Item 10 from file: 357)

0241329 DBA Accession No.: 1999-11430

N-terminally deleted streptokinase - expression in Escherichia sp., Bacillus sp., Streptomyces sp., Saccharomyces sp., insect, bird, mammal or plant cell, for dissolving blood clots using fibrin-dependent

- 20/6/139 (Item 11 from file: 357)  
0240412 DBA Accession No.: 1999-11017  
Anti-tumor agents - interleukin-18 encoding gene complexed with a liposome,  
used for cancer gene therapy 1999
- 20/6/140 (Item 12 from file: 357)  
0237413 DBA Accession No.: 99-07514  
Enhanced therapeutic efficiency of tumor RNA-pulsed dendritic cells after  
genetic **modification** with lymphotactin - increases  
tumor-inhibiting activity of recombinant vaccine 1999
- 20/6/141 (Item 13 from file: 357)  
0237371 DBA Accession No.: 99-07472  
New mutant Salmonella sp. - phage **vector**-mediated msbB and purI  
biosynthetic pathway mutant gene transfer and expression in Salmonella  
sp., used for cancer therapy 1999
- 20/6/142 (Item 14 from file: 357)  
0236789 DBA Accession No.: 99-06890  
Altered tropism of an ovine adenovirus carrying the fiber protein cell  
binding domain of human adenovirus type 5 - sheep adeno virus  
**vector** can be **modified** to infect different cells by  
replacing the cell binding domain of the fiber protein 1998
- 20/6/143 (Item 15 from file: 357)  
0236572 DBA Accession No.: 99-06673  
New amino-terminally truncated C-C chemokines have antagonistic activity  
for treatment of immune, inflammatory and infectious diseases -  
recombinant N-terminal truncated C-C chemokine used in disease  
diagnosis and therapy 1999
- 20/6/144 (Item 16 from file: 357)  
0235203 DBA Accession No.: 99-05304  
Use of chemokine with a conserved Cys Xaa Cys (CXC) sequence - and lacking  
motif enabling neutrophil activation, used for the therapy of e.g.  
cancer, glaucoma, diabetic retinopathy, psoriasis, rheumatoid  
arthritis, atherosclerosis, etc. 1999
- 20/6/145 (Item 17 from file: 357)  
0234530 DBA Accession No.: 99-04631  
DNA encoding active thrombomodulin analogs resistant to proteolysis -  
recombinant thrombomodulin production in CHO cell, protease-resistant,  
useful for e.g. myocardial infarction, deep vein thrombosis,  
**pulmonary** thrombosis, etc. therapy and prevention 1999
- 20/6/146 (Item 18 from file: 357)  
0232039 DBA Accession No.: 99-02190  
A recombinant adenoviral **vector** expressing full-length human  
retinoblastoma susceptibility gene inhibits human tumor cell growth -  
**vector** plasmid pACN-mediated retinoblastoma and  
beta-galactosidase reporter gene transfer and expression in 293 cell  
for potential cancer gene therapy 1998
- 20/6/147 (Item 19 from file: 357)



0231452 DBA Accession No.: 99-01553

Identifying modulator of interaction between alpha-d unit of human beta-2 integrin and vascular cell adhesion molecule-1 - plasmid or virus **vector** expression in host cell or transgenic animal, and monoclonal antibody preparation by hybridoma cell culture, used for drug screening or disease therapy 1998

20/6/148 (Item 20 from file: 357)

0231400 DBA Accession No.: 99-01501

In vivo study of tumors and metastases - tumor metastasis research using tumor that expresses recombinant green fluorescent protein 1998

20/6/149 (Item 21 from file: 357)

0230974 DBA Accession No.: 99-01075

Using adeno viruses with **modified** fiber proteins for gene transfer - **vector**-mediated therapeutic gene transfer and expression in host cell; virus serotype head portion replacement for **lung** disease, cystic fibrosis or tumor gene therapy, etc. 1998

20/6/150 (Item 22 from file: 357)

0229237 DBA Accession No.: 98-10834

Identification of modulators of calcium/calmodulin sensitive cyclic nucleotide-phosphodiesterase - uses recombinant cells expressing the enzyme and monitoring protein expression in the presence of potential modulators 1998

20/6/151 (Item 23 from file: 357)

0227937 DBA Accession No.: 98-09534

SLC, a human CC-type chemokine which binds specifically to CCR7 receptor - DNA encoding it and antibody recognising it are useful in the diagnosis and therapy of inflammatory, immune-related, infectious and neoplastic disorders 1998

20/6/152 (Item 24 from file: 357)

0226779 DBA Accession No.: 98-08376

Tissue fibrosis-inhibitor containing an arginase or **modified** arginase - recombinant enzyme preparation, for use in therapy 1998

20/6/153 (Item 25 from file: 357)

0225563 DBA Accession No.: 98-07160

New **modified** glucocorticoid receptor able to bind non-natural ligands - human fusion protein preparation by **vector** plasmid pGR0403R-mediated gene expression in human or yeast cell and transgenic animal, used for arthritis or asthma therapy or gene therapy etc. 1998

20/6/154 (Item 26 from file: 357)

0224036 DBA Accession No.: 98-05633

Treatment or prevention of melanoma using melanoma cell expressing shared immunodominant antigen - granulocyte-macrophage colony stimulating factor expression in mammal melanoma cell using **vector** 1998

20/6/155 (Item 27 from file: 357)

0223613 DBA Accession No.: 98-05210

New derivative of human plasminogen activator cleavable by thrombin - produced by site-directed mutagenesis and expressed in e.g. Escherichia coli 1998

20/6/156 (Item 28 from file: 357)  
0217559 DBA Accession No.: 97-12680  
Isolated and purified cysteine-rich protein-61, Cyr61 - human recombinant protein and DNA sequence, for use as a vulnerary, etc., or in gene therapy 1997

20/6/157 (Item 29 from file: 357)  
0215252 DBA Accession No.: 97-10373  
Gene delivery vehicle comprising dendritic cell targeting element - antigen gene transfer using a retro virus or alpha virus **vector**, for use in gene therapy of cancer, infection, heart disease, etc. 1997

20/6/158 (Item 30 from file: 357)  
0215112 DBA Accession No.: 97-10233  
New obesity (OB) protein derivatives - with extended half-life, and IgG fusion protein expression, for use as an anorectic or antidiabetic, etc. 1997

20/6/159 (Item 31 from file: 357)  
0211318 DBA Accession No.: 97-06439  
Therapeutic antitumor response after immunization with an admixture of recombinant vaccinia viruses expressing a **modified** MUC1 gene and the murine T-cell costimulatory molecule B7 - vaccinia virus **vector**-mediated gene transfer and mouse T-lymphocyte costimulatory molecule B7 coexpression for e.g. **lung** cancer immunotherapy 1997

20/6/160 (Item 32 from file: 357)  
0211311 DBA Accession No.: 97-06432  
Purified protein from epithelial cells indicative of cancer or precancer - heterogeneous nuclear ribonucleoprotein-like epithelium protein, peptide or variant production by **vector** expression and DNA probe for use in computer-assisted early cancer diagnosis 1997

20/6/161 (Item 33 from file: 357)  
0206963 DBA Accession No.: 97-02084  
**Modified** glucocorticoid receptor protein capable of binding non-natural ligand - **vector** plasmid pGR0403R expression in muscle, **lung**, and synovial cell culture, and in transgenic animal, for arthritis, asthma, and abnormal muscle development disease gene therapy 1996

20/6/162 (Item 34 from file: 357)  
0203950 DBA Accession No.: 96-14721  
HEV-derived promoters direct liver-specific expression of an adeno virally transduced LDL receptor gene - adeno virus **vector**-mediated human low density lipoprotein receptor gene transfer and hepatitis B virus chimeric promoter-driven liver tissue-specific gene expression 1996

20/6/163 (Item 35 from file: 357)  
0199062 DBA Accession No.: 96-10417  
New peptides based on the EGF-2 domain of Factor-VII - epidermal growth factor-2 domain peptide 1996

20/6/164 (Item 36 from file: 357)  
0197893 DBA Accession No.: 96-08664

New DNA encoding **modified** forms of optionally activated protein-C - protein engineering and expression in tk-ts13-BHK, 3, COS-1, Rat HepI, Rat HepII, 10MK, human **lung**, human hepatoma HepG2, mouse liver or DUKX cell culture, for thrombotic disease therapy 1996

20/6/165 (Item 37 from file: 357)

0192550 DBA Accession No.: 96-02743

In vivo antitumor effect of cytotoxic T-lymphocytes engineered to produce interferon-gamma by adeno virus-mediated genetic transduction - mouse tumor model application in **lung** carcinoma adoptive immunotherapy, and in gene therapy 1996

20/6/166 (Item 38 from file: 357)

0190103 DBA Accession No.: 96-00874

Migration selected cell populations - cancer gene therapy by prodrug activation, cytokine-mediated gene therapy, etc., using a transduced cancer (e.g. mamma carcinoma, neuroblastoma soft tissue sarcoma, etc.) cell line 1995

20/6/167 (Item 39 from file: 357)

0189951 DBA Accession No.: 96-00722

A new protein and its preparation - recombinant protein production via gene expression in transformant e.g. human embryo **lung** diploid cell culture; application in therapy 1995

20/6/168 (Item 40 from file: 357)

0189443 DBA Accession No.: 96-00214

Combined vaccination with major histocompatibility class-I and interleukin-2 gene-transduced melanoma cells synergizes the cure of postsurgical established **lung** metastases - retro virus **vector**-mediated gene transfer to melanoma cell for **lung** carcinoma therapy 1995

20/6/169 (Item 41 from file: 357)

0188254 DBA Accession No.: 95-15769

Adoptive immunogene therapy for cancer with cytokine gene-**modified** tumor-specific T-lymphocytes - interleukin-2 or interferon-gamma gene transfer to cytotoxic T-lymphocyte cell culture and use in adoptive immunotherapy and cytokine-mediated gene therapy of colon carcinoma (conference abstract) 1995

20/6/170 (Item 42 from file: 357)

0188233 DBA Accession No.: 95-15748

Utilization of retro viral **vector-modified** murine tumor cells expressing the TNF-alpha gene to elicit therapeutic CTL - (conference abstract) 1995

20/6/171 (Item 43 from file: 357)

0184571 DBA Accession No.: 95-11392

Gene therapy for solid tumors - solid cancer cytokine-mediated gene therapy; mouse immunity; review 1995

20/6/172 (Item 44 from file: 357)

0131592 DBA Accession No.: 95-05809

Increasing secretory protein production by administering calnexin suppressor agent - preferably using a **vector** construct expressing the **modified** calnexin gene 1995

20/6/173 (Item 45 from file: 357)  
0180899 DBA Accession No.: 95-08919  
Cytokines and clinical gene therapy - cytokine-mediated gene therapy; a review 1995

20/6/174 (Item 46 from file: 357)  
0178920 DBA Accession No.: 95-06330  
Recombinant human monocyte growth factor and its encoding DNA - production by gene cloning from human **lung** cancer cell culture T3M-30Lu and expression 1995

20/6/175 (Item 47 from file: 357)  
0177014 DBA Accession No.: 95-03835  
New protein disulfide redox reagent, especially **modified** protein - containing recombinant protein-disulfide-isomerase, protein-disulfide-oxidoreductase or thioredoxin mutein for use in food, cataract therapy, hair treatment, fabric cleaning, etc. 1995

20/6/176 (Item 48 from file: 357)  
0175887 DBA Accession No.: 95-02708  
High efficiency genetic **modification** of unstimulated primary CD8+ and CD34+ cells using liposome AAV plasmid complexes - interleukin-2 gene transfer to hematopoietic stem cells by lipofection with an adeno-associated virus **vector** for use in adoptive immunotherapy and gene therapy (conference abstract) 1994

20/6/177 (Item 49 from file: 357)  
0174122 DBA Accession No.: 95-00943  
Efficient gene transduction to NSCLC cells with Adex1CA **vector** - adeno virus **vector** plasmid Adex1CA series containing fowl beta-actin promoter and cytomegalo virus enhancer for **lung** carcinoma cytokine-mediated gene therapy (conference abstract) 1994

20/6/178 (Item 50 from file: 357)  
0174095 DBA Accession No.: 95-00916  
Immunogene therapy for cancer by cytokine gene-**modified** tumor vaccine and tumor-infiltrating lymphocytes - granulocyte-macrophage colony stimulating factor gene transfer for cancer cytokine-mediated gene therapy (conference abstract) 1994

20/6/179 (Item 51 from file: 357)  
0173642 DBA Accession No.: 95-00469  
Inhibition of collagen synthesis by cells - human procollagen pro-alpha-1(I) chain minigene and **antisense** gene transfer using an adeno virus or retro virus **vector**, for use in cirrhosis or fibrosis gene therapy 1994

20/6/180 (Item 52 from file: 357)  
0173579 DBA Accession No.: 95-00400  
Early region 4 deleted adeno virus 2 vectors for cystic fibrosis gene therapy - **vector** series construction (conference abstract) 1994

20/6/181 (Item 53 from file: 357)  
0173442 DBA Accession No.: 95-00263  
Genetically **modified** tumors enhance the generation of sensitized T

cells for use in adoptive immunotherapy - lymph node draining  
cytokine-secreting recombinant tumor transfer to mouse **lung** tumor  
model for T-lymphocyte sensitization; cytokine-mediated gene therapy  
(conference abstract) 1994

20/6/182 (Item 54 from file: 357)  
0172761 DBA Accession No.: 94-15312  
Petro virus-mediated gene transfer of the human IL-2 gene into human tumor  
cells growing in tissue culture - interleukin-2 gene expression in  
human tumor cell culture using a mouse Moloney leukemia virus  
**vector** for application in gene therapy (conference abstract)  
1994

20/6/183 (Item 55 from file: 357)  
0172760 DBA Accession No.: 94-15311  
High efficiency genetic **modification** of unstimulated primary CD8+ and  
CD34+ cells using adeno-associated virus plasmid liposome complexes -  
interleukin-2 gene expression in mamma, **lung** or ovary tumor or  
T-lymphocyte cell culture, for use in gene therapy and adoptive  
immunotherapy (conference abstract) 1994

20/6/184 (Item 56 from file: 357)  
0166060 DBA Accession No.: 94-08611  
Inhibition of protein-kinase-C-alpha expression in human A549 cells by  
**antisense** oligonucleotides inhibits induction of intercellular  
adhesion molecule-1 (ICAM-1) mRNA by phorbol esters - intercellular  
adhesion molecule-inhibitor expression in human **lung**  
adenocarcinoma A549 cell culture using **antisense** RNA and  
**antisense** DNA for potential tumor gene therapy 1994

20/6/185 (Item 57 from file: 357)  
0163180 DBA Accession No.: 94-05731  
Cholesterol-**modified** triplex DNA-forming **oligonucleotide** -  
triplex DNA-forming **oligonucleotide** sequence-specific binding  
application in herpes simplex virus, HIV virus, mamma carcinoma,  
**lung** carcinoma or cervix carcinoma therapy 1994

20/6/186 (Item 58 from file: 357)  
0157713 DBA Accession No.: 94-00264  
Stable in vivo expression of the cystic fibrosis transmembrane conductance  
regulator with an adeno-associated virus **vector** - for potential  
use for gene therapy 1993

20/6/187 (Item 59 from file: 357)  
0155241 DBA Accession No.: 93-13293  
Immunotherapeutic strategies for cancer using pox virus vectors -  
tumor-associated antigen and cytokine expression by e.g. vaccinia virus  
**vector**, and cell-based immunotherapy; a review (conference paper)  
1993

20/6/188 (Item 60 from file: 357)  
0146427 DBA Accession No.: 93-04479  
Correction of the ion transport defect in cystic fibrosis transgenic mice  
by gene therapy - liposome application in cystic fibrosis transmembrane  
conductance regulator expression by plasmid pREP8-CFTR targeting to  
**lung** of transgenic mouse or expression in HeLa cell culture 1993

20/6/189 (Item 61 from file: 357)  
 0139336 DBA Accession No.: 92-12328  
 Transcriptional modulation of oncogene or tumor suppressor genes - tumor suppressor gene transcription modulation by triplex DNA or **antisense** RNA for potential human cancer or leukemia gene therapy, gene targeting or drug screening 1992

20/6/190 (Item 62 from file: 357)  
 0132402 DBA Accession No.: 92-04894  
 New DNA probe specific for Toxoplasma gondii - useful for in vitro detection and typing of T. gondii strains; potential diagnosis 1992

20/6/191 (Item 63 from file: 357)  
 0131322 DBA Accession No.: 92-03814  
 New amidated derivatives of human prourokinase - **vector** plasmid pPUK-Gly expression in Escherichia coli; used to treat acute myocardial infarction, **pulmonary** embolism or deep venous thrombosis 1992

20/6/192 (Item 64 from file: 357)  
 0120413 DBA Accession No.: 91-08055  
**Modified** human heparin cofactor-II (Leu-444 to Arg) - gene cloning; site-directed mutagenesis; protein engineering 1991

20/6/193 (Item 65 from file: 357)  
 0120402 DBA Accession No.: 91-08044  
 Gene transfer into rat airway epithelial cells using retroviral vectors - potential application of retro virus to gene therapy of e.g. cystic fibrosis 1991

20/6/194 (Item 66 from file: 357)  
 0117935 DBA Accession No.: 91-05577  
 Viruses as delivery vectors for vaccines - recombinant vaccine production using a virus **vector** (conference paper) 1989

20/6/195 (Item 67 from file: 357)  
 0110322 DBA Accession No.: 90-13013  
 Novel DNA encoding **modified** tissue plasminogen-activator - by altering DNA sequence in the protease domain to closely mimic DNA of the urokinase protease domain; protein engineering 1990

20/6/196 (Item 68 from file: 357)  
 0106073 DBA Accession No.: 90-08764  
 Transient production and secretion of human transforming growth factor TGF-beta-2 - **vector** plasmid pOTGF-beta-2, plasmid pOTGF-beta-2-mat and plasmid pRJB-TGF-beta-2 expression in COS cell culture 1989

20/6/197 (Item 69 from file: 357)  
 0099346 DBA Accession No.: 90-02037  
**Modified** plasminogen-activator - tissue plasminogen-activator, single-chain urinary plasminogen-activator with greater fibrin selectivity and circulating half-life; DNA sequence; **vector** 1989

20/6/198 (Item 70 from file: 357)  
 0094950 DBA Accession No.: 89-12941  
 Polymerase chain reaction with single sided specificity: analysis of T cell

20/6/199 (Item 71 from file: 357)

0091591 DBA Accession No.: 89-09582

Production of tissue plasminogen-activator - by human fetus **lung**  
fibroblast cell culture transformed with **vector** plasmid pSV3neo,  
containing the SV40 virus T-antigen gene 1989

20/6/200 (Item 72 from file: 357)

0087727 DBA Accession No.: 89-05718

Applications of protein engineering: the examples of human  
alpha-1-antitrypsin and HIV env protein - (conference abstract) 1987

20/6/201 (Item 73 from file: 357)

0067946 DBA Accession No.: 87-12294

Tissue-type plasminogen-activator mutants - recombinant thrombolytic enzyme  
preparation for thrombosis therapy 1987

20/6/202 (Item 74 from file: 357)

0062906 DBA Accession No.: 87-07254

Novel tissue plasminogen-activator derivatives - plasmid **vector**  
construction and gene expression in Escherichia coli 1987

20/6/203 (Item 75 from file: 357)

0058777 DBA Accession No.: 87-03125

New mutant form of human tissue plasminogen-activator - resistant to  
enzymatic conversion and new DNA coding sequences vectors and  
transformed cells 1986

20/6/204 (Item 76 from file: 357)

0055064 DBA Accession No.: 86-12912

Isolation and characterization of cDNA clones for the 35-kDa  
**pulmonary** surfactant-associated protein - cotranslational  
modifications 1986

20/6/205 (Item 77 from file: 357)

0054525 DBA Accession No.: 86-12373

Protoplast fusion - for stably transfecting human cells with recombinant  
plasmid capable of replication in Escherichia coli 1986

?

PLEASE ENTER A COMMAND OR BE LOGGED OFF IN 5 MINUTES

? ds

Set	Items	Description
S1	6596	(PULMONARY OR LUNG OR AEROSOL OR AEROSOLIZE OR INHALATE OR INHALATION) AND (OLIGONUCLEOTIDE OR VECTOR OR ANTISENSE OR RI-BOZYME)
S2	13	AU="BENNETT, CLARENCE F." OR AU="BENNETT, CLARENCE FRANK"
S3	116	AU="BENNETT, C. F." OR AU="BENNETT, C. FRANK"
S4	129	S2 OR S3
S5	123	RD (unique items)
S6	17	S1 AND S5
S7	17	RD (unique items)
S8	13	S1 AND NEBULIZER
S9	11	RD (unique items)
S10	11	S9 NOT S6
S11	1308	S1 AND OLIGONUCLEOTIDE

S12 1289 S1 AND (ANTISENSE OR RIBOZYME)  
 S13 308 S11 AND S12  
 S14 234 RD (unique items)  
 S15 0 S1 AND ALKOXYALKOXY  
 S16 0 S1 AND DIALKYLAMINOXYALKYL  
 S17 0 S1 AND METHYLENEDIPHOSPHONATE  
 S18 291 S1 AND (MODIFIED OR MODIFICATION)  
 S19 262 S18 NOT S14  
 S20 205 RD (unique items)  
 ? t s20/7/185,128,124

20/7/185 (Item 57 from file: 357)  
 DIALOG(R)File 357:Derwent Biotechnology Abs  
 (c) 2000 Derwent Publ Ltd. All rts. reserv.

0163180 DBA Accession No.: 94-05731 PATENT  
 Cholesterol-**modified** triplex DNA-forming **oligonucleotide** -  
 triplex DNA-forming **oligonucleotide** sequence-specific binding  
 application in herpes simplex virus, HIV virus, mamma carcinoma,  
**lung** carcinoma or cervix carcinoma therapy  
 PATENT ASSIGNEE: Triplex-Pharm.; Baylor-Coll.Med. 1994  
 PATENT NUMBER: WO 9404550 PATENT DATE: 940303 WPI ACCESSION NO.:  
 94-083097 (9410)  
 PRIORITY APPLIC. NO.: US 53040 APPLIC. DATE: 930423  
 NATIONAL APPLIC. NO.: WO 93US7743 APPLIC. DATE: 930817  
 LANGUAGE: English  
 ABSTRACT: A method for enhancing the sequence-specific binding of a  
 synthetic triplex DNA-forming **oligonucleotide** (TFO) involves  
 contacting the TFO with a cell (where the TFO comprises a nucleotide  
 sequence of at least 20 nucleotides including G+T, is chemically  
**modified** with a lipophilic compound (tocopherol, cholesterol or  
 1,2-di-O-hexadecyl-3-glycerol) and is capable of binding to duplex DNA  
 to form triplex DNA). The synthetic TFO is preferably bound to  
 cholesterol via a linker and optionally a multi-phosphate group or an  
 oligo-cytidine group. The target sequence is preferably a herpes  
 simplex virus-type 2, HIV virus or an oncogene sequence (c-myc, c-erb  
 B2/neu(HER2)). Also claimed is a method for herpes simplex virus type 2  
 or HIV virus disease or mamma carcinoma, **lung** carcinoma, or  
 cervical carcinoma therapy involving administering a TFO of at least 20  
 nucleotides with an attached lipophilic compound. (86pp)

20/7/128 (Item 16 from file: 399)  
 DIALOG(R)File 399:CA SEARCH(R)  
 (c) 2000 American Chemical Society. All rts. reserv.

120291459 CA: 120(23)291459d PATENT  
 Cholesteryl-modified triple-helix forming oligonucleotides and their uses  
 INVENTOR(AUTHOR): Jayaraman, Krishna; Vu, Huynh; Zendequi, Joseph; Hogan,  
 Michael E.  
 LOCATION: USA  
 ASSIGNEE: Triplex Pharmaceutical Corp.; Baylor College of Medicine  
 PATENT: PCT International ; WO 9404550 A1 DATE: 940303  
 APPLICATION: WO 93US7743 (930817) \*US 934065 (920821) \*US 53040 (930423)  
 PAGES: 85 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C07H-021/02A;  
 A61K-048/00B; C12Q-001/68B DESIGNATED COUNTRIES: CA; JP  
 DESIGNATED REGIONAL: AT; BE; CH; DE; DK; ES; FR; GB; GR; IE; IT; LU; MC;  
 NL; PT; SE  
 SECTION:  
 CA203001 Biochemical Genetics  
 CA201XXX Pharmacology  
 IDENTIFIERS: cholesteryl oligonucleotide triple helix forming  
 DESCRIPTORS:  
 Lung,neoplasm, inhibitors... Mammary gland,neoplasm, inhibitors... Neoplasm



inhibitors... Neoplasm inhibitors, lung... Neoplasm inhibitors, mammary gland  
 ... Neoplasm inhibitors, uterus cervix... Uterus, neoplasm cervix,  
 inhibitors...  
 cholesteryl esters of triple helix-forming oligonucleotides, inhibition  
 of gene expression by  
 Glass, oxide...  
 controlled pore, immobilization of dimethoxytrityl cholesterol derivs.  
 on, for synthesis of triple helix-forming oligonucleotide cholesterol  
 esters  
 Virus, animal, herpes simplex 2... Virus, animal, human immunodeficiency 1...  
 Virus, animal, human immunodeficiency 2...  
 gene expression during infection by, inhibition of, cholesteryl esters  
 of triple helix-forming oligonucleotides for  
 Virus...  
 genes of, inhibition of expression of, cholesteryl esters of triple  
 helix-forming oligonucleotides for  
 Gene, transforming... Gene, animal, c-erbB2... Gene, animal, c-myc...  
 inhibition of expression of, cholesteryl esters of triple helix-forming  
 oligonucleotides for  
 Cell proliferation...  
 virus-stimulated, inhibition of, inhibition of gene expression in,  
 cholesteryl esters of triple helix-forming oligonucleotides for  
 Nucleotides, oligo-, esters, polymers...  
 with triple helix-forming cholesterol, for therapeutics, synthesis of,  
 increased cellular uptake and effectiveness of  
 CAS REGISTRY NUMBERS:  
 133975-64-1DP 133975-70-9DP 149460-94-6DP 155001-66-4DP 155001-67-5DP  
 conjugates with cholesterol, prepn. of, triple helix formation by,  
 cellular uptake of, inhibition of CAT gene expression by  
 136841-34-4DP conjugates with dimethoxytrityl cholesterol derivs., prepn.  
 of, for synthesis of triple helix-forming oligonucleotide cholesterol  
 esters  
 153737-99-6DP 154928-26-4DP 154928-29-7DP 154928-32-2DP 154928-35-5DP  
 conjugates with oligonucleotides, immobilized, prepn. of, triple helix  
 formation by, cellular uptake of, inhibition of gene expression by  
 153083-93-3DP 153737-98-5DP 153738-00-2DP 154928-25-3DP 154928-27-5DP  
 154928-28-6DP 154928-31-1DP 154928-33-3DP 154928-34-4DP  
 154928-36-6DP 154928-38-8DP 154928-39-9DP 154928-44-6DP conjugates  
 with oligonucleotides, prepn. of, triple helix formation by, cellular  
 uptake of, inhibition of gene expression by  
 155001-68-6DP 155001-70-0DP esters with cholesterol derivs., prepn. of,  
 for inhibition of gene expression by formation of triple helix  
 155001-69-7DP esters with cholesterol derivs., prepn. of, for inhibition  
 of HSV-2 gene expression by formation of triple helix  
 57-88-5DP 1406-18-4DP 6076-35-3DP esters with oligonucleotides, triple  
 helix-forming, for inhibition of gene expression, synthesis of,  
 increased cellular uptake and effectiveness of  
 16418-26-1P 112538-31-5P 131606-42-3P 153083-93-3P 153737-97-4P  
 153737-98-5P 153737-99-6P 154928-25-3P 154928-26-4P 154928-29-7P  
 154928-40-2P 154928-41-3P 154928-43-5P prepn. and reactions of, in  
 prepn. cholesteryl conjugates with triple helix-forming  
 oligonucleotides  
 154928-44-6P prepn. of, triple helix formation by, cellular uptake of,  
 inhibition of gene expression in HIV by  
 2592-95-2 125700-67-6 reactions of, in immobilization of cholesterol  
 derivs., in prepn. triple helix-forming oligonucleotide cholesteryl  
 esters for inhibition of gene expression  
 60-32-2 100-79-8 534-03-2 556-33-2 929-06-6 7087-68-5 28920-43-6  
 40615-36-9 57951-36-7 89992-70-1 reactions of, in prepn. cholesteryl  
 conjugates with triple helix-forming oligonucleotides  
 68181-17-9 69340-58-5 reactions of, in prepn. oligonucleotide disulfides  
 for conjugation with cholesterol derivs., in prepn. cholesteryl triple  
 helix-forming oligonucleotides  
 107-13-1 reactions, reactions of, in prepn. cholesteryl conjugates with  
 triple helix-forming oligonucleotides

1249-81-6 reactions with oligonucleotide disulfides of in prepn.  
cholesteryl tripl helix-forming oligonucleotides

20/7/124 (Item 12 from file: 399)  
DIALOG(R) File 399:CA SEARCH(R)  
(c) 2000 American Chemical Society. All rts. reserv.

127229652 CA: 127(17)229652c PATENT  
Sugar-modified gapped oligonucleotides for induction of mRNA degradation  
by RNase H  
INVENTOR(AUTHOR): Cook, Phillip D.; Monia, Brett; Altmann, Karl-Heinz;  
Martin, Pierre  
LOCATION: USA  
ASSIGNEE: Isis Pharmaceuticals, Inc.; Novartis A.-G.; Cook, Phillip D.;  
Monia, Brett; Altmann, Karl-Heinz; Martin, Pierre  
PATENT: PCT International ; WO 9730067 A1 DATE: 19970821  
APPLICATION: WO 97US2043 (19970207) \*US 11620 (19960214)  
PAGES: 86 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C07H-021/04A  
DESIGNATED COUNTRIES: AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; CA; CH; CN;  
CU; DE; DK; EE; ES; FI; GB; GE; HU; IL; IS; JP; KE; KG; KP; KR; KZ; LC;  
LK; LR; LS; LT; LU; LV; MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD;  
SE; SG; SI; SK; TJ; TM; TR; TT; UA; UG; US; UZ; VN; YU; AM; AZ; BY; KG; KZ;  
MD; PU; TJ; TM DESIGNATED REGIONAL: KE; LS; MW; SD; SZ; UG; AT; BE; CH; DE  
; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI;  
CM; GA; GN; ML; MR; NE; SN; TD; TG  
SECTION:  
CA201001 Pharmacology  
IDENTIFIERS: oligonucleotide modified RNase H activation, mRNA degra  
tumor inhibitor modified oligonucleotide  
DESCRIPTORS:  
Lung carcinoma inhibitors...  
adenocarcinoma; sugar-modified gapped oligonucleotides for induction of  
mRNA degra. by RNase H  
Genes(animal)...  
c-raf, targeting of mRNA of; sugar-modified gapped oligonucleotides for  
induction of mRNA degra. by RNase H  
Lung adenocarcinoma...  
inhibitors; sugar-modified gapped oligonucleotides for induction of  
mRNA degra. by RNase H  
Adenocarcinoma inhibitors...  
lung; sugar-modified gapped oligonucleotides for induction of mRNA  
degra. by RNase H  
Oligonucleotides...  
methoxyethoxy sugar-contg.; sugar-modified gapped oligonucleotides for  
induction of mRNA degra. by RNase H  
Antitumor agents... Colon tumor inhibitors... mRNA...  
sugar-modified gapped oligonucleotides for induction of mRNA degra. by  
RNase H  
rev gene(microbial)...  
targeting of mRNA of HIV; sugar-modified gapped oligonucleotides for  
induction of mRNA degra. by RNase H  
c-Ha-ras gene(animal)...  
targeting of mRNA of; sugar-modified gapped oligonucleotides for  
induction of mRNA degra. by RNase H  
CAS REGISTRY NUMBERS:  
141436-78-4 .alpha. subunit, targeting of mRNA for; sugar-modified gapped  
oligonucleotides for induction of mRNA degra. by RNase H  
79-30-1 93-97-0 288-88-0 629-93-6 1463-10-1 2096-10-8 9050-76-4  
14983-42-7 22423-26-3P 40615-36-9 102691-36-1 163759-49-7P  
163759-50-0P 163759-94-2P 182495-98-3P 182496-00-0P 182496-01-1P  
185971-29-3P 185971-31-7P 192564-84-4P 192564-85-5 192564-86-6P  
195253-09-9P 195397-89-8P 195397-90-1P 195397-91-2P sugar-modified  
gapped oligonucleotides for induction of mRNA degra. by RNase H  
? logoff

16may00 14:02: User233835 Session D405.4  
\$2.63 821 DialUnits File155  
\$2.80 14 Type(s) in Format 5  
\$0.00 152 Type(s) in Format 6  
\$0.60 3 Type(s) in Format 7  
\$3.40 169 Types  
\$6.03 Estimated cost File155  
\$5.36 0.957 DialUnits File5  
\$0.00 67 Type(s) in Format 6  
\$11.55 7 Type(s) in Format 7  
\$11.55 74 Types  
\$16.91 Estimated cost File5  
\$55.51 4.423 DialUnits File399  
\$43.00 86 Type(s) in Format 6  
\$30.60 31 Type(s) in Format 7  
\$123.60 117 Types  
\$179.11 Estimated cost File399  
\$15.22 1.288 DialUnits File357  
\$0.00 134 Type(s) in Format 6  
\$4.40 2 Type(s) in Format 7  
\$4.40 136 Types  
\$19.62 Estimated cost File357  
OneSearch, 4 files, 7.489 DialUnits FileOS  
\$2.30 TYMNET  
\$223.97 Estimated cost this search  
\$225.01 Estimated total session cost 7.723 DialUnits  
Logoff: level 00.05.02 D 14:02:26

File 5: Biosis Previews(R) 1994-2003/Aug W2  
(c) 2002 BIOSIS

File 6: NTIS 1964-2003/Aug W3  
(c) 2003 NTIS, Intl Copyright All Rights Res

File 34: SciSearch(R) Cited Ref Sci 1990-2003/Aug W2  
(c) 2002 Inst for Sci Info

File 40: EnviroLine(R) 1975-2003/Aug

File 50: CAB Abstracts 1971-2003/Jul  
(c) 2003 CAB International

File 65: Inside Conferences 1992-2003/Aug W3  
(c) 2002 BLDSC all rts. reserv.

File 71: ELSEVIER BIOBASE 1994-2003/Aug W3  
(c) 2003 Elsevier Science B.V.

File 72: EMBASE 1974-2003/Aug W1  
(c) 2003 Elsevier Science B.V.

File 94: JICST-EPlus 1985-2003/Aug W3  
(c) 2002 Japan Science and Tech Corp(JST)

File 98: General Sci Abs/Full-Text 1984-2003/Jul  
(c) 2003 The HW Wilson Co.

File 103: Energy SciTec 1974-2003/Aug B1  
(c) 2003 Contains copyrighted material

File 143: Biol. & Agric. Index 1983-2003/Jul  
(c) 2003 The HW Wilson Co

File 144: Pascal 1973-2003/Aug W2  
(c) 2003 INIST/CNRS

File 155: MEDLINE(R) 1966-2003/Aug W3  
(c) format only 2003 The Dialog Corp.

File 156: ToxFile 1965-2003/Aug W3  
(c) format only 2003 The Dialog Corporation

File 162: Global Health 1982-2003/Jul  
(c) 2002 CAB International

File 172: EMBASE Alert 2003/Aug W3  
(c) 2002 Elsevier Science B.V.

File 305: Analytical Abstracts 1980-2003/Jul W4  
(c) 2003 Royal Soc Chemistry

File 359: New Scientist 1994-2003/Aug W2  
(c) 2003 Reed Business Information Ltd.

File 370: Science 1996-1999/Jul W3  
(c) 1999 AAAS

File 399: CA SEARCH(R) 1967-2003/UD=13908  
(c) 2003 American Chemical Society

File 434: SciSearch(R) Cited Ref Sci 1974-1989/Dec  
(c) 1998 Inst for Sci Info

File 8: Ei Compendex(R) 1970-2003/Aug W2  
(c) 2003 Elsevier Eng. Info. Inc.

File 99: Wilson Appl. Sci & Tech Abs 1982-2003/Jul  
(c) 2003 The HW Wilson Co.

File 135: NewsEx Weekly Reports 1995-2003/Aug W2  
(c) 2003 NewsEx

File 266: FEDRIP 2002/Jun  
Comp & dist by NTIS, Intl Copyright All Rights Res

File 315: ChemEng & Biotech Abs 1970-2002/Jul  
(c) 2003 DECHEMA

File 357: Derwent Biotech Res \_1982-2003/Aug W4  
(c) 2003 Thomson Derwent & ISI

File 358: Current BioTech Abs 1983-2003/Jul  
(c) 2003 DECHEMA

File 35: Dissertation Abs Online 1861-2003/Jul  
(c) 2003 ProQuest Info&Learning

File 48: SPORTDiscus 1962-2003/Aug  
(c) 2003 Sport Information Resource Centre

File 91: MANTIS(TM) 1890-2001/Dec  
2003 (c) Action Potential

File 149: TGG Health&Wellness DB(SM) 1976-2003/Aug W1  
(c) 2003 The Gale Group

File 159: Cancerlit 1975-2001/Dec  
(c) format only 2002 Dialog Corporation

File 164 Allied & Complementary Medicine 1984-2003/Aug  
 (c) 2003 BLHCIS  
 File 444 New England Journal of Med. 1985-2003/Aug W3  
 (c) 2003 Mass. Med. Soc.  
 File 467 ExtraMED(tm) 2001/Dec  
 (c) 2001 Informania Ltd.

Set	Items	Description
S1	725	(ANTISENSE OR RIBOZYME?) AND INHAL?
S2	11	S1 AND (LUNG (EN) DELIVER?)
S3	12	ED (unique items)
S4	8	S1 NOT PY>1991
S5	6	ED (unique items)

>>>KWIC option is not available in file(s): 299

5/3,K/1 (Item 1 from file: 34)  
 DIALOG(R)File 34:SciSearch(R) Cited Ref Sci  
 (c) 2003 Inst for Sci Info. All rts. reserv.

01280553 Genuine Article#: HQ278 No References: 1995  
**Title: THE SUPEROXIDE-FORMING NADPH OXIDASE OF PHAGOCYTES - AN ENZYME-SYSTEM REGULATED BY MULTIPLE MECHANISMS**  
 Author(s): SEIFERT R; SCHULTE G  
 Corporate Source: FREE UNIV BERLIN, KLINIKUM RUDOLF VIRCHOW, INST PHARMAKOL, THIELALLE 69-83/W-1000 BERLIN 32//GERMANY/  
 Journal: REVIEWS OF PHYSIOLOGY BIOCHEMISTRY AND PHARMACOLOGY, 1991, V117, P 1-232  
 ISSN 0303-4240  
 Language: ENGLISH Document Type: REVIEW

...Research Fronts: ACTIVATION; EXPRESSION OF ALKALINE-PHOSPHATASE; TYROSINE PHOSPHORYLATION)  
 91-2041 004 (AIRWAY INFLAMMATION IN ASTHMA; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; LATE BRONCHIAL RESPONSES; GUINEA-PIGS FOLLOWING \*INHALED\* ANTIGEN CHALLENGE)  
 91-2574 004 (SIGNAL TRANSDUCTION IN OLFACTORY NEURONS; BRAIN GUANINE NUCLEOTIDE-BINDING REGULATORY PROTEINS; ADENYLYL CYCLASE; ODOR RECEPTORS; GTPASE ACTIVITY)  
 91-3798 004...  
 ...MADE VITREOUS FIBERS)  
 91-0268 001 (TERMINAL COMPLEMENT COMPLEXES; RAT MESANGIAL CELLS; IMMUNE GLOMERULAR INJURY; IGA NEPHROPATHY; PASSIVE HEYMAN'S NEPHRITIS; FUNCTIONAL EXPRESSION)  
 91-0328 001 (\*ANTISENSE\* OLIGONUCLEOTIDES; PHOSPHOROTHIOATE ANALOGS; PHOSPHODIESTER LINKAGES RECOGNIZE DUPLEX DNA VIA TRIPLE-HELIX FORMATION)  
 91-0623 001 (POLYMORPHONUCLEAR LEUKOCYTES; INTRACELLULARLY GENERATED CHEMILUMINESCENCE, OXYGEN RADICALS; ACTIVATION OF BOVINE...

5/3,K/2 (Item 1 from file: 266)  
 DIALOG(R)File 266 FEDEIF  
 Comp & dist by NTIS, Intl Copyright All Rights Res. All rts. reserv.

00244824  
 IDENTIFYING NO.: 5R01HL69968-02 AGENCY CODE: CRISP  
**Nitric Oxide Tolerance in Smooth Muscle**  
 PRINCIPAL INVESTIGATOR: PERKINS, WILLIAM J  
 ADDRESS PERKINS@MAYO.EDU MAYO CLINIC ROCHESTER 200 FIRST STREET SW ROCHESTER, MN 55905  
 PERFORMING ORG : MAYO CLINIC ROCHESTER, ROCHESTER, MINNESOTA  
 SPONSORING ORG.: NATIONAL HEART, LUNG, AND BLOOD INSTITUTE  
 DATES: 2004/01/02 TO 2003 11/06 FY : 2003

SUMMARY Nitric oxide (NO) is widely used by surgeons, anesthesiologists and critical care physicians managing critically-ill patients (e.g., \*inhaled\* NO for treatment of pulmonary hypertension and nitrovasodilators

for decreasing afterload and for improving myocardial perfusion. Tolerance to these NO-based therapies occurs clinically and...

... induced NO hyporesponsiveness will aid in the development of future NO-based therapeutic strategies. This is of particular relevance in the pulmonary circulation, in which \*inhaled\* NO is administered as a therapy for pulmonary hypertension, yet a large fraction of these patients are unresponsive to the NO. Methods used in the...

... PCR and immunoblotting to measure expression of each, and sGC and cGK enzyme activity measurement. We will use a combination of pharmacological probes and novel \*antisense\* oligomers to determine the mechanism by which chronic NO treatment decreases the expression and activity of sGC subunits and cGK isoforms.

5/3,K/3 (Item 2 from file: 266)

DIALOG(R)File 266:FEDRIP

Comp & dist by NTIS, Intl Copyright All Rights Res. All rts reserv.

00341237

IDENTIFYING NO.: 5P5GHL56401-07 0001 AGENCY CODE: CRISP

**SURFACTANT PROTEINS AND TYPE II CELL DIFFERENTIATION**

PRINCIPAL INVESTIGATOR: BALLARD, PHILIP

ADDRESS: CHILDREN'S HOSP OF PHILADELPHIA 3516 CIVIC CENTER BLVD  
PHILADELPHIA, PA 19104-4318

PERFORMING ORG.: CHILDREN'S HOSPITAL OF PHILADELPHIA, PHILADELPHIA, PENNSYLVANIA

SPONSORING ORG.: NATIONAL HEART, LUNG, AND BLOOD INSTITUTE

DATES: 2009/01/96 TO 2007/31/06 FY : 2002

...SUMMARY: will be carried out in the cultured type II cell model and SP-B or -C gene expression will be selectively inhibited using adenovirus expressing \*antisense\* mRNAs. Processing and intracellular trafficking of each SP will be studied using epitope specific antibodies, pulse/chase labeling, and tagged recombinant proteins. In addition, processing...

...will be determined. Aim III will investigate expression of SP-B and SP-C in surfactant from infants with lung disease and after treatment with \*inhaled\* nitric oxide. It is hypothesized that a deficiency of SP-B and/or SP-C occurs in infants with severe BPD, and that this process...

5/3,K/4 (Item 3 from file: 266)

DIALOG(R)File 266:FEDRIP

Comp & dist by NTIS, Intl Copyright All Rights Res. All rts. reserv.

00341150

IDENTIFYING NO.: 5R01HL55949-08 AGENCY CODE: CRISP

**MOLECULAR PATHOGENESIS OF PULMONARY HISTOPLASMOSIS**

PRINCIPAL INVESTIGATOR: WOODS, JON F

ADDRESS: JFWOODS@FACTAFF.WISC.EDU UNIVERSITY OF WISCONSIN 1300  
UNIVERSITY AVENUE MADISON, WISCONSIN 53706-1532

PERFORMING ORG : UNIVERSITY OF WISCONSIN MADISON, MADISON, WISCONSIN

SPONSORING ORG : NATIONAL HEART, LUNG, AND BLOOD INSTITUTE

DATES: 2009/30/95 TO 2008/31/05 FY : 2002

...SUMMARY: immunocompromised patients. Disease manifestations may be pulmonary or systemic, resulting from the respiratory route of infection and dissemination through the mononuclear phagocytic system. From host \*inhalation\* of mold elements through conversion to a budding yeast, entry in macrophages, and survival within a harsh intracellular compartment, this dimorphic fungus successfully faces a...

... expression technology (IVET) was used to identify a number of Hc early response genes including yps-3 and a gene encoding a small transcript in \*antisense\* orientation to a homology of an immunogenic protein found in the cell wall and culture supernatant. Its predicted homology with

mammalian EGF-like proteins and...

...infection of the other gene targeted in this proposal. Our second aim is to determine the function of this gene, including its role in potential \*antisense\* down regulation of the protein kinase homolog as part of the fungus's adaption to the host intracellular environment. Both yps-3 and IVET-identified...

5/3,K/5 (Item 4 from file: 266)

DIALOG(R)File 266:FEDRIF

Comp & dist by NTIS, Intl Copyright All Rights Res. All rts. reserv.

00324603

IDENTIFYING NO.: 5R01ES06766-09 AGENCY CODE: CRISP

**GROWTH FACTORS IN ASBESTOS INDUCED PULMONARY FIBROSIS**

PRINCIPAL INVESTIGATOR: BRODY, ARNOLD R

ADDRESS: ABRODY@TMC.TULANE.EDU TULANE UNIV SCHOOL OF MEDICINE 1430 TULANE AVE SL79 NEW ORLEANS, LA 70112

PERFORMING ORG.: TULANE UNIVERSITY OF LOUISIANA, NEW ORLEANS, LOUISIANA

SPONSORING ORG.: NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES

DATES: 2004/11/94 TO 2008/31/04 FY : 2002

SUMMARY: The molecular mechanisms through which \*inhaled\* inorganic particles cause interstitial pulmonary fibrosis (IPF) are being investigated. Since there are numerous potential mediators that will be expressed during disease development, it is...

... that could be key. We have shown that tumor necrosis factor alpha receptor knock out (TNF-alphaRKO) mice are protected from the fibrogenic effects of \*inhaled\* asbestos fibers. These animals exhibit reduced expression of other cytokines such as platelet-derived growth factor, transforming growth factor alpha (TGF-alpha) and TGF-beta1...

... beta1 and pro alpha1(I) collagen (as postulated) is completely unknown in primary pulmonary cells from normal and knockout through treatment of mesenchymal cells with \*antisense\* vectors directed at expression of the TNF-alpha and TGF-beta genes. As a potential therapeutic approach, we show that an anti-sense TGF-beta1...

5/3,K/6 (Item 5 from file: 266)

DIALOG(R)File 266:FEDRIF

Comp & dist by NTIS, Intl Copyright All Rights Res All rts. reserv.

00298918

IDENTIFYING NO.: 7R44AI46079-03 AGENCY CODE: CRISP

**2-5A \*ANTISENSE\* INHIBITION OF RESPIRATORY SYNCYTIAL VIRUS**

PRINCIPAL INVESTIGATOR: CRAMER, HAGEN

ADDRESS: CRAMERH@CCF.ORG RIDGEWAY BIOSYSTEMS, INC THIRD FLOOR CLEVELAND, OH 44106

PERFORMING ORG.: RIDGEWAY BIOSYSTEMS, INC., CLEVELAND, OHIO

SPONSORING ORG.: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

DATES: 2008/01/01 TO 2007/31/04 FY : 2001

**2-5A \*ANTISENSE\* INHIBITION OF RESPIRATORY SYNCYTIAL VIRUS**

...SUMMARY: reach epidemic proportions during the winter months, accounting for roughly 90,000 hospitalizations and 4,500 deaths per year. Gemini Technologies, Inc. is developing novel \*antisense\* chimeras for use in the treatment of RSV infections. These chimeras are comprised of an \*antisense\* component to the targeted viral RNA genome, while the 2-5A portion of the chimera attracts and activates RNase L, an endoribonuclease that can cleave...

DESCRIPTORS: Cercopithecidae; laboratory rat; chemical synthesis; polymerase chain reaction; antiviral agent; \*inhalation\* drug administration; pharmacokinetics; drug screening /evaluation; drug design /synthesis /production; \*antisense\* nucleic acid; high performance liquid chromatography; adenine nucleotide; respiratory disorder chemotherapy;

nonhuman therapy evaluation; tissue /cell culture; virus application;  
respiratory syncytial virus; biotherapeutic agent  
?s sl and py<1992

Processing

Processed 10 of 37 files . .

Processing

Processed 20 of 37 files . .

Processing

>>>One or more prefixes are unsupported

>>> or undefined in one or more files.

Processing

Processed 30 of 37 files . .

Completed processing all files

725 S1

69092193 PY<1992

S6 1 S1 AND PY<1992

?show files;ds;t/3,k/all

File 5 Biosis Previews(R) 1969-2003/Aug W2

(c) 2003 BIOSIS

File 6:NTIS 1964-2003/Aug W2

(c) 2003 NTIS, Intl Copyright All Rights Res

File 34:SciSearch(R) Cited Ref Sci 1990-2003/Aug W2

(c) 2003 Inst for Sci Info

File 40:Enviroline(R) 1975-2003/Aug

File 50:CAB Abstracts 1972-2003/Jul

(c) 2003 CAB International

File 65:Inside Conferences 1993-2003/Aug W3

(c) 2003 BLESC all rts. reserv.

File 71:ELSEVIER BIOBASE 1994-2003/Aug W3

(c) 2003 Elsevier Science B.V.

File 72:EMBASE 1974-2003/Aug W2

(c) 2003 Elsevier Science B.V.

File 94:JICST-EPlus 1985-2003/Aug W3

(c)2003 Japan Science and Tech Corp(JST)

File 98:General Sci Abs/Full-Text 1984-2003/Jul

(c) 2003 The HW Wilson Co.

File 103:Energy SciTec 1974-2003/Aug B1

(c) 2003 Contains copyrighted material

File 143:Biol. & Agric. Index 1983-2003/Jul

(c) 2003 The HW Wilson Co

File 144:Pascal 1973-2003/Aug W2

(c) 2003 INIST/CNRS

File 155:MEDLINE(R) 1960-2002/Aug W3

(c) format only 2002 The Dialog Corp.

File 156:ToxFile 1965-2003/Aug W3

(c) format only 2002 The Dialog Corporation

File 162:Global Health 1982-2003/Jul

(c) 2003 CAB International

File 172:EMBASE Alert 2003/Aug W3

(c) 2003 Elsevier Science B.V.

File 305:Analytical Abstracts 1980-2002/Jul W4

(c) 2003 Royal Soc Chemistry

File 369:New Scientist 1994-2003/Aug W2

(c) 2003 Reed Business Information Ltd.

File 370:Science 1996-1999/Jul W3

(c) 1999 AAAS

File 399:CA SEARCH(R) 1967-2003/UD=13908

(c) 2003 American Chemical Society

File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec

(c) 1998 Inst for Sci Info

File 8:EI Compendex(R) 1970-2003/Aug W2

(c) 2003 Elsevier Eng. Info. Inc.

File 99 Wilson Appl Sci & Tech Abs 1983-2003/Jul

(c) 2003 The HW Wilson Co.

File 135 NewsRx Weekly Reports 1995-2003/Aug W2

(c) 2003 NewsRx

File 266 FEDRIP 2003, Jun



Comp & dist by NTIS, Intl Copyright All Rights Res  
 File 315:ChemEng & Biotec Abs 1970-2003/Jul  
 (c) 2003 DECHEMA  
 File 357:Derwent Biotech Res 1982-2003/Aug W4  
 (c) 2003 Thomson Derwent & ISI  
 File 358:Current BioTech Abs 1983-2003/Jul  
 (c) 2003 DECHEMA  
 File 35:Dissertation Abs Online 1961-2003/Jul  
 (c) 2003 ProQuest Info&Learning  
 File 48:SPORTDiscus 1962-2003/Aug  
 (c) 2003 Sport Information Resource Centre  
 File 91:MAINTIS(TM) 1980-2002/Dec  
 2003 (c) Action Potential  
 File 149:TGG Health&Wellness DB(SM) 1976-2003/Aug W1  
 (c) 2003 The Gale Group  
 File 159:Cancerlit 1975-2002/Oct  
 (c) format only 2002 Dialog Corporation  
 File 164:Allied & Complementary Medicine 1984-2003/Aug  
 (c) 2003 BLHCIS  
 File 444:New England Journal of Med. 1985-2003/Aug W3  
 (c) 2003 Mass. Med. Soc.  
 File 467:ExtraMED(tm) 2000/Dec  
 (c) 2001 Informania Ltd.

Set	Items	Description
S1	735	(ANTISENSE OF RIBOSYME?) AND INHAL?
S2	21	S1 AND (LUNG (5N) DELIVER?)
S3	12	RD (unique items)
S4	8	S1 NOT PY>1991
S5	6	RD (unique items)
S6	1	S1 AND PY<1991

>>>KWIC option is not available in file(s): 399

6/3,K/1 (Item 1 from file: 34)

DIALOG(R)File 34:SciSearch(R) Cited Ref Sci  
 (c) 2003 Inst for Sci Info. All rts. reserv.

02280553 Genuine Article#: WQ278 No. References: 1995

**Title: THE SUPEROXIDE-FORMING NADPH OXIDASE OF PHAGOCYTES - AN  
 ENZYME-SYSTEM REGULATED BY MULTIPLE MECHANISMS**

Author(s): SEIFERT R; SCHULTZ G

Corporate Source: FREE UNIV BERLIN,KLINIKUM RUDOLF VIRCHOW,INST  
 PHARMAKOL,THIELALLE 69-63/W-1000 BERLIN 33//GERMANY/

Journal: REVIEWS OF PHYSIOLOGY BIOCHEMISTRY AND PHARMACOLOGY, \*1991\*, V117  
 , P1-332

ISSN: 0303-4240

Language: ENGLISH Document Type: REVIEW

, \*1991\*

...Research Fronts: ACTIVATION; EXPRESSION OF ALKALINE-PHOSPHATASE;  
 TYROSINE PHOSPHORYLATION)

91-2041 004 (AIRWAY INFLAMMATION IN ASTHMA; GRANULOCYTE-MACROPHAGE  
 COLONY-STIMULATING FACTOR; LATE BRONCHIAL RESPONSES; GUINEA-PIGS  
 FOLLOWING \*INHALED\* ANTIGEN CHALLENGE)

91-3574 004 (SIGNAL TRANSDUCTION IN OLFACTORY NEURONS; BRAIN GUANINE  
 NUCLEOTIDE-BINDING REGULATORY PROTEINS; ADENYLYL CYCLASE; ODOR  
 RECEPTORS; GTPASE ACTIVITY)

91-3798 004...

...MADE VITREOUS FIBERS)

91-0268 001 (TERMINAL COMPLEMENT COMPLEXES; RAT MESANGIAL CELLS; IMMUNE  
 GLOMERULAR INJURY; IGA NEPHROPATHY; PASSIVE HEYMANN NEPHRITIS;  
 FUNCTIONAL EXPRESSION)

91-0328 001 (\*ANTISENSE\* OLIGONUCLEOTIDES; PHOSPHOROTHIOATE ANALOGS;  
 PHOSPHODIESTER LINKAGES RECOGNIZE DUPLEX DNA VIA TRIPLE-HELIX  
 FORMATION)

91-0633 001 (POLYMORPHONUCLEAR LEUKOCYTES; INTRACELLULARLY GENERATED  
 CHEMILUMINESCENCE; OXYGEN RADICALS, ACTIVATION OF BOVINE...

